Virology

• 

  Subject Areas on Research

  • "Getting to Zero" Among Men Who Have Sex with Men in China: a Review of the HIV Care Continuum. 
  • "We Need to Deploy Them Very Thoughtfully and Carefully": Perceptions of Analytical Treatment Interruptions in HIV Cure Research in the United States-A Qualitative Inquiry. 
  • 114 Role of Vaccine-induced V2 Antibodies in Protection From HIV Infection of Recipients in the RV144 Clinical Vaccine Trial 
  • 116 Autologous and Heterologous Neutralizing Antibody Responses in HIV-1 Infection 
  • 142 HIV Frequently Elicits Mucosal and Plasma Env-Specific IgA With a Rapid Initial Decline In Acute Infection 
  • 1993 Annual Meeting of the Laboratory of Tumor Cell Biology: Introduction 
  • 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. 
  • 2F5-Like Antibody Identified from an HIV-Infected Patient Concurrent with the Development of Autoimmune Antibodies 
  • 2F5-like Cross-Reactive HIV-1-Neutralizing Monoclonal Antibodies with Low Number of Somatic Mutations 
  • 50 Years of Emmonsia Disease in Humans: The Dramatic Emergence of a Cluster of Novel Fungal Pathogens. 
  • 69: The role of primary human herpesvirus 6, 7 (HHV-6, HHV-7) infection in febrile status epilepticus 
  • A 43-nucleotide RNA cis-acting element governs the site-specific formation of the 3' end of a poxvirus late mRNA. 
  • A Bivalent, Chimeric Rabies Virus Expressing Simian Immunodeficiency Virus Envelope Induces Multifunctional Antibody Responses. 
  • A Brief Mental Health and Substance Abuse Screener For Persons with HIV 
  • A CRISPR Screen Identifies the Cell Polarity Determinant Crumbs 3 as an Adeno-associated Virus Restriction Factor in Hepatocytes. 
  • A Combined Saavi MVA-C and Novartis Gp140 Env Protein Vaccine Boost Elicits Robust HIV Cellular and Humoral Responses in a Nonhuman Primate Model 
  • A DNA Prime/Protein Boost Vaccine Leads to Higher B-Cell Responses than a Vector Prime/Protein Boost or DNA Prime/Vector Boost Regimens 
  • A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity. 
  • A Fluorescent Cell-Based System for Imaging Zika Virus Infection in Real-Time. 
  • A Gag-Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts, and reduce viral loads after pathogenic intrarectal SIV(mac)251 challenge in rhesus Macaques. 
  • A Gap Between Willingness and Uptake: Findings From Mixed Methods Research on HIV Prevention Among Black and Latina Transgender Women. 
  • A Highly Conserved Residue of the HIV-1 gp120 Inner Domain Is Important for Antibody-Dependent Cellular Cytotoxicity Responses Mediated by Anti-cluster A Antibodies. 
  • A Holistic framework to integrate HIV and cardiovascular disease care in sub-saharan Africa. 
  • A Late Third HIV-MVA Vaccination Boosted Strong and Potent Immune Responses in Tanzanian Volunteers Previously Immunized with HIV-DNA and HIV-MVA 
  • A Lysine Residue Essential for Geminivirus Replication Also Controls Nuclear Localization of the Tomato Yellow Leaf Curl Virus Rep Protein. 
  • A MUC16 IgG Binding Activity Selects for a Restricted Subset of IgG Enriched for Certain Simian Immunodeficiency Virus Epitope Specificities. 
  • A Mixed Methods Approach to Understanding Antiretroviral Treatment Preferences: What Do Patients Really Want? 
  • A PEPTIDE INHIBITOR OF HIV-1 REPLICATION - CORRELATION BETWEEN SOLUTION STRUCTURE AND VIRAL INHIBITION 
  • A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. 
  • A Prime/Boost Vaccine Regimen Alters the Rectal Microbiome and Impacts Immune Responses and Viremia Control Post-Simian Immunodeficiency Virus Infection in Male and Female Rhesus Macaques. 
  • A Review of Recent Literature on Trauma Among Individuals Living with HIV. 
  • A Screen for Extracellular Signal-Regulated Kinase-Primed Glycogen Synthase Kinase 3 Substrates Identifies the p53 Inhibitor iASPP. 
  • A Single Immunization with Integrase Defective Lentiviral Vector Expressing gp140 Induces Persistent and Functional Immune Response in Rhesus Monkeys 
  • A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques. 
  • A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice. 
  • A brief mental health and substance abuse screener for persons with HIV. 
  • A call to action for concentrated HIV epidemics. 
  • A cluster of HIV type 1 subtype C sequences from Ethiopia, observed in full genome analysis, is not sustained in subgenomic regions. 
  • A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease. 
  • A combination of independent transcriptional regulators shapes bacterial virulence gene expression during infection. 
  • A combined microfinance and training intervention can reduce HIV risk behaviour in young female participants. 
  • A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. 
  • A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. 
  • A comparison of height and weight velocity as a part of the composite endpoint in pediatric HIV. 
  • A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen. 
  • A comparison of performance-based measures of function in HIV-associated neurocognitive disorders. 
  • A comparison of the extents of methylation of vesicular stomatitis virus messenger RNA. 
  • A composite of multisystem injury and neurocognitive impairment in HIV infection: association with everyday functioning. 
  • A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. 
  • A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1. 
  • A cost-effectiveness analysis of alternative HIV retesting strategies in sub-saharan Africa. 
  • A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. 
  • A cross-site, comparative effectiveness study of an integrated HIV and substance use treatment program. 
  • A diverse population of Cryptococcus gattii molecular type VGIII in southern Californian HIV/AIDS patients. 
  • A feline immunodeficiency virus vif-deletion mutant remains attenuated upon infection of newborn kittens. 
  • A four-fold increase in the sensitivity of the SIV viral load assay at the nonhuman primate core virology laboratory for AIDS vaccine research and development 
  • A functional antigenomic promoter for the paramyxovirus simian virus 5 requires proper spacing between an essential internal segment and the 3' terminus. 
  • A fungal lytic polysaccharide monooxygenase is required for cell wall integrity, thermotolerance, and virulence of the fungal human pathogen Cryptococcus neoformans. 
  • A genetic screen reveals Arabidopsis stomatal and/or apoplastic defenses against Pseudomonas syringae pv. tomato DC3000. 
  • A genomic approach to identify regulatory nodes in the transcriptional network of systemic acquired resistance in plants. 
  • A genomic approach to identify regulatory nodes in the transcriptional network of systemic acquired resistance in plants. 
  • A genomic survey of positive selection in Burkholderia pseudomallei provides insights into the evolution of accidental virulence. 
  • A genomic survey of positive selection in Burkholderia pseudomallei provides insights into the evolution of accidental virulence. 
  • A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. 
  • A highly sensitive and specific enzyme-linked immunosorbent assay of antibodies to hepatitis C virus. 
  • A kinome RNAi screen identified AMPK as promoting poxvirus entry through the control of actin dynamics. 
  • A laboratory-adapted HCV JFH-1 strain is sensitive to neutralization and can gradually escape under the selection pressure of neutralizing human plasma. 
  • A macaque adherent cell line that expresses human CD4 is susceptible to SIV: utility for assessing neutralizing antibody. 
  • A mass spectrometry-based proteomic approach to study Marek's Disease Virus gene expression. 
  • A model for alignment of Env V1 and V2 hypervariable domains from human and simian immunodeficiency viruses. 
  • A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. 
  • A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3. 
  • A neutralizing antibody target in early HIV-1 infection was recapitulated in rhesus macaques immunized with the transmitted/founder envelope sequence. 
  • A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice. 
  • A new HIV/HBV co-infection model: hepatocytic expression of human sodium taurocholate cotransporting polypeptide (NTCP) Enables Hepatitis B Virus Infection of Macaques 
  • A new circulating recombinant form, CRF15_01B, reinforces the linkage between IDU and heterosexual epidemics in Thailand. 
  • A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. 
  • A novel TLR4-mediated signaling pathway leading to IL-6 responses in human bladder epithelial cells. 
  • A novel TLR4-mediated signaling pathway leading to IL-6 responses in human bladder epithelial cells. 
  • A novel method for detection and ex vivo expansion of HIV type 1-specific cytolytic T lymphocytes. 
  • A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design. 
  • A novel variant marking HLA-DP expression levels predicts recovery from hepatitis B virus infection. 
  • A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. 
  • A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group. 
  • A pilot analytic study of a research-level, lower-cost human papillomavirus 16, 18, and 45 test. 
  • A polymorphism in the HCP5 gene associated with HLA-B*5701 does not restrict HIV-1 in vitro. 
  • A proposed nomenclature for the virion proteins of oncogenic RNA viruses. 
  • A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. 
  • A randomized controlled trial of the efficacy of a stigma reduction intervention for HIV-infected women in the Deep South. 
  • A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. 
  • A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C. 
  • A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. Terry Beirn Community Programs for Clinical Research on AIDS. 
  • A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses. 
  • A recent outbreak of human immunodeficiency virus type 1 infection in southern China was initiated by two highly homogeneous, geographically separated strains, circulating recombinant form AE and a novel BC recombinant. 
  • A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. 
  • A sensitive epitope-blocking ELISA for the detection of Chikungunya virus-specific antibodies in patients. 
  • A short segment in the HIV-1 gp120 V1/V2 region is a major determinant of neutralization resistance to PG9-like antibodies 
  • A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. 
  • A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cells. 
  • A single gp120 residue can affect HIV-1 tropism in macaques. 
  • A single, improbable B cell receptor mutation confers potent neutralization against cytomegalovirus. 
  • A small yeast RNA blocks hepatitis C virus internal ribosome entry site (HCV IRES)-mediated translation and inhibits replication of a chimeric poliovirus under translational control of the HCV IRES element (vol 72, pg 5638, 1998) 
  • A small yeast RNA blocks hepatitis C virus internal ribosome entry site (HCV IRES)-mediated translation and inhibits replication of a chimeric poliovirus under translational control of the HCV IRES element. 
  • A soluble factor(s) secreted from CD8(+) T lymphocytes inhibits human immunodeficiency virus type 1 replication through STAT1 activation. 
  • A strongly selected mutation in the HIV-1 genome is independent of T cell responses and neutralizing antibodies. 
  • A tailored minimal self-help intervention to promote condom use in young women: results from a randomized trial. 
  • A two-phase innate host response to alphavirus infection identified by mRNP-tagging in vivo 
  • A two-phase innate host response to alphavirus infection identified by mRNP-tagging in vivo. 
  • A vaccination regimen to enhance immune responses associated with reduced risk of mother-to-child transmission of HIV 
  • A vaccine against CCR5 protects a subset of macaques upon intravaginal challenge with simian immunodeficiency virus SIVmac251. 
  • A world of choices: preference elicitation methods for improving the delivery and uptake of HIV prevention and treatment. 
  • A-102 Antibody binding to HIV-1 infected cells as mechanism for treatment of HIV infection 
  • A-112 DNA and Protein Co-immunization Improves the Magnitude, Longevity, and mucosal dissemination of Immune Responses 
  • AAV exploits subcellular stress associated with inflammation, endoplasmic reticulum expansion, and misfolded proteins in models of cystic fibrosis. 
  • ADAP2 Is an Interferon Stimulated Gene That Restricts RNA Virus Entry. 
  • ADCC Titers to HIV-Infected Cells Are Detectable in the Majority of Vaccine Recipients in the RV144 Trial 
  • ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection. 
  • AIDS 1990. Vaccines and immunology: overview. 
  • AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period. 
  • ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type. 
  • ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. 
  • AN ENV GENE DERIVED FROM A PRIMARY HIV-1 ISOLATE CONFERS HIGH IN-VIVO REPLICATIVE CAPACITY TO A CHIMERIC SIMIAN/HUMAN IMMUNODEFICIENCY VIRUS IN RHESUS-MONKEYS 
  • ANTIVIRAL ACTIVITY AND MECHANISM OF INHIBITION OF GP41 DERIVED SYNTHETIC PEPTIDES 
  • ARHGEF26 enhances Salmonella invasion and inflammation in cells and mice. 
  • Absence of recoverable infectious virus and unique immune responses in an asymptomatic HIV+ long-term survivor. 
  • Abstracts of AIDS Vaccine 2009. Paris, France. October 19-22, 2009. 
  • Acceptance of rapid HIV testing among medical inpatients in New York City. 
  • Access of HIV-2 to CD169-dependent dendritic cell-mediated trans infection pathway is attenuated. 
  • Accumulation of Cytotoxic CD16+ NK Cells in Simian Immunodeficiency Virus-Infected Lymph Nodes Associated with In Situ Differentiation and Functional Anergy. 
  • Activation of interleukin 4- and interleukin 6-secreting cells by HIV-specific synthetic peptides. 
  • Acute Dengue fever causes false-positive reactivity in OraQuick rapid HIV-1/2 antibody test. 
  • Acute HIV Infection and CD4/CD8 Ratio Normalization After Antiretroviral Therapy Initiation. 
  • Acute HIV infection among pregnant women in Malawi. 
  • Acute HIV-1 infection in the Southeastern United States: a cohort study. 
  • Acute Liver Damage Associated with Innate Immune Activation in a Small Nonhuman Primate Model of Hepacivirus Infection. 
  • Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. 
  • Acute respiratory infection with mouse adenovirus type 1. 
  • Acute-phase CD8 T cell responses that select for escape variants are needed to control live attenuated simian immunodeficiency virus. 
  • Adaptation of an ICAM-1-tropic enterovirus to the mouse respiratory tract. 
  • Adaptation of an R5 Simian-Human Immunodeficiency Virus Encoding an HIV Clade A Envelope with or without Ablation of Adaptive Host Immunity: Differential Selection of Viral Mutants. 
  • Adaptations across clinical sites of an integrated treatment model for persons with HIV and substance abuse. 
  • Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons. 
  • Additive cortical gray matter deficits in people living with HIV who use cocaine. 
  • Addressing Hepatitis C in the American Incarcerated Population: Strategies for Nationwide Elimination. 
  • Addressing Racism's Role in the US HIV Epidemic: Qualitative Findings From Three Ending the HIV Epidemic Prevention Projects. 
  • Addressing the challenges of adherence. 
  • Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo. 
  • Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry. 
  • Adherence to antiretroviral therapy among patients with HIV: a critical link between behavioral and biomedical sciences. 
  • Adjuvant Dependent Mucosal V2 Responses and RAS Activation in Vaccine Induced Protection from SIVmac251 Acquisition. 
  • Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. 
  • Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge. 
  • Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice. 
  • Adoptive immunotherapy using autologous EBV specific cytotoxic T lymphocytes in an HIV infected patient with refractory Epstein Barr virus expressing B cell lymphoma 
  • Advances and challenges: dendritic cell vaccination strategies for glioblastoma. 
  • Advancing the HIV Pre-Exposure Prophylaxis Continuum: A Collaboration Between a Public Health Department and a Federally Qualified Health Center in the Southern United States. 
  • Adverse events in humans associated with accidental exposure to the livestock brucellosis vaccine RB51. 
  • Affinity maturation pathway of an anti-MPER neutralizing mAb, CAP206-CH12 
  • African Early Infection Cohort as a Platform for Vaccine Discovery: The IAVI Protocol C Experience 
  • African strains of hepatitis E virus that are distinct from Asian strains. 
  • Age-Dependent Effects of Immunoproteasome Deficiency on Mouse Adenovirus Type 1 Pathogenesis. 
  • Aggregate complexes of HIV-1 induced by multimeric antibodies 
  • Aggregate complexes of HIV-1 induced by multimeric antibodies. 
  • Aging of the Liver: What This Means for Patients with HIV. 
  • Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates (vol 5, pg 347, 2006) 
  • Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. 
  • Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. 
  • All Known Cross-Reactive HIV-1 Neutralizing Antibodies are Highly Divergent from Germline and Their Elicitation May Require Prolonged Periods of Time 
  • Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen. 
  • Alterations of the B-cell response by HIV-1 replication. 
  • Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals. 
  • Alum and MF59, in Combination with ALVAC-SIV and Gp120 Vaccines Recruit Functionally Different NK Cells to the Gut of Vaccinated Rhesus Macaque 
  • Amino acid residue at position 13 in HLA-DR beta chain plays a critical role in the development of Kaposi's sarcoma in AIDS patients. 
  • Amplification and spread of viruses in a growing plaque. 
  • Amplification of a complete simian immunodeficiency virus genome from fecal RNA of a wild chimpanzee. 
  • An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates. 
  • An HIV DNA Vaccine Delivered by Electroporation and Boosted by rVSV HIV-1 Gag Is Safe and Immunogenic in Healthy HIV-uninfected Adults 
  • An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. 
  • An In Vivo Model of Echovirus-Induced Meningitis Defines the Differential Roles of Type I and Type III Interferon Signaling in Central Nervous System Infection. 
  • An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains. 
  • An analysis of type-C retrovirus polypeptides and their associations in the virion. 
  • An effective tool for identifying HIV-1 subtypes B, C, CRF01_AE, their recombinant forms, and dual infections in Southeast Asia by the multi-region subtype specific PCR (MSSP) assay. 
  • An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies. 
  • An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. 
  • An inducible HIV type 1 gp41 HR-2 peptide-binding site on HIV type 1 envelope gp120. 
  • An inducible heat shock protein 70 small molecule inhibitor demonstrates anti-dengue virus activity, validating Hsp70 as a host antiviral target. 
  • An isolate of human immunodeficiency virus type 1 originally classified as subtype I represents a complex mosaic comprising three different group M subtypes (A, G, and I). 
  • An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults. 
  • An siRNA Screen Identifies the U2 snRNP Spliceosome as a Host Restriction Factor for Recombinant Adeno-associated Viruses. 
  • An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral. 
  • An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. 
  • An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. 
  • Analyses on mutation patterns, detection of population bottlenecks, and suggestion of deleterious-compensatory evolution among members of the genus Potyvirus. 
  • Analysis of Broad Neutralizing B Cell Lineages to Guide HIV-1 Immunogen Design 
  • Analysis of Epstein-Barr virus-regulated host gene expression changes through primary B-cell outgrowth reveals delayed kinetics of latent membrane protein 1-mediated NF-κB activation. 
  • Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates. 
  • Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial. 
  • Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. 
  • Analysis of partial pol and env sequences indicates a high prevalence of HIV type 1 recombinant strains circulating in Gabon. 
  • Analysis of the immune responses in chimpanzees infected with HIV type 1 isolates. 
  • Analysis of trans activation by human papillomavirus type 16 E7 and adenovirus 12S E1A suggests a common mechanism. 
  • Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. 
  • Analytical performance of and real sample analysis with an HBV gene visual detection chip 
  • Ancestral and consensus envelope immunogens for HIV-1 subtype C. 
  • Anti-Ebola MAb 17A3 reacts with bovine and human alpha-2-macroglobulin proteins. 
  • Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC. 
  • Anti-glycoprotein D monoclonal antibody protects against herpes simplex virus type 1-induced diseases in mice functionally depleted of selected T-cell subsets or asialo GM1+ cells. 
  • Anti-inflammatory effects of recreational marijuana in virally suppressed youth with HIV-1 are reversed by use of tobacco products in combination with marijuana. 
  • Anti-lipid Human Monoclonal Antibodies Inhibit HIV-1 Infection of PBMC by Binding to Host Cells 
  • Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds. 
  • Antibodies against retroviral proteins and nuclear antigens in a subset of idiopathic CD4+ T lymphocytopenia patients. 
  • Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. 
  • Antibodies for prevention of mother-to-child transmission of HIV-1. 
  • Antibodies to the envelope protein protect macaques from SIVmac251 acquisition in an immunization regimen that mimics the RV-144 Thai trial 
  • Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. 
  • Antibody Repertoire Induced by the Multiclade (Env A, B, C) HIV-1 DNA Prime, rAd5 Boost VRC Vaccine 
  • Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes. 
  • Antibody is critical for the clearance of murine norovirus infection. 
  • Antibody lineages with evidence of somatic hypermutation persisting for >4 years in a South African subject with broad neutralizing activity 
  • Antibody persistence in children aged 6–7 years one year following booster immunization with two MMR vaccines applied by aerosol or by injection 
  • Antibody responses among adolescent females receiving the quadrivalent HPV vaccine series corresponding to standard or non-standard dosing intervals. 
  • Antibody responses and virus escape: implications for HIV-1 vaccine and therapeutic design 
  • Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates. 
  • Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. 
  • Antibody-DEPENDENT, FcγRI-mediated neutralization of HIV-1 in TZM-bl cells occurs independently of phagocytosis. 
  • Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses. 
  • Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial preferentially use the VH1 gene family 
  • Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. 
  • Antibody-dependent enhancement of SIV infection: further characterization and cross reactivity between macaque and sooty mangabey isolates. 
  • Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques. 
  • Antibody-independent, complement-mediated enhancement of HIV-1 infection by mannosidase I and II inhibitors. 
  • Antibody-mediated inhibition of HIV-1 elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults 
  • Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells. 
  • Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development. 
  • Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor. 
  • Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. 
  • Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. 
  • Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. 
  • Antigenicity and immunogenicity of transmitted/founder HIV envelope oligomers compared to chronic HIV envelopes 
  • Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1. 
  • Antiretroviral Pre-exposure Prophylaxis and Risk of Decreased Glomerular Filtration Rate among HIV Uninfected Men and Women 
  • Antiretroviral drug concentrations in hair are associated with virologic outcomes among young people living with HIV in Tanzania. 
  • Antiretroviral drug resistance among treatment-naïve HIV-1-infected persons in Washington, D.C. 
  • Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation. 
  • Antiretroviral therapy reduces but does not normalize immune and vascular inflammatory markers in adults with chronic HIV infection in Kenya. 
  • Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV. 
  • Antiretroviral treatment strategies in resource-limited settings. 
  • Antisense-Derived HIV-1 Cryptic Epitopes Are Not Major Drivers of Viral Evolution during the Acute Phase of Infection. 
  • Antiviral activity of mixed-valence rare earth borotungstate heteropoly blues against influenza virus in mice. 
  • Antiviral antibodies are necessary for control of simian immunodeficiency virus replication. 
  • Antiviral effects of Retro-2cycl and Retro-2.1 against Enterovirus 71 in vitro and in vivo. 
  • Apoptotic microparticles generated during acute HIV-1 infection inhibit human dendritic cells via CD44 
  • Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries. 
  • Approaches to the development of broadly protective HIV vaccines: challenges posed by the genetic, biological and antigenic variability of HIV-1: Report from a meeting of the WHO-UNAIDS Vaccine Advisory Committee Geneva, 21-23 February 2000. 
  • Approaching a decade since HPV vaccine licensure: Racial and gender disparities in knowledge and awareness of HPV and HPV vaccine. 
  • Ascertainment of vaccination status by self-report versus source documentation: Impact on measuring COVID-19 vaccine effectiveness. 
  • Assessing bias introduced in estimated glomerular filtration rate by the inhibition of creatinine tubular secretion from common antiretrovirals. 
  • Assessing patient perceptions of cytomegalovirus infection in pregnancy. 
  • Assessing the Influence of Community Health Worker Support on Early Antiretroviral Therapy Adherence, Anticipated Stigma, and Mental Health Among People Living with HIV in Tanzania. 
  • Assessing the magnitude of the HIV/AIDS epidemic in Burma. 
  • Assessing university students' sexual risk behaviors as predictors of human papillomavirus (HPV) vaccine uptake behavior. 
  • Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope. 
  • Assessment of biomarkers of cardiovascular risk among HIV type 1-infected adolescents: role of soluble vascular cell adhesion molecule as an early indicator of endothelial inflammation. 
  • Assessment of pain in herpes zoster: lessons learned from antiviral trials. 
  • Assessment of the Frequency of VRC01 Class Naive B Cells in Different Populations That Can Potentially Engage an HIV CD4 Binding Site Immunogen 
  • Assisting functional assignment for hypothetical Heamophilus influenzae gene products through structural genomics. 
  • Association Between Missed Early Visits and Mortality Among Patients of China National Free Antiretroviral Treatment Cohort 
  • Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire. 
  • Association of 3' terminal RNA sequences with avian leukosis viruses causing a high incidence of osteopetrosis. 
  • Association of Fc gamma RIIC Polymorphism with Vaccine Efficacy and Correlates of HIV-1 Infection Risk in RV144 
  • Association of HIV serostatus and metabolic syndrome with neurobehavioral disturbances. 
  • Association of HIV-1 Env Antibody Responses with Postnatal Mother-to-Child Transmission of HIV-1 via Breastfeeding. 
  • Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1. 
  • Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. 
  • Association of cervical biopsy with HIV type 1 genital shedding among women on highly active antiretroviral therapy. 
  • Association of ebola virus matrix protein VP40 with microtubules. 
  • Association of p62c-yes with polyomavirus middle T-antigen mutants correlates with transforming ability. 
  • Association of vaccine-related attitudes and beliefs between parents and health care providers 
  • Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. 
  • Associations between persistent symptoms after mild COVID-19 and long-term health status, quality of life, and psychological distress. 
  • Associations of consistent condom use among men who have sex with men in Abuja, Nigeria. 
  • Asymptomatic SARS-CoV-2 Infection Is Common Among ART-Treated People With HIV. 
  • At a crossroads: human DNA tumor viruses and the host DNA damage response. 
  • Attachment of bovine parvovirus to O-linked alpha 2,3 neuraminic acid on glycophorin A. 
  • Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. 
  • Attenuation of herpes simplex virus neurovirulence with picornavirus cis-acting genetic elements. 
  • Attenuation of neurovirulence, biodistribution, and shedding of a poliovirus:rhinovirus chimera after intrathalamic inoculation in Macaca fascicularis. 
  • Authors’ reply: To the editor 
  • B-101 Placental exosomes in maternal-placental-fetal communication and viral resistance 
  • B-MuX: a unique murine C-type virus containing the "env" gene of xenotropic viruses and the "gag" gene of the ecotropic virus. 
  • BINDING OF HIV-1 TO THE C3B/C4B RECEPTOR, CR-1 (CD35), IN THE PRESENCE OF COMPLEMENT AND ANTIBODIES FROM INFECTED INDIVIDUALS AND GP160-VACCINATED VOLUNTEERS 
  • BPIFB3 Regulates Endoplasmic Reticulum Morphology To Facilitate Flavivirus Replication. 
  • BPIFB6 Regulates Secretory Pathway Trafficking and Enterovirus Replication. 
  • Bacterial effector activates jasmonate signaling by directly targeting JAZ transcriptional repressors. 
  • Barrett's esophagus and esophageal cancer: Links to microbes and the microbiome. 
  • Barriers to antiretroviral adherence: the importance of depression, abuse, and other traumatic events. 
  • Base mutations in the terminal noncoding regions of the genome of vesicular stomatitis virus isolated from persistent infections of L cells. 
  • Baseline prevalence and predictors of liver fibrosis among HIV-positive individuals: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. 
  • Basic residues in the nucleocapsid domain of Gag are critical for late events of HIV-1 budding. 
  • Battling brain-eating amoeba: Enigmas surrounding immunity to Naegleria fowleri. 
  • Benefits, risk, and uncertainty: preferences of antiretroviral-naïve African Americans for HIV treatments. 
  • Beyond Viral Neutralization. 
  • Beyond coverage: Rural-urban disparities in the timeliness of childhood vaccinations in Tanzania. 
  • Biological, immunological, and biochemical evidence that HIX virus is a recombinant between Moloney leukemia virus and a murine xenotropic C type virus. 
  • Biological, molecular, and structural analysis of a cytopathic variant from a molecularly cloned simian immunodeficiency virus. 
  • Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. 
  • Biomarkers of impaired renal function. 
  • Biophysical and ultrastructural characterization of adeno-associated virus capsid uncoating and genome release. 
  • Boosting Antibody Responses with gp140 Protein Two Years After DNA/MVA Priming: Results from the HVTN 073E Phase I Vaccine Trial 
  • Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. 
  • Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency. 
  • Born to sweet delight: Using natural models of malaria protection to understand and neutralize P. falciparum pathogenesis. 
  • Brain inositol is a novel stimulator for promoting Cryptococcus penetration of the blood-brain barrier. 
  • Breadth and magnitude of antigen-specific antibody responses in the control of plasma viremia in simian immunodeficiency virus infected macaques. 
  • Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. 
  • Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models. 
  • Bridging Vaccine-induced Antibody Responses in Rabbit and Rhesus Macaque Animal Models 
  • Brief Report 
  • Brief Report: Antibody Responses to Quadrivalent HPV Vaccination in HIV-Infected Young Women as Measured by Total IgG and Competitive Luminex Immunoassay. 
  • Brief Report: Blood and Genital Fluid Viral Load Trajectories Among Treated and Untreated Persons With Acute HIV Infection in Malawi. 
  • Brief Report: Diagnostic Accuracy of Oral Mucosal Transudate Tests Compared with Blood-Based Rapid Tests for HIV Among Children Aged 18 Months to 18 Years in Kenya and Zimbabwe. 
  • Brief Report: Frequency of Monitoring Kidney Function in HIV-Uninfected Persons Using Daily Oral Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis. 
  • Brief Report: Kidney Dysfunction Does Not Contribute Significantly to Antiretroviral Therapy Modification in Treatment-Naive PLWH Receiving Initial ART. 
  • Brief Report: Macrophage Activation in HIV-Infected Adolescent Males Contributes to Differential Bone Loss by Sex: Adolescent Trials Network Study 021. 
  • Brief Report: Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01. 
  • Brief Report: Relationship Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease in Persons With HIV. 
  • Bringing the path toward an HIV-1 vaccine into focus. 
  • Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4. 
  • Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies. 
  • Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. 
  • Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women. 
  • Building on the HIV chronic care platform to address noncommunicable diseases in sub-Saharan Africa: a research agenda. 
  • Burden of HIV, Syphilis, and Hepatitis B and C Among Inmates in a Prison State System in Mexico. 
  • CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibition. 
  • CBF, Myb, and Ets binding sites are important for activity of the core I element of the murine retrovirus SL3-3 in T lymphocytes. 
  • CCR5del32 in perinatal HIV-1 infection. 
  • CD169-mediated trafficking of HIV to plasma membrane invaginations in dendritic cells attenuates efficacy of anti-gp120 broadly neutralizing antibodies. 
  • CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV. 
  • CD4 ⁺ T-Cell Help Enhances NK Cell Function following Therapeutic HIV-1 Vaccination 
  • CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials. 
  • CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States. 
  • CD4+ memory T cells are the predominant population of HIV-1-infected lymphocytes in neonates and children. 
  • CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies. 
  • CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus (SIV) vaccine enhances protection against neutralization-resistant mucosal SIV infection. 
  • CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge. 
  • CD8+ T cells: mechanistic target of rapamycin and eukaryotic initiation factor 2 in elite HIV-1 control. 
  • CD8+ T lymphocyte-mediated inhibition of HIV-1 long terminal repeat transcription: a novel antiviral mechanism. 
  • CD8+ cell lines isolated from HIV-1-infected children have potent soluble HIV-1 inhibitory activity that differs from beta-chemokines. 
  • CD8+T-LYMPHOCYTE-MEDIATED INHIBITION OF HIV-1 LTR TRANSCRIPTION 
  • CD8⁺ T lymphocyte-mediated inhibition of HIV-1 long terminal repeat transcription: A novel antiviral mechanism 
  • CD8⁺ cell lines isolated from HIV-1-infected children have potent soluble HIV-1 inhibitory activity that differs from β-chemokines 
  • CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. 
  • CHANGES IN THE ENVELOPE GLYCOPROTEINS ARE ASSOCIATED WITH INFECTIVITY OF SIV AND DOWN-MODULATION OF CD4 
  • COMPARISON OF CELLULAR ANTIVIRAL CYTOTOXICITIES PRESENT IN HIV-1 INFECTED HUMANS AND CHIMPANZEES 
  • COMPLEMENT-MEDIATED BINDING OF HIV-1 TO CR-1 AND CR-2 
  • COMPLEMENT-MEDIATED, INFECTION-ENHANCING ANTIBODIES IN HIV AND SIV INFECTION AND VACCINE TRIALS 
  • COMT Val158Met Polymorphism, Cardiometabolic Risk, and Nadir CD4 Synergistically Increase Risk of Neurocognitive Impairment in Men Living With HIV. 
  • COVID-19 vaccination intention and activation among health care system employees: A mixed methods study. 
  • COVID-19 vaccine deliberation in individuals directly impacted by incarceration. 
  • CSF, plasma viral load and HIV associated dementia. 
  • CTL cross reactivity between HIV strains. 
  • CYTOTOXIC T-LYMPHOCYTE REACTIVITIES AMONG HIV-1 VACCINE RECIPIENTS IN THE AIDS VACCINE EVALUATION NETWORK 
  • Calcineurin Targets Involved in Stress Survival and Fungal Virulence. 
  • Calcineurin plays key roles in the dimorphic transition and virulence of the human pathogenic zygomycete Mucor circinelloides. 
  • Canadian Association for Immunization Research and Evaluation (CAIRE) guidelines for industry-sponsored clinical trial and epidemiology contract research. 
  • Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity. 
  • Capric acid and hydroxypropylmethylcellulose increase the immunogenicity of nasally administered peptide vaccines. 
  • Cardiorespiratory Fitness Is Associated With Better White Matter Integrity in Persons Living With HIV. 
  • Cardiovascular Disease Risk Among Transgender People with HIV. 
  • Caribbean and La Réunion Chikungunya Virus Isolates Differ in Their Capacity To Induce Proinflammatory Th1 and NK Cell Responses and Acute Joint Pathology. 
  • Catch me if you can: the link between autophagy and viruses. 
  • Caveats associated with the use of human cervical tissue for HIV and microbicide research. 
  • Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine. 
  • Cell-mediated cytotoxicity of murine cytomegalovirus-infected target cells allows for release of residual infectious virus. 
  • Cell-type specific regulation of gene expression by simian virus 40 T antigens. 
  • Cell-type-specific repression of internal ribosome entry site activity by double-stranded RNA-binding protein 76. 
  • Cellular CD44S as a determinant of human immunodeficiency virus type 1 infection and cellular tropism. 
  • Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trial. 
  • Cellular fatty acid synthase is required for late stages of HIV-1 replication. 
  • Cellular gene expression in papillomas of the choroid plexus from transgenic mice that express the simian virus 40 large T antigen. 
  • Cellular immune response to viral peptides in patients exposed to HIV. 
  • Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. 
  • Centralized HIV-1 envelope immunogens and neutralizing antibodies. 
  • Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. 
  • Ceramide regulates SR protein phosphorylation during adenoviral infection 
  • Challenge of coadministering antiretroviral therapy and oral anticoagulants in HIV-positive patients. 
  • Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection. 
  • Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine. 
  • Changing HIV treatment eligibility under health system constraints in sub-Saharan Africa 
  • Changing antiretroviral therapy in the setting of virologic relapse: review of the current literature. 
  • Chapter 19: Cost-effectiveness of cervical cancer screening. 
  • Characterisation of the Genetic Bottle-Neck in HIV-1 Subtype C, Heterosexually Infected Men and Women from Malawi and South Africa 
  • Characteristics of Age-Discordant Partnerships Associated With HIV Risk Among Young South African Women (HPTN 068). 
  • Characteristics of HIV voluntary counseling and testing clients before and during care and treatment scale-up in Moshi, Tanzania. 
  • Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. 
  • Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. 
  • Characterization of Simian Immunodeficiency Virus Variants Anatomically Compartmentalized in Plasma and Milk in Chronically Infected African Green Monkeys. 
  • Characterization of a thymus-tropic HIV-1 isolate from a rapid progressor: role of the envelope. 
  • Characterization of a trimeric MPER containing HIV-1 gp41 antigen. 
  • Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry 
  • Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry. 
  • Characterization of human immunodeficiency virus type 1 in saliva and blood plasma by V3-specific heteroduplex tracking assay and genotype analyses. 
  • Characterization of primary isolate-like variants of simian-human immunodeficiency virus. 
  • Characterization of protective immune response elicited by a trimeric envelope protein from an Indian clade C HIV-1 isolate in rhesus macaques. 
  • Characterization of the Adeno-Associated Virus 1 and 6 Sialic Acid Binding Site. 
  • Characterization of the CD4BS-specific neutralizing antibody response in a macaque with autologous tier 2 neutralizing antibodies 
  • Characterization of the Transmitted Virus in an Ongoing HIV-1 Epidemic Driven by Injecting Drug Use. 
  • Characterization of the emerging HIV type 1 and HCV epidemics among injecting drug users in Dushanbe, Tajikistan. 
  • Characterization of the immune response to the major glycoprotein (gp 71) of Friend leukemia virus. I. Response in BALB/c mice. 
  • Characterization of the immune response to the major glycoprotein (gp71) of Friend leukemia virus. II. Response in C57BL/6 mice. 
  • Characterization of the immune response to the major glycoprotein (gp71) of Friend leukemia virus. III. Influence on endogenous MuLV-mediated pathogenesis. 
  • Characterization of the trans-activation properties of equine herpesvirus 1 EICP0 protein. 
  • Characterizing Env-specific Monoclonal Antibodies Isolated From US and Malawian HIV-infected Non-transmitting and Transmitting Women 
  • Checkpoint blockade in combination with cancer vaccines. 
  • Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals. 
  • Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants. 
  • Chikungunya virus nsP3 & nsP4 interacts with HSP-90 to promote virus replication: HSP-90 inhibitors reduce CHIKV infection and inflammation in vivo. 
  • Childhood trauma and health outcomes in HIV-infected patients: an exploration of causal pathways. 
  • Chimeric Sindbis/eastern equine encephalitis vaccine candidates are highly attenuated and immunogenic in mice. 
  • Chimeric alphavirus vaccine candidates for chikungunya. 
  • Chimpanzee SIV Envelope-derived Trimer Guides an Immunofocused HIV Cross-neutralizing Ab Response in V2-apex bnAb UCA Expressing Knock-in Mice 
  • Chromosome-Specific Human Herpesvirus 6 Integration and Hematologic Malignancies. 
  • Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments. 
  • Chronic kidney disease in HIV infection: an urban epidemic. 
  • Chronicity and remission of fatigue in patients with established HIV infection. 
  • Circular viral DNA and anomalous junction sequence in PBMC of HIV-infected individuals with no detectable plasma HIV RNA. 
  • Clearance of depot vaccine SPIO-labeled antigen and substrate visualized using MRI. 
  • Clinical characteristics and outcome of Penicillium marneffei infection among HIV-infected patients in northern Vietnam 
  • Clinical characteristics and outcomes of critically ill mechanically ventilated COVID-19 patients receiving interleukin-6 receptor antagonists and corticosteroid therapy: a preliminary report from a multinational registry. 
  • Clinical epidemiology and outcome of HIV-associated talaromycosis in Guangdong, China, during 2011-2017. 
  • Clinical evaluation of a single oral dose of human-bovine (UK) reassortant rotavirus vaccines Wa x UK (P1A[8],G6) and Wa x (DS-1 x UK) (P1A[8],G2). 
  • Clinical isolates of measles virus use CD46 as a cellular receptor. 
  • Clinical presentation and response to treatment of novel influenza A H1N1 in a university-based summer camp population. 
  • Clonal amplification and maternal-infant transmission of nevirapine-resistant HIV-1 variants in breast milk following single-dose nevirapine prophylaxis. 
  • Clonal isolate of the simian sarcoma virus codes for a Gag-related 65,000-dalton protein. 
  • Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells. 
  • Cloning of the terminal loop of vaccinia virus DNA. 
  • Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes. 
  • Clustering of pattern recognition receptors for fungal detection. 
  • Co-administration of 3 Doses of DNA/Protein Improves Antibody Responses to a Prime-boost Approach, but Needle-free Injection of DNA Shows No Benefit 
  • Coadministration of CH31 Broadly Neutralizing Antibody Does Not Affect Development of Vaccine-Induced Anti-HIV-1 Envelope Antibody Responses in Infant Rhesus Macaques. 
  • Cocaine dependence does not contribute substantially to white matter abnormalities in HIV infection. 
  • Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1. 
  • Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: in vitro expression and immune responses in DNA-vaccinated mice. 
  • Coevolution of Adeno-associated Virus Capsid Antigenicity and Tropism through a Structure-Guided Approach. 
  • Colocalization of different influenza viral RNA segments in the cytoplasm before viral budding as shown by single-molecule sensitivity FISH analysis. 
  • Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge. 
  • Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk. 
  • Combined Mucosal and Systemic C.1086 Envelope Immunization of Lactating Monkeys Induces Potent IgA and Functional IgG Antibody Responses in Milk 
  • Combined systemic and mucosal immunization with microsphere-encapsulated inactivated simian immunodeficiency virus elicits serum, vaginal, and tracheal antibody responses in female rhesus macaques. 
  • Common human genetic variants and HIV-1 susceptibility: a genome-wide survey in a homogeneous African population. 
  • Comorbid diabetes and the risk of progressive chronic kidney disease in HIV-infected adults: data from the Veterans Aging Cohort Study. 
  • Comparable Antigenicity and Immunogenicity of Multimeric Forms of a Novel, Acute HIV-1 Subtype C Gp145 Envelope for Clinical Development 
  • Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research. 
  • Comparative Evaluation of Assays for Fc Receptor-Mediated Antibody Effector Functions Targeting HIV-1 
  • Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques. 
  • Comparative analysis of the genome sequences and replication profiles of chikungunya virus isolates within the East, Central and South African (ECSA) lineage. 
  • Comparative chemical properties of avian oncornavirus polypeptides. 
  • Comparative effectiveness of dual vs. single-action antidepressants on HIV clinical outcomes in HIV-infected people with depression. 
  • Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview. 
  • Comparative evaluation of simian, simian-human, and human immunodeficiency virus infections in the pigtail macaque (Macaca nemestrina) model. 
  • Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs. 
  • Comparing Different Priming Strategies to Optimize HIV Vaccine Antibody Responses: Results from HVTN 096/EV04 (NCT01799954) 
  • Comparing influenza and RSV viral and disease dynamics in experimentally infected adults predicts clinical effectiveness of RSV antivirals. 
  • Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies. 
  • Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. 
  • Comparison of Population and 454 “Deep” Sequence Analysis for HIV Type 1 Tropism Versus the Original Trofile Assay in Non-B Subtypes 
  • Comparison of immunogenicity, efficacy and transcriptome changes of inactivated rabies virus vaccine with different adjuvants. 
  • Comparison of intradermal and intramuscular delivery followed by in vivo electroporation of SIV Env DNA in macaques. 
  • Comparison of methods to detect recent HIV type 1 infection in cross-sectionally collected specimens from a cohort of female sex workers in the Dominican Republic. 
  • Comparison of multiple vaccine vectors in a single heterologous prime-boost trial. 
  • Comparison of systemic and mucosal responses after DNA and protein co-immunization 
  • Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the United States. 
  • Comparison of the depth of vaccine-elicited HIV-1 Env epitope-specific CD8+ T lymphocyte responses 
  • Comparison of the genomes of the wild-type French viscerotropic strain of yellow fever virus with its vaccine derivative French neurotropic vaccine. 
  • Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults. 
  • Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. 
  • Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. 
  • Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. 
  • Comparisons of CD8+ T cells specific for human immunodeficiency virus, hepatitis C virus, and cytomegalovirus reveal differences in frequency, immunodominance, phenotype, and interleukin-2 responsiveness. 
  • Compensatory T cell responses in IRG-deficient mice prevent sustained Chlamydia trachomatis infections. 
  • Competitive translation efficiency at the picornavirus type 1 internal ribosome entry site facilitated by viral cis and trans factors. 
  • Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. 
  • Complement-activating antibodies in sera from infected individuals and vaccinated volunteers that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1, CD35). 
  • Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors. 
  • Complement-mediated binding of naturally glycosylated and glycosylation-modified human immunodeficiency virus type 1 to human CR2 (CD21). 
  • Complement-mediated, infection-enhancing antibodies in plasma from vaccinated macaques before and after inoculation with live simian immunodeficiency virus. 
  • Complementary Roles of Antibody Heavy and Light Chain Somatic Hypermutation in Conferring Breadth and Potency to the HIV-1-Specific CAP256-VRC26 bNAb Lineage. 
  • Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer. 
  • Complete functional mapping of infection- and vaccine-elicited antibodies against the fusion peptide of HIV. 
  • Complete genome analysis of one of the earliest SIVcpzPtt strains from Gabon (SIVcpzGAB2). 
  • Complete genome sequencing and analysis of six enterovirus 71 strains with different clinical phenotypes. 
  • Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages. 
  • Complications and Route of Delivery in a Large Cohort Study of HIV-1-Infected Women-IMPAACT P1025. 
  • Comprehensive Characterization of the Transmitted/Founder env Genes From a Single MSM Cohort in China. 
  • Computationally identified mutations suspected to cause gp120 charge inversion and gp41-mediated allosteric effects impact IgG1b12 susceptibility 
  • Concurrent administration of inactivated hepatitis A vaccine with immune globulin in healthy adults. 
  • Conditionally replicating lentiviral-hybrid episomal vectors for suicide gene therapy. 
  • Conference on advances in AIDS vaccine development--1993. Summary: correlates of HIV Immunity Working Group. 
  • Conformation of gp120 determines the sensitivity of HIV-1 DH012 to the entry inhibitor IC9564. 
  • Conservation of the 3' terminal nucleotide sequences of Ebola and Marburg virus. 
  • Considerations for Increasing Racial, Ethnic, Gender, and Sexual Diversity in HIV Cure-Related Research with Analytical Treatment Interruptions: A Qualitative Inquiry. 
  • Construction and characterization of infectious cDNA clones of enterovirus 71 (EV71). 
  • Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F. 
  • Context, COVID-19 and comorbidities: exploring emergent directions in syndemics and HIV research. 
  • Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy. 
  • Contraception use, family planning, and unprotected sex: few differences among HIV-infected and uninfected postpartum women in four US states. 
  • Contributions of CD8 T cells to the pathogenesis of mouse adenovirus type 1 respiratory infection. 
  • Contributions of E1A to mouse adenovirus type 1 pathogenesis following intranasal inoculation. 
  • Control of Heterologous Simian Immunodeficiency Virus SIVsmE660 Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques. 
  • Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform. 
  • Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. 
  • Control of innate immune signaling and membrane targeting by the Hepatitis C virus NS3/4A protease are governed by the NS3 helix α0. 
  • Control of viremia and maintenance of intestinal CD4(+) memory T cells in SHIV(162P3) infected macaques after pathogenic SIV(MAC251) challenge. 
  • Cooperation between somatic mutation and germline-encoded residues enables antibody recognition of HIV-1 envelope glycans. 
  • Cooperation between the Hepatitis C Virus p7 and NS5B Proteins Enhances Virion Infectivity. 
  • Coping strategies and patterns of alcohol and drug use among HIV-infected patients in the United States Southeast. 
  • Cord blood lipids in infants born to HIV-1-infected women treated with combination antiretroviral therapy. 
  • Correction for Chakrabarti et al., Robust Neutralizing Antibodies Elicited by HIV-1 JRFL Envelope Glycoprotein Trimers in Nonhuman Primates. 
  • Correction for Garrido et al., "Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo". 
  • Correction for Hraber et al., "Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments". 
  • Correction for Kibler et al., "Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC". 
  • Correction to Heavy Chain-Only IgG2b Llama antibody effects Near-Pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of coreceptor- and CD4-binding sites [Journal of Virology 87, 18, (2013) 10173-10181] 
  • Correction: Cryptococcus neoformans resists to drastic conditions by switching to viable but non-culturable cell phenotype. 
  • Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. 
  • Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. 
  • Correction: Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. 
  • Correction: The Tripartite Associations between Bacteriophage, Wolbachia, and Arthropods 
  • Correction: Thy1 Nk Cells from Vaccinia Virus-Primed Mice Confer Protection against Vaccinia Virus Challenge in the Absence of Adaptive Lymphocytes. 
  • Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type. 
  • Correlates of HIV vaccine trial participation: an Indian perspective. 
  • Correlates of Water-Based Lubricant Use Among Men Who Have Sex with Men in Blantyre, Malawi. 
  • Correlates of human papillomavirus (HPV) vaccination initiation and completion among 18-26 year olds in the United States. 
  • Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques. 
  • Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing viral tropism co receptor usage of HIV-1 for from 200 treatment-naïve HIV patients screened for Study A4001078 
  • Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. 
  • Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group. 
  • Corrigendum 
  • Corrigendum to "Beyond coverage: Rural-urban disparities in the timeliness of childhood vaccinations in Tanzania" [Vaccine 40(37) (2022) 5483-5493]. 
  • Corrigendum to "Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies" [Virology 363 (2007) 79-90] (DOI:10.1016/j.virol.2007.01.015) 
  • Corrigendum to: Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes [Virology 475 (2015) 37-45] 
  • Cortico-striatal networking deficits associated with advanced HIV disease and cocaine use. 
  • Cost-benefit comparisons of investments in improved water supply and cholera vaccination programs. 
  • Cost-effectiveness analysis of an additional birth dose of Hepatitis B vaccine to prevent perinatal transmission in a medical setting in Mozambique. 
  • Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening. 
  • Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease. 
  • Cost-effectiveness of rotavirus vaccination in children under five years of age in 195 countries: A meta-regression analysis. 
  • Cost-effectiveness of sub-national geographically targeted vaccination programs: A systematic review. 
  • Country Level Diversity of the HIV-1 Pandemic between 1990 and 2015. 
  • Covalent complexes of antigen and alpha(2)-macroglobulin: evidence for dramatically-increased immunogenicity. 
  • Covalent gp120 Immunization: Induction of Neutralizing Monoclonal Antibodies but Failure to Enhance Vaccine-Relevant Polyclonal Antibody Activity 
  • Cowpox virus and other members of the orthopoxvirus genus interfere with the regulation of NF-kappaB activation. 
  • Cowpox virus contains two copies of an early gene encoding a soluble secreted form of the type II TNF receptor. 
  • Cowpox virus genome encodes a second soluble homologue of cellular TNF receptors, distinct from CrmB, that binds TNF but not LT alpha. 
  • Cowpox virus induces interleukin-10 both in vitro and in vivo. 
  • Cowpox virus inhibits human dendritic cell immune function by nonlethal, nonproductive infection. 
  • Cre/LoxP-HBV plasmids generating recombinant covalently closed circular DNA genome upon transfection. 
  • Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. 
  • Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques. 
  • Cross-clade ADCC Activities in Human Volunteer Sera Elicited by a Polyvalent DNA Prime-protein Boost HIV Vaccine DP6-001 
  • Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians. 
  • Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups. 
  • Cross-protective immunity to porcine reproductive and respiratory syndrome virus by intranasal delivery of a live virus vaccine with a potent adjuvant. 
  • Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. 
  • Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. 
  • Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens. 
  • Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins. 
  • Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection. 
  • Cross-reactivity of HIV vaccine responses and the microbiome. 
  • Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen. 
  • Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. 
  • Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. 
  • Crowdsourcing Methods to Enhance HIV and Sexual Health Services: A Scoping Review and Qualitative Synthesis. 
  • Crowdsourcing to Improve HIV and Sexual Health Outcomes: a Scoping Review. 
  • Cryptococcal cell morphology affects host cell interactions and pathogenicity. 
  • Cryptococcus gattii VGIII Isolates Causing Infections in HIV/AIDS Patients in Southern California: Identification of the Local Environmental Source as Arboreal 
  • Cryptococcus gattii VGIII isolates causing infections in HIV/AIDS patients in Southern California: identification of the local environmental source as arboreal. 
  • Cryptococcus neoformans resists to drastic conditions by switching to viable but non-culturable cell phenotype. 
  • Crystal Structure of Reovirus Attachment Protein σ1 in Complex with Sialylated Oligosaccharides 
  • Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane proximal external region 
  • Current practices in nutrition management and disease incidence of common marmosets (Callithrix jacchus). 
  • Cyclocreatine (1-carboxymethyl-2-iminoimidazolidine) inhibits the replication of human herpes viruses. 
  • Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine. NIAID AIDS Vaccine Evaluation Group. 
  • Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. 
  • Cytoplasmic domain truncation enhances fusion activity by the exterior glycoprotein complex of human immunodeficiency virus type 2 in selected cell types. 
  • Cytoplasmic localization of the transforming protein of Fujinami sarcoma virus: salt-sensitive association with subcellular components. 
  • Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo. 
  • D-107 Vaccination establishes CXCR5+PD1+CD4+ peripheral blood germinal center T follicular helper cell relatives in humans 
  • DIRECT GENE-TRANSFER AND MOLECULAR INTERVENTIONS FOR AIDS AND CANCER 
  • DNA AND PROTEIN CO-IMMUNIZATION IMPROVES THE MAGNITUDE, LONGEVITY, AND MUCOSAL DISSEMINATION OF IMMUNE RESPONSES 
  • DNA and Protein Co-delivery Vaccines Using TLR-4-based Adjuvants Induce Potent Immune Responses Able to Delay Heterologous SIV Acquisition 
  • DNA and Protein Co-immunization Improves the Magnitude, Longevity, and Mucosal Dissemination of Immune Responses. 
  • DNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660 
  • DNA and combination vaccines achieve high levels of long lasting and protective cellular and humoral responses 
  • DNA and protein co-delivery vaccines using TLR-4-based adjuvants induce potent immune responses able to delay heterologous SIV acquisition 
  • DNA and recombinant adenovirus serotype 35 and 5 preventive HIV-1 vaccines with Env A inserts elicit cross-clade binding and V1V2 antibodies 
  • DNA immunization of infants: potential and limitations. 
  • DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant. 
  • DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus. 
  • DNA vaccination by intradermal electroporation induces long-lasting immune responses in rhesus macaques. 
  • DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers. 
  • DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. 
  • DNA vaccines. 
  • DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory. 
  • DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies. 
  • DNA-prime Induces Higher Magnitude Humoral Responses Than ALVAC-prime in HIV Vaccine Regimens With the Same Protein Boost 
  • DNA/MVA HIV Vaccine Producing Virus-like Particles (VLPs) Is Well-tolerated and Induces Durable Functional Antibodies (Abs) in HVTN 094 
  • DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime. 
  • Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. 
  • Decrease in the Ratio of Infectious to Total Virions During Acute HIV-1 Infection 
  • Decreased sexual risk behavior in the era of HAART among HIV-infected urban and rural South Africans attending primary care clinics. 
  • Decreasing CD4+ T-cell count during suppressed or low-level viraemia in patients with HIV infection. 
  • Decreasing incidence of HIV and sexually transmitted diseases in young Thai men: evidence for success of the HIV/AIDS control and prevention program. 
  • Deep Sequencing of Influenza A Virus from a Human Challenge Study Reveals a Selective Bottleneck and Only Limited Intrahost Genetic Diversification. 
  • Defects in intracellular trafficking of fungal cell wall synthases lead to aberrant host immune recognition. 
  • Defensins: natural anti-HIV peptides. 
  • Defining the HIV pre-exposure prophylaxis care continuum. 
  • Delayed and Repetitive Boosting of RV144 Vaccinees Improves Antiviral Immunity Associated With Correlates of HIV-1 Infection Risk 
  • Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity. 
  • Delayed-type hypersensitivity testing in Tanzanian adults with HIV infection. 
  • Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. 
  • Deletion of Cryptococcus neoformans AIF ortholog promotes chromosome aneuploidy and fluconazole-resistance in a metacaspase-independent manner. 
  • Delivery of an HIV prevention counseling program in an infectious diseases clinic: implementation process and lessons learned. 
  • Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. 
  • Dengue Virus Selectively Annexes Endoplasmic Reticulum-Associated Translation Machinery as a Strategy for Co-opting Host Cell Protein Synthesis. 
  • Dengue Virus Targets Nrf2 for NS2B3-Mediated Degradation Leading to Enhanced Oxidative Stress and Viral Replication. 
  • Derivation and Characterization of a CD4-Independent, Non-CD4-Tropic Simian Immunodeficiency Virus. 
  • Derivation and characterization of a simian immunodeficiency virus SIVmac239 variant with tropism for CXCR4. 
  • Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes within V1/V2 
  • Design of epitope-specific probes for sera analysis and antibody isolation 
  • Design, display and immunogenicity of HIV1 gp120 fragment immunogens on virus-like particles. 
  • Design, synthesis and structure relationships of new N,N',N",N"'-tetrakis (omega-amino alkyl) tetraazamacrocycles. 
  • Designing Dual Compartment HIV Prevention Products: Women's Sensory Perceptions and Experiences of Suppositories for Rectal and Vaginal Use. 
  • Designing preclinical perceptibility measures to evaluate topical vaginal gel formulations: relating user sensory perceptions and experiences to formulation properties. 
  • Designing synthetic vaccines for HIV. 
  • Detecting respiratory viruses in asymptomatic children. 
  • Detection of CD4-Binding Site Antibodies in Three HIV-1 Seroconverter Cohorts 
  • Detection of Cross-Clade T- and B-Cell-Mediated Immune Responses among HIV-1 Infected Individuals in Northern Tanzania 
  • Detection of Ebola virus envelope using monoclonal and polyclonal antibodies in ELISA, surface plasmon resonance and a quartz crystal microbalance immunosensor. 
  • Detection of HIV-1 neutralizing antibodies by a simple, rapid, colorimetric assay. 
  • Detection of a transformation-specific glycopeptide in SSV-infected cells. 
  • Detection of anti-human cell antibodies in sera from macaques immunized with whole inactivated virus. 
  • Detection of antibodies to the α4β7 integrin binding site on HIV-1 gp120 V2 loop using a novel cell adhesion assay 
  • Detection of mucosal antibodies in HIV type 1-infected individuals. 
  • Detection of polyomavirus SV40 in tonsils from immunocompetent children. 
  • Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity. 
  • Determinants of disease in the simian immunodeficiency virus-infected rhesus macaque: characterizing animals with low antibody responses and rapid progression. 
  • Determinants of poliovirus neurovirulence. 
  • Determination of neutralization activities by a new versatile assay using an HIV-1 genome carrying the Gaussia luciferase gene. 
  • Deterministic Compartment PK Model for Rectal Tenofovir (TFV) Delivery by an Enema 
  • Deterministic Compartmental Pharmacokinetic Model for an Intravaginal Ring (IVR) 
  • Development and characterization of an Fv-1-sensitive retrovirus-packaging system: single-hit titration kinetics observed in restrictive cells. 
  • Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus. 
  • Development and preclinical evaluation of an alphavirus replicon vaccine for influenza. 
  • Development and use of SIV-based Integrase defective lentiviral vector for immunization. 
  • Development of CAVD/EQAPOL Long-Term PBMC Repository ('07-'10) @ DUMC; T-Cell Functionality as Measured by ELISpot and Flow Cytometry Is Maintained Ov 
  • Development of SARS2 qPCR assays to support COVID-19 research in human, NHP and small animal studies 
  • Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CLpro Reporter Assay. 
  • Development of a HIV-1 vaccine using an orally-administered, replication-competent adenovirus serotype 4 vector expressing Env clade C glycoprotein 
  • Development of a multiplex PCR assay for the simultaneous detection and discrimination of HIV-1, HIV-2, HTLV-I and HTLV-II. 
  • Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120. 
  • Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis. 
  • Development of a vaccine for the prevention of AIDS, a critical appraisal. 
  • Development of an Early Stage Investigator Scholar Program for Preclinical Researchers 
  • Development of broad neutralization activity in simian/human immunodeficiency virus-infected rhesus macaques after long-term infection. 
  • Diagnosing HIV infection in primary care settings: missed opportunities. 
  • Diagnosis and screening of HIV/AIDS using clinical criteria in Tanzanian adults. 
  • Diagnosis and treatment of chronic hepatitis C infection. 
  • Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment. 
  • Diagnostic performance of two highly multiplexed respiratory virus assays in a pediatric cohort. 
  • Dicistronic polioviruses as expression vectors for foreign genes. 
  • Diet in a global cohort of adults with HIV at low-to-moderate traditional cardiovascular disease risk. 
  • Differences in HIV-specific T cell responses between HIV-exposed and -unexposed HIV-seronegative individuals. 
  • Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. 
  • Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate. 
  • Differential expression of the alternatively spliced OPRM1 isoform μ-opioid receptor-1K in HIV-infected individuals. 
  • Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production. 
  • Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E. 
  • Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation. 
  • Differential role for TLR3 in respiratory syncytial virus-induced chemokine expression. 
  • Differential willingness to accept adverse event (AE) risks among ART-naive HIV-positive African Americans (AA) 
  • Diploids in the Cryptococcus neoformans serotype A population homozygous for the alpha mating type originate via unisexual mating. 
  • Direct interactions between autoantigen La and human immunodeficiency virus leader RNA. 
  • Direct interactions between autoantigen La and human immunodeficiency virus leader RNA. 
  • Discovery of prosimian and afrotherian foamy viruses and potential cross species transmissions amidst stable and ancient mammalian co-evolution. 
  • Discrimination, Medical Distrust, Stigma, Depressive Symptoms, Antiretroviral Medication Adherence, Engagement in Care, and Quality of Life Among Women Living With HIV in North Carolina: A Mediated Structural Equation Model. 
  • Dismantling Barriers and Transforming the Future of Pre-Exposure Prophylaxis Uptake in Young Black and Latinx Sexual Minority Men and Transgender Women. 
  • Disparate adjuvant properties among three formulations of "alum". 
  • Disparities in healthcare access and utilization and human papillomavirus (HPV) vaccine initiation in the United States. 
  • Disparities in human papillomavirus (HPV) vaccine initiation and completion based on sexual orientation among women in the United States. 
  • Disparities in preschool immunization coverage associated with maternal age 
  • Disparities in viral load and CD4 count trends among HIV-infected adults in South Carolina. 
  • Distinct VH Gene Usage and HIV Envelope Specificity of Colostrum and Peripheral B Cell Monoclonal Antibodies of HIV-Infected, Lactating African Women 
  • Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate. 
  • Distinct single amino acid replacements in the control of virulence regulator protein differentially impact streptococcal pathogenesis. 
  • Diverse antiviral IgG effector activities are predicted by unique biophysical antibody features. 
  • Diversity of full-length subtype E HIV type 1 env sequences in early seroconvertors from northern Thailand. 
  • Does access to health care impact survival time after diagnosis of AIDS? 
  • Drivers of HIV Infection Among Cisgender and Transgender Female Sex Worker Populations in Baltimore City: Results From the SAPPHIRE Study. 
  • Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV. 
  • Drug resistance and HCV coinfection in former blood donors infected with HIV type 1 in China. 
  • Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response. 
  • Dual Maturation Pathways from the Unmutated Common Ancestor of HIV-1 Envelope Broadly Neutralizing Antibodies Overcome Glycan Barriers 
  • Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene. 
  • Dual stem loops within the poliovirus internal ribosomal entry site control neurovirulence. 
  • Dual tropism of HIV-1 envelopes derived from renal tubular epithelial cells of patients with HIV-associated nephropathy. 
  • DuoGel™: The Development of A Multi-drug Dual Chamber Vaginal/Rectal Anti-HIV Microbicide Gel 
  • Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. 
  • Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies. 
  • Dusp3 and Psme3 are associated with murine susceptibility to Staphylococcus aureus infection and human sepsis. 
  • Dynamic Epstein-Barr virus gene expression on the path to B-cell transformation. 
  • Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection. 
  • Dynamin- and lipid raft-dependent entry of decay-accelerating factor (DAF)-binding and non-DAF-binding coxsackieviruses into nonpolarized cells. 
  • Dysregulated Tim-3 expression on natural killer cells is associated with increased Galectin-9 levels in HIV-1 infection 
  • E-102 Advances in Prophylactic HIV Vaccine Development 
  • E-103 The pathway to HIV vaccine development 
  • E-DNA IM or ID delivery prime enhances antibody and T cell responses following recombinant gp120 env boost 
  • EV06 Trial: Modulation of the Immunogenicity of the DNA-HIV-PT123 and AIDSVAX (R) B/E combination HIV vaccine in adult Ugandans by S. mansoni Infection 
  • EVALUATION OF V3 REGION BASED SYNTHETIC PEPTIDE INOCULA AS VACCINES FOR HIV-1 AND SIV 
  • Early Appearance of ADCC- and ADCVI-mediating Antibody Responses Against Autologous HIV-1 Transmitted/Founder Virus 
  • Early B-cell activation after West Nile virus infection requires alpha/beta interferon but not antigen receptor signaling. 
  • Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164. 
  • Early cardiac dysfunction in children and young adults with perinatally acquired HIV. 
  • Early detection: the next steps. 
  • Early intensification with abacavir in subjects at high risk for incomplete viral suppression. 
  • Early intracellular events in the replication of bacteriophage T4 deoxyribonucleic acid. VI. Newly synthesized proteins in the T4 protein-deoxyribonucleic acid complex. 
  • Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. 
  • Early plasma B cell responses to transmitted HIV-1 are directed to envelope gp41 and originate by the activation of mutated B cell clones 
  • Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania. 
  • Eastern equine encephalitis leading to multi-organ failure and sepsis. 
  • Economic evaluation of ART in resource-limited countries. 
  • Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C. 
  • Editorial 
  • Editorial comment: renal insufficiency in HIV-infected patients may not always be HIVAN. 
  • Editorial introductions 
  • Editorial overview of Pearls Microbiome Series: E pluribus unum. 
  • Efavirenz: innocent bystander or direct nephrotoxin? 
  • Effect of B-cell depletion on viral replication and clinical outcome of simian immunodeficiency virus infection in a natural host. 
  • Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques. 
  • Effect of Depot Medoxyprogesterone Acetate on Immune Functions and Inflammatory Markers of HIV-Infected Women. 
  • Effect of Fc gamma-receptor polymorphisms in rhesus macaques on SIVmac251 setpoint viremia 
  • Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations. 
  • Effect of alternating passage on adaptation of sindbis virus to vertebrate and invertebrate cells. 
  • Effect of antipyretic analgesics on immune responses to vaccination. 
  • Effect of atorvastatin on humoral immune response to 23-valent pneumococcal polysaccharide vaccination in healthy volunteers: The StatVax randomized clinical trial. 
  • Effect of complement consumption by cobra venom factor on the course of primary infection with simian immunodeficiency virus in rhesus monkeys. 
  • Effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infection. 
  • Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. 
  • Effect of interferon on murine leukemia virus infection. II. Synthesis of viral components in exogenous infection. 
  • Effect of particulate adjuvant on the anthrax protective antigen dose required for effective nasal vaccination. 
  • Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. 
  • Effect of protease inhibitor-based antiretroviral therapy on lipid metabolism and lactate levels in pregnancy (ACTG A5084) 
  • Effect of recent seasonal influenza vaccination on serum antibody responses to candidate pandemic influenza A/H5N1 vaccines: A meta-analysis. 
  • Effect of recombinant human growth hormone on exercise capacity in patients with HIV-associated wasting on HAART 
  • Effect of recombinant human growth hormone on exercise capacity in patients with HIV-associated wasting on HAART. 
  • Effect of smoking on the clinical progression of HIV-1 infection. 
  • Effect of trimethoprim-sulfamethoxazole prophylaxis on antimicrobial resistance of fecal Escherichia coli in HIV-infected patients in Tanzania. 
  • Effective antibody therapy in herpes simplex virus ocular infection. Characterization of recipient immune response. 
  • Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1. 
  • Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions. 
  • Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzee. 
  • Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. 
  • Effectiveness of 'catch-up' human papillomavirus vaccination to prevent cervical neoplasia in immunosuppressed and non-immunosuppressed women. 
  • Effectiveness of HIV prevention interventions in developing countries. 
  • Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia. 
  • Effectiveness of the 10-valent pneumococcal conjugate vaccine against radiographic pneumonia among children in rural Bangladesh: A case-control study. 
  • Effects of a couple-based intervention to reduce risks for HIV, HCV, and STIs among drug-involved heterosexual couples in Kazakhstan: a randomized controlled trial. 
  • Effects of allergic airway disease on mouse adenovirus type 1 respiratory infection. 
  • Effects of cellular activation on anti-HIV-1 restriction factor expression profile in primary cells. 
  • Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection. 
  • Effects of early human immunodeficiency virus infection on cerebral white matter blood flow autoregulation. 
  • Effects of genital tract inflammation on human immunodeficiency virus type 1 V3 populations in blood and semen. 
  • Effects of gp140 Protein Booster Immunizations to DNA/MVA SHIV Vaccine on Immunogenicity and Protection against Intravaginal Tier-2 SHIV Challenges 
  • Effects of human immunodeficiency virus type 1 infection on CCR5 and CXCR4 coreceptor expression on CD4 T lymphocyte subsets in infants and adolescents. 
  • Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. 
  • Effects of raltegravir on 2-long terminal repeat circle junctions in HIV type 1 viremic and aviremic patients. 
  • Effects of the src gene product on microfilament and microtubule organization in avian and mammalian cells infected with the same temperature-sensitive mutant of Rous sarcoma virus. 
  • Effects of tumor necrosis factor on viral replication and pulmonary inflammation during acute mouse adenovirus type 1 respiratory infection. 
  • Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates. 
  • Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus. 
  • Efficacy of HIV Vaccine Candidate in Macaques Dependent on the Dose of SIVmac251 Challenge Exposure: Immune Correlates of Vaccine Efficacy 
  • Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. 
  • Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. 
  • Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection. 
  • Efficiency of placental transfer of vaccine-elicited antibodies relative to prenatal Tdap vaccination status. 
  • Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry. 
  • Elevated chemokine responses are maintained in lungs after clearance of viral infection. 
  • Elevation of intact and proteolytic fragments of acute phase proteins constitutes the earliest systemic antiviral response in HIV-1 infection. 
  • Elevation of intact and proteolytic fragments of acute phase proteins constitutes the earliest systemic antiviral response in HIV-1 infection. 
  • Elevations in Serum Creatinine With Tenofovir-Based HIV Pre-Exposure Prophylaxis: A Meta-Analysis of Randomized Placebo-Controlled Trials. 
  • Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence. 
  • Eliminating Autoreactivity of Variants of Antibody VRC07 by Glycan Masking 
  • Elite Control, Gut CD4 T Cell Sparing, and Enhanced Mucosal T Cell Responses in Macaca nemestrina Infected by a Simian Immunodeficiency Virus Lacking a gp41 Trafficking Motif. 
  • Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. 
  • Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the northwest United States. 
  • Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the northwest United States. 
  • Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. 
  • Emerging HIV infections with distinct subtypes of HIV-1 infection among injection drug users from geographically separate locations in Guangxi Province, China. 
  • Emerging antiviral therapeutics for human adenovirus infection: Recent developments and novel strategies. 
  • Emerging immunotherapies for autoimmune kidney disease. 
  • Emerging prevalence of fatty liver disease in HIV 
  • Emergomyces: The global rise of new dimorphic fungal pathogens. 
  • Employee designation and health care worker support of an influenza vaccine mandate at a large pediatric tertiary care hospital. 
  • Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study. 
  • Ending AIDS as a public health threat by 2030: Scientific Developments from the 2016 INTEREST Conference in Yaoundé, Cameroon. 
  • Ending the invisibility of sex workers in the US HIV/AIDS surveillance and prevention strategy. 
  • Engagement of NKG2D on bystander memory CD8 T cells promotes increased immunopathology following Leishmania major infection. 
  • Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition. 
  • Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells. 
  • Engineered influenza virions reveal the contributions of non-hemagglutinin structural proteins to vaccine mediated protection. 
  • Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes. 
  • Engineering a Next Generation VRC01-Like Antibody with Improved In Vitro and In Vivo Function 
  • Engineering antibody-based molecules for HIV treatment and cure. 
  • Engineering immunity for next generation HIV vaccines: The intersection of bioengineering and immunology. 
  • Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins. 
  • Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins. 
  • Enhanced Neutralization of HIV-1 by gp41 MPER-Specific Antibodies in Cells that Express Fcg Receptors 
  • Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. 
  • Enhanced green fluorescent protein as a marker for localizing murine cytomegalovirus in acute and latent infection. 
  • Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. 
  • Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. 
  • Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. 
  • Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. 
  • Enhancing benefits or increasing harms: community responses for HIV among men who have sex with men, transgender women, female sex workers, and people who inject drugs. 
  • Enhancing linkage and retention in HIV care: a review of interventions for highly resourced and resource-poor settings. 
  • Enriching the mix: incorporating structural factors into HIV prevention. 
  • Enterovirus causes rapidly progressive dementia in a 28-year-old immunosuppressed woman. 
  • Enteroviruses: The role of receptors in viral pathogenesis. 
  • Env Binding to the alpha 4 beta 7 Integrin Complex Is Not a General Property of Most HIV-1 Variants 
  • Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). 
  • Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. 
  • Envelope diversity, coreceptor usage and syncytium-inducing phenotype of HIV-1 variants in saliva and blood during primary infection. 
  • Envelope glycoprotein binding to the integrin α4β7 is not a general property of most HIV-1 strains. 
  • Epidemiologic links between drug use and HIV epidemics: an international perspective. 
  • Epidemiology of HIV-1 infection in opiate users in Northern Thailand. 
  • Epigenetic Silencing of Recombinant Adeno-associated Virus Genomes by NP220 and the HUSH Complex. 
  • Epigenetic regulation of CD8(+) T-lymphocyte mediated suppression of HIV-1 replication. 
  • Episodic Use of Pre-Exposure Prophylaxis Among Young Cisgender Women in Siaya County, Kenya. 
  • Epitope Specificities of Elite Neutralizing Sera from HIV-1-Infected Individuals 
  • Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein. 
  • Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses. 
  • Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. 
  • Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques. 
  • Epstein-Barr Virus Genomes Reveal Population Structure and Type 1 Association with Endemic Burkitt Lymphoma. 
  • Epstein-Barr virus induces global changes in cellular mRNA isoform usage that are important for the maintenance of latency. 
  • Erratum to " Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1" [Vaccine 28 (42) (2010) 6901-6914] 
  • Erratum to Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies [Journal of Virology, 85, 21, (2011) 11401-11408] DOI: 10.1128/JVI.05312-11 
  • Erratum to: Alterations of the B-cell response by HIV-1 replication (Current HIV/AIDS Reports (2011) 8, (23-30) DOI: 10.1007/s11904-010-0064-2) 
  • Erratum to: HIV Prevention Among Transgender Populations: Knowledge Gaps and Evidence for Action. 
  • Erratum: A small yeast RNA blocks hepatitis C virus internal ribosome entry site (HCV IRES)-mediated translation and inhibits replication of a chimeric poliovirus under translational control of the HCV IRES element (Journal of Virology (1998) 72:7 (5638-5647)) 
  • Erratum: Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates (Expert Review of Vaccines (2006) 5, 3, (347-363)) 
  • Erratum: Biomarkers of impaired renal function (Current Opinion in HIV and AIDS (2010) 5 (524-530)) 
  • Erratum: Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection (Journal of Virology (2006) 80, 22, (11094-11104)) 
  • Erratum: Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles (Journal of Virology (2000) 74:1 (371-378)) 
  • Escherichia coli global gene expression in urine from women with urinary tract infection. 
  • Establishing PBMC Repository for T Cell Assays Optimization and Proficiency Testing in CTC-VIMC Laboratories 
  • Establishment of cell lines with increased susceptibility to EV71/CA16 by stable overexpression of SCARB2. 
  • Establishment, Persistence, and Reactivation of Latent HIV-1 Infection in Renal Epithelial Cells. 
  • Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. 
  • Ethnic/Racial Disparities in Longitudinal Neurocognitive Decline in People With HIV. 
  • Evaluation of CD8+ T-cell and antibody responses following transient increased viraemia in rhesus macaques infected with live, attenuated simian immunodeficiency virus. 
  • Evaluation of IRES-mediated, cell-type-specific cytotoxicity of poliovirus using a colorimetric cell proliferation assay. 
  • Evaluation of a dried blood spot HIV-1 RNA program for early infant diagnosis and viral load monitoring at rural and remote healthcare facilities. 
  • Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain. 
  • Evaluation of host cellular responses to Epstein-Barr virus (EBV) in adult lung transplant patients with EBV-associated diseases. 
  • Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus. 
  • Evaluation of immune responses to porcine reproductive and respiratory syndrome virus in pigs during early stage of infection under farm conditions. 
  • Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. 
  • Evaluation of the Abbott m2000rt RealTime HIV-1 assay with manual sample preparation compared with the ROCHE COBAS AmpliPrep/AMPLICOR HIV-1 MONITOR v1.5 using specimens from East Africa. 
  • Evaluation of the blood stabilizers TransFix and Cyto-Chex BCT for low-cost CD4 T-cell methodologies. 
  • Evaluation of two frailty indices, with practical application in a vaccine clinical trial. 
  • Evaluation of vaccine-induced antibody responses: impact of new technologies. 
  • Evidence against phagocytosis in Fc gamma RI-mediated HIV neutralization by MPER antibodies in TZM-bl cells 
  • Evidence for immune-mediated reduction of viral replication in Macaca nemestrina mucosally immunized with inactivated SHIV(89.6). 
  • Evidence of Epstein-Barr virus heterogeneous gene expression in adult lung transplant recipients with posttransplant lymphoproliferative disorder. 
  • Evidence of two distinct subsubtypes within the HIV-1 subtype A radiation. 
  • Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. 
  • Evidence that a precursor glycoprotein is cleaved to yield the major glycoprotein of avian tumor virus. 
  • Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage. 
  • Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. 
  • Evidence that mannosyl residues are involved in human immunodeficiency virus type 1 (HIV-1) pathogenesis. 
  • Evidence that the src gene product of Rous sarcoma virus is membrane associated. 
  • Evolution and diversity in human herpes simplex virus genomes. 
  • Evolution and probable transmission of intersubtype recombinant human immunodeficiency virus type 1 in a Zambian couple. 
  • Evolution of Antibody Responses in HIV-1 CRF01_AE Acute Infection: Founder Envelope V1V2 Impacts the Timing and Magnitude of Autologous Neutralizing Antibodies. 
  • Evolution of drug-resistant viral populations during interruption of antiretroviral therapy. 
  • Evolution of the Same HIV-1 Transmitted/Founder Virus in Two Hosts 
  • Evolutionarily conserved epitopes on human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus reverse transcriptases detected by HIV-1-infected subjects. 
  • Evolutionary implications of primate endogenous retroviruses. 
  • Evolutionary relationships of endemic/epidemic and sylvatic dengue viruses. 
  • Examining How Health Navigation Affects Mental Health Among Gay, Bisexual, and Other Men Who Have Sex with Men Living with Human Immunodeficiency Virus in Guatemala. 
  • Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. 
  • Examining the role of serostatus disclosure on unprotected sex among people living with HIV. 
  • Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. 
  • Exceptionally Potent, Broadly-Neutralizing IgAs from Survivors of Prolonged HIV Infection 
  • Exhausted CD8 T cells downregulate the IL-18 receptor and become unresponsive to inflammatory cytokines and bacterial co-infections. 
  • Exogenous Expression of HIV-1 Envelope Glycoprotein Trimer in Suspension Culture-Adapted HEK293 and CHO-K1 Cells 
  • Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. 
  • Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate. 
  • Expanding regulatory T cells alleviates chikungunya virus-induced pathology in mice. 
  • Expanding the space: inclusion of most-at-risk populations in HIV prevention, treatment, and care services. 
  • Expansion of VH1-2*02 Env-specific B Cells in a Non-neutralizing HIV-1 Env Vaccine Regimen 
  • Experience with a cross-study endpoint review committee for AIDS clinical trials. Terry Beirn Community Programs for Clinical Research on AIDS. 
  • Explaining continued high HIV prevalence in South Africa: socioeconomic factors, HIV incidence and sexual behaviour change among a rural cohort, 2001-2004. 
  • Exploiting and subverting Tor signaling in the pathogenesis of fungi, parasites, and viruses. 
  • Exploration of broadly neutralizing antibody fragments produced in bacteria for the control of HIV. 
  • Exploring patterns and predictors of suicidal ideation among pregnant and postpartum women living with HIV in Kilimanjaro, Tanzania. 
  • Exploring the role of economic empowerment in HIV prevention. 
  • Exposure modality influences viral kinetics but not respiratory outcome of COVID-19 in multiple nonhuman primate species. 
  • Exposures in adult outpatients with COVID-19 infection during early community transmission, Tennessee. 
  • Expression levels of TLRs involved in viral recognition in PBMCs from HIV-1-infected patients failing antiretroviral therapy. 
  • Expression of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1. 
  • Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques. 
  • Expression of complete SIV p27 Gag and HIV gp120 engineered outer domains targeted by broadly neutralizing antibodies in live rubella vectors. 
  • Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. 
  • Expression of the Major Viral Glycoprotein of Avian Tumor Virus in Cells of chf(+) Chicken Embryos. 
  • Expression of the human poliovirus receptor/CD155 gene during development of the central nervous system: implications for the pathogenesis of poliomyelitis. 
  • Expression of the vaccinia virus A2.5L redox protein is required for virion morphogenesis. 
  • Extracellular Virions: The Advance Guard of Poxvirus Infections. 
  • FAT10: a novel mediator of Vpr-induced apoptosis in human immunodeficiency virus-associated nephropathy. 
  • FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. 
  • Factors associated with decreased kidney function in HIV-infected adults enrolled in the MTCT-Plus Initiative in sub-Saharan Africa. 
  • Factors associated with recurrence of cervical intraepithelial neoplasia 2+ after treatment among HIV-infected women in Western Kenya. 
  • Factors associated with survival among adults with HIV-associated TB in Guangxi, China: a retrospective cohort study 
  • Falling through the cracks: the gaps between depression prevalence, diagnosis, treatment, and response in HIV care. 
  • False-positivity of HIV-2 immunoblots in a cohort of elite suppressors infected with HIV-1. 
  • Fas activity mediates airway inflammation during mouse adenovirus type 1 respiratory infection. 
  • Fatal SV40-associated pneumonia and nephropathy following renal allotransplantation in rhesus macaque. 
  • Favorable and unfavorable HLA class I alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1. 
  • Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial. 
  • Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001. 
  • Feasibility of a Combination HIV Prevention Program for Men Who Have Sex With Men in Blantyre, Malawi. 
  • Features of Recently Transmitted HIV-1 Clade C Viruses That Impact Antibody Recognition: Implications for Active and Passive Immunization 
  • Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. 
  • Features of cardiovascular disease in low-income and middle-income countries in adults and children living with HIV. 
  • Fine structure mapping and phenotypic analysis of five temperature-sensitive mutations in the second largest subunit of vaccinia virus DNA-dependent RNA polymerase. 
  • Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection. 
  • Five pillars of centromeric chromatin in fungal pathogens. 
  • Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability. 
  • Flavivirus RNA transactions from viral entry to genome replication. 
  • Foci of endemic simian immunodeficiency virus infection in wild-living eastern chimpanzees (Pan troglodytes schweinfurthii). 
  • Follow YOUR Heart: development of an evidence-based campaign empowering older women with HIV to participate in a large-scale cardiovascular disease prevention trial. 
  • Foreword 
  • Frequency of atazanavir-associated leukocyturia development and renal function decline. 
  • Frequency of transmitted drug resistance among acute and recently HIV-infected patients in North Carolina is similar to reports from more urbanized areas 
  • Frequency of transmitted drug resistance among acute and recently HIV-infected patients in North Carolina is similar to reports from more urbanized areas 
  • Friends or foes? The knowns and unknowns of natural killer cell biology in COVID-19 and other coronaviruses in July 2020. 
  • From magic spot ppGpp to MESH1: Stringent response from bacteria to metazoa. 
  • Functional Analysis of the Quasispecies env Population in Individuals Infected with HIV-1 Subtype C Viruses 
  • Functional Comparison of HIV-1 env Gene Quasispecies Populations from Acutely and Chronically Infected Individuals 
  • Functional Perturbation of Mucosal Group 3 Innate Lymphoid and Natural Killer Cells in Simian-Human Immunodeficiency Virus/Simian Immunodeficiency Virus-Infected Infant Rhesus Macaques. 
  • Functional analysis of the simian immunodeficiency virus Vpx protein: identification of packaging determinants and a novel nuclear targeting domain. 
  • Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. 
  • Functional cure of SIVagm infection in rhesus macaques results in complete recovery of CD4+ T cells and is reverted by CD8+ cell depletion. 
  • Further characterization of the oncornavirus inactivating factor in normal mouse serum. 
  • Further investigation of simian immunodeficiency virus Vif function in human cells. 
  • Fusion of the termini of the murine cytomegalovirus genome after infection. 
  • Future therapies for food allergy. 
  • GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. 
  • GM-CSF as an adjuvant for protective immune responses 
  • Gammaherpesvirus modulation of mouse adenovirus type 1 pathogenesis. 
  • Gender differences in human immunodeficiency virus type 1-specific CD8 responses in the reproductive tract and colon following nasal peptide priming and modified vaccinia virus Ankara boosting. 
  • Gene A of X174. 1. Isolation and identification of its products. 
  • Generation and characterization of anti-Adeno-associated virus serotype 8 (AAV8) and anti-AAV9 monoclonal antibodies. 
  • Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env. 
  • Generation of Robust Antibody Responses to HIV-1 Membrane Proximal External Region (MPER) Antigens 
  • Generation of infectious molecular clones of simian immunodeficiency virus from fecal consensus sequences of wild chimpanzees. 
  • Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. 
  • Generation of random mutant libraries with multiple primers in a single reaction. 
  • Generation of reovirus core-like particles in cells infected with hybrid vaccinia viruses that express genome segments L1, L2, L3, and S2. 
  • Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. 
  • Generators of phenotypic diversity in the evolution of pathogenic microorganisms. 
  • Genetic adaptation to untranslated region-mediated enterovirus growth deficits by mutations in the nonstructural proteins 3AB and 3CD. 
  • Genetic and Immunological Evidence for a Role of Env-V3 Antibodies in the RV144 Trial 
  • Genetic and epigenetic engines of diversity in pathogenic microbes. 
  • Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. 
  • Genetic and phenotypic changes accompanying the emergence of epizootic subtype IC Venezuelan equine encephalitis viruses from an enzootic subtype ID progenitor. 
  • Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor. 
  • Genetic determinants of cell type-specific poliovirus propagation in HEK 293 cells. 
  • Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. 
  • Genetic relationships and evolution of genotypes of yellow fever virus and other members of the yellow fever virus group within the Flavivirus genus based on the 3' noncoding region. 
  • Genetic typing of HIV-2 from a Senegalese/German heterosexual transmission. 
  • Genetic variation among strains of wild-type yellow fever virus from Senegal. 
  • Genetic variation in the 3' non-coding region of dengue viruses. 
  • Genetic variation in yellow fever virus: duplication in the 3' noncoding region of strains from Africa. 
  • Genetic variation of HIV type 1 in four World Health Organization-sponsored vaccine evaluation sites: generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. WHO Network for HIV Isolation and Characterization. 
  • Genetically and epidemiologically related "non-syncytium-inducing" isolates of HIV-1 display heterogeneous growth patterns in macrophages. 
  • Genetically divergent strains of human immunodeficiency virus type 2 use multiple coreceptors for viral entry. 
  • Genetically stable picornavirus expression vectors with recombinant internal ribosomal entry sites. 
  • Genital herpes evaluation by quantitative TaqMan PCR: correlating single detection and quantity of HSV-2 DNA in cervicovaginal lavage fluids with cross-sectional and longitudinal clinical data. 
  • Genome nucleotide lengths that are divisible by six are not essential but enhance replication of defective interfering RNAs of the paramyxovirus simian virus 5. 
  • Genome-Wide Significant Association of the GM 23 Allotype with gp120-Specific IgG2 Titers in an Efficacy Trial of AIDSVAX B/B 
  • Genome-wide Association Study for HIV-1 Heterosexual Acquisition and Plasma HIV Set Point Among African Serodiscordant Couples 
  • Germline-targeting and Reverse Engineering to Elicit CH235.12 Lineage bNAbs 
  • Global Epidemiology of HIV Among Women and Girls Who Use or Inject Drugs: Current Knowledge and Limitations of Existing Data. 
  • Global Epidemiology of HIV Infection and Related Syndemics Affecting Transgender People. 
  • Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata. 
  • Global estimates and epidemiology of HIV-1 infections and AIDS: further heterogeneity in spread and impact. 
  • Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. 
  • Glomerular filtration rate estimated using creatinine, cystatin C or both markers and the risk of clinical events in HIV-infected individuals. 
  • Glycan binding avidity determines the systemic fate of adeno-associated virus type 9. 
  • Glycoengineering HIV-1 Env Creates "Supercharged" and "Hybrid" Glycans to Increase Neutralizing Antibody Potency, Breadth and Saturation 
  • Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation. 
  • Glycoprotein B of human herpesvirus 8 is a component of the virion in a cleaved form composed of amino- and carboxyl-terminal fragments. 
  • Glycosaminoglycan binding properties of natural venezuelan equine encephalitis virus isolates. 
  • Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers. 
  • Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge. 
  • Group-specific antigenic determinants of the large envelope glycoprotein of avian oncornaviruses. 
  • Growth failure and AIDS-like cachexia syndrome in HIV-1 transgenic mice. 
  • Growth patterns reflect response to antiretroviral therapy in HIV-positive infants: potential utility in resource-poor settings. 
  • Growth phenotypes and biosafety profiles in poliovirus-receptor transgenic mice of recombinant oncolytic polio/human rhinoviruses. 
  • Guidance for Providing Informed-Choice Counseling on Sexual Health for Women Interested in Pre-Exposure Prophylaxis in Kenya and South Africa. 
  • Gut microbiota dysbiosis is associated with worse emotional states in HIV infection. 
  • H5-type influenza virus hemagglutinin is functionally recognized by the natural killer-activating receptor NKp44. 
  • HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques. 
  • HIV ENV-SPECIFIC IGG3 RESPONSES ARE DIFFERENTIALLY ELICITED IN NONHUMAN PRIMATE BY ENV VACCINES WITH DIFFERENT ADJUVANTS 
  • HIV Neutralization in Breast Milk Mirrors that of Plasma and Is Mainly Mediated by IgG Antibodies 
  • HIV Neutralizing Antibodies Induced by Native-like Envelope Trimers Incorporated Into a Rhabdoviral Vector Vaccine 
  • HIV Preexposure Prophylaxis Implementation at Local Health Departments: A Statewide Assessment of Activities and Barriers. 
  • HIV Prevention Among Transgender Populations: Knowledge Gaps and Evidence for Action. 
  • HIV Prevention in a Time of COVID-19: A Report from the HIVR4P // Virtual Conference 2021. 
  • HIV Research for Prevention 2018: From Research to Impact Conference Summary and Highlights. 
  • HIV Resistance and Prevention of Mother-to-Child Transmission Regimen in HIV-Infected Infants in Northern Tanzania. 
  • HIV Testing and PrEP Use in a National Probability Sample of Sexually Active Transgender People in the United States. 
  • HIV Transmission Patterns Among Immigrant Latinos Illuminated by the Integration of Phylogenetic and Migration Data. 
  • HIV and noncommunicable cardiovascular and pulmonary diseases in low- and middle-income countries in the ART era: what we know and best directions for future research. 
  • HIV and the aging kidney. 
  • HIV antibodies and vaccine design. 
  • HIV drug resistance in a cohort of HIV-infected MSM in the United States. 
  • HIV epidemics among transgender women. 
  • HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. 
  • HIV fusion and its inhibition. 
  • HIV immune reconstitution syndrome in sub-Saharan Africa. 
  • HIV infection in young men in northern Thailand, 1991-1998: increasing role of injection drug use. 
  • HIV infection-induced transcriptional program in renal tubular epithelial cells activates a CXCR2-driven CD4+ T-cell chemotactic response. 
  • HIV medical care provider practices for reducing high-risk sexual behavior: results of a qualitative study. 
  • HIV on the brain: is neurosignalling damage irreversible even on antiretroviral therapy? 
  • HIV persistence in the gut mucosa of HIV-infected subjects undergoing antiretroviral therapy correlates with immune activation and increased levels of LPS. 
  • HIV prevalence and risks among injection and noninjection drug users in northern Thailand: need for comprehensive HIV prevention programs. 
  • HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multisite study. 
  • HIV testing in the emergency department 
  • HIV treatment cascade in MSM, people who inject drugs, and sex workers. 
  • HIV type 1 V3 region primer-induced antibody suppression is overcome by administration of C4-V3 peptides as a polyvalent immunogen. 
  • HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry. 
  • HIV type 1 subtypes in Malaysia, determined with serologic assays: 1992-1996. 
  • HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization, and quantitation. 
  • HIV viremia contributes to neurocognitive impairments in persons who use cocaine. 
  • HIV voluntary counseling and testing and HIV incidence in male injecting drug users in northern Thailand: evidence of an urgent need for HIV prevention. 
  • HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques. 
  • HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies. 
  • HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds. 
  • HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. 
  • HIV-1 Immune Complexes are part of the Initial B cell Response in Acute HIV-1 infection 
  • HIV-1 Infection Primes Macrophages Through STAT Signaling to Promote Enhanced Inflammation and Viral Replication. 
  • HIV-1 MPER-directed Broadly Neutralizing Antibodies from an Acute-infection Cohort RV217 Subject 
  • HIV-1 Nef induces dedifferentiation of podocytes in vivo: a characteristic feature of HIVAN. 
  • HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group. 
  • HIV-1 SPECIFIC CTL RESPONSES AMONG RECIPIENTS OF CANDIDATE AIDS VACCINES 
  • HIV-1 Specific Binding Antibody Titres in Blood Predict Detection in the Female Genital Tract in Women Who Became Infected in the CAPRISA 004 Microbicide 
  • HIV-1 Vaccine Elicited IgA and IgG Antibody Specificities 
  • HIV-1 Vpr activates cell cycle inhibitor p21/Waf1/Cip1: a potential mechanism of G2/M cell cycle arrest. 
  • HIV-1 Vpr activates the DNA damage response in renal tubule epithelial cells. 
  • HIV-1 co/super-infection in intravenous drug users 
  • HIV-1 drug resistance in antiretroviral-naive individuals with HIV-1-associated tuberculous meningitis initiating antiretroviral therapy in Vietnam. 
  • HIV-1 dynamics in haemodialysis patients. 
  • HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. 
  • HIV-1 envelope glycoprotein trimers display open quaternary conformation when bound to the gp41 membrane-proximal external-region-directed broadly neutralizing antibody Z13e1. 
  • HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development. 
  • HIV-1 extrachromosomal 2-LTR circular DNA is long-lived in human macrophages. 
  • HIV-1 gp120 V1V2-Scaffolds for Structural Analysis and Immunogen Design 
  • HIV-1 gp120 Vaccination Elicits a Robust and Durable Anti-V1/V2 IgG Response and Yet No HIV-1 Env-Specific IgA Response in HIV-Exposed Infants 
  • HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine. 
  • HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. 
  • HIV-1 infected women and prenatal care utilization: barriers and facilitators. 
  • HIV-1 infection in the lymphoid organs. 
  • HIV-1 infection initiates an inflammatory cascade in human renal tubular epithelial cells. 
  • HIV-1 infection of renal epithelial cells: 30 years of evidence from transgenic animal models, human studies and in vitro experiments. 
  • HIV-1 infection of the kidney: mechanisms and implications. 
  • HIV-1 infection stimulates T cell invasiveness and synthesis of the 92-kDa type IV collagenase. 
  • HIV-1 intrapatient sequence diversity in the immunogenic V3 region. 
  • HIV-1 neutralizing monoclonal antibodies induced by a synthetic peptide. 
  • HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells. 
  • HIV-1 sequence subtype D in the United States. 
  • HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers. 
  • HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. 
  • HIV-1 viral protein r induces ERK and caspase-8-dependent apoptosis in renal tubular epithelial cells. 
  • HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. 
  • HIV-1-specific antibody responses during acute and chronic HIV-1 infection. 
  • HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. 
  • HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine. 
  • HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies. 
  • HIV-specific health care utilization and mortality among tuberculosis/HIV coinfected persons. 
  • HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates. 
  • HIV/HCV-coinfected natural viral suppressors have better virologic responses to PEG-IFN and ribavirin than ARV-treated HIV/HCV patients. 
  • HLA Class II Genes Interact with the Immune Correlates from the RV144 Vaccine Efficacy Trial and Impact HIV-1 Acquisition 
  • HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. 
  • HTLV REACTIVITY IN NORMAL POPULATION OF SOUTHERN APULIA (ITALY) 
  • HTLV-II Establishes a Persistent Infection in Rhesus Macaques and Does Not Exacerbate SIV Infection 
  • HTPN 078: an enhanced case management study to achieve viral suppression among viremic HIV-positive men who have sex with men in the United States. 
  • HVTN 097: Evaluation of the RV144 Vaccine Regimen in HIV Uninfected South African Adults 
  • HVTN 505: Efficacy of a Multi-Gene DNA Prime/Recombinant Adeno 5 (rAd5) Vector Boost Vaccine in Men & Transgender Women (TGW) Who Have Sex with Men 
  • HVTN114: A Phase 1 Trial to Evaluate Late Boosts With AIDSVAX B/E of Participants Previously Vaccinated With MVA/HIV62B in DNA/MVA or MVA Regimens 
  • Harnessing innate and adaptive immunity for viral vaccine design 
  • Harvard HIV and Aging Workshop: Perspectives and Priorities from Claude D. Pepper Centers and Centers for AIDS Research. 
  • Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. 
  • Health care utilization in HIV-infected patients: assessing the burden of hepatitis C virus coinfection. 
  • Health impact of incarceration on HIV-positive African American males: a qualitative exploration. 
  • Healthy-days time equivalents for outcomes of acute rotavirus infections. 
  • Heavy chain-only IgG2b llama antibody effects near-pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of coreceptor- and CD4-binding sites. 
  • Helicobacter pylori and colorectal cancer-A bacterium going abroad? 
  • Helper Th1 and Th2 cell responses following mucosal or systemic immunization with cholera toxin. 
  • Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. 
  • Hemoglobinopathies: slicing the Gordian knot of Plasmodium falciparum malaria pathogenesis. 
  • Hepatic immunopathology during occult hepacivirus re-infection. 
  • Hepatitis B immunization: a potential incentive to HIV vaccine trial participation in Thailand? 
  • Hepatitis B vaccination and booster in predialysis patients: a 4-year analysis. 
  • Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy--pathogenesis and management. 
  • Hepatitis C Virus Infection Is Inhibited by a Noncanonical Antiviral Signaling Pathway Targeted by NS3-NS4A. 
  • Hepatitis C Virus. Strategies to Evade Antiviral Responses. 
  • Hepatitis C and the risk of kidney disease and mortality in veterans with HIV. 
  • Herpes Simplex Virus 1 Infection of Tree Shrews Differs from That of Mice in the Severity of Acute Infection and Viral Transcription in the Peripheral Nervous System. 
  • Herpes simplex virus proteins ICP27 and UL47 associate with polyadenylate-binding protein and control its subcellular distribution. 
  • Herpesvirus saimiri transformation of HIV type 1 suppressive CD8+ lymphocytes from an HIV type 1-infected asymptomatic individual. 
  • Heterogeneity in codon usages of sobemovirus genes. 
  • Heterogeneity of Anti-V2 ADCC Ab Responses and Implications for Vaccine Development 
  • Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. 
  • Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. 
  • Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectors. 
  • Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. 
  • High Affinity Recognition of Synthetic Glycopeptides by HIV-1 gp120 V1V2 Loop Broadly Neutralizing Antibodies and Their Unmutated Common Ancestors 
  • High HIV, hepatitis C and sexual risks among drug-using men who have sex with men in northern Thailand. 
  • High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. 
  • High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. 
  • High Psychosocial Burden Relates to Poorer Antiretroviral Treatment Adherence Among Black/African American People with HIV. 
  • High magnitude and multifunctionality epitope-specific CD8+T-cell responses are associated are associated with selection of escape mutants in acute HIV infection 
  • High rates of AIDS-related mortality among older adults in rural Kenya. 
  • High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. 
  • High throughput functional analysis of HIV-1 env genes without cloning. 
  • High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. 
  • High titers of cross-clade ADCC-mediating antibodies are detectable in plasma samples collected from individuals with broadly neutralizing antibodies 
  • High-Frequency Illegitimate Strand Transfers of Nascent DNA Fragments During Reverse Transcription Result in Defective Retrovirus Genomes. 
  • High-density binding to Plasmodium falciparum circumsporozoite protein repeats by inhibitory antibody elicited in mouse with human immunoglobulin repertoire. 
  • High-level synthesis of biologically active reovirus protein sigma 1 in a mammalian expression vector system. 
  • High-level, lasting antiviral immunity induced by a bimodal AIDS vaccine and boosted by live-virus exposure: prevention of viremia. 
  • High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection. 
  • High-resolution deep sequencing reveals biodiversity, population structure, and persistence of HIV-1 quasispecies within host ecosystems. 
  • High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. 
  • Higher HIV Neutralization Breadth in Young Children Than in Chronically Infected Adults 
  • Higher soluble CD14 levels are associated with lower visuospatial memory performance in Youth with HIV (YWH). 
  • Highly Complex Neutralization Determinants on a Monophyletic Lineage of Newly Transmitted Subtype C HIV-1 Env Clones from India 
  • Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. 
  • Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. 
  • Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. 
  • Hijacked: Co-option of host behavior by entomophthoralean fungi. 
  • Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies. 
  • Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus. 
  • Horsepox: Framing a dual use research of concern debate. 
  • Host genetic variation in susceptibility to Punta Toro virus. 
  • Host response to Chikungunya virus and perspectives for immune-based therapies 
  • Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. 
  • Hsp90: A key target in HIV infection 
  • Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization. 
  • Human FcRn expression and Type I Interferon signaling control Echovirus 11 pathogenesis in mice. 
  • Human HIV-1 Vaccine Induced Antibody Durability and Env IgG3 Responses 
  • Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge. 
  • Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. 
  • Human T-cell leukemia virus type 1 tax attenuates the ATM-mediated cellular DNA damage response. 
  • Human cytomegalovirus US2 endoplasmic reticulum-lumenal domain dictates association with major histocompatibility complex class I in a locus-specific manner. 
  • Human epithelial cell expression of an Epstein-Barr virus receptor. 
  • Human galectin 3 binding protein interacts with recombinant adeno-associated virus type 6. 
  • Human genome-wide RNAi screen identifies an essential role for inositol pyrophosphates in Type-I interferon response. 
  • Human herpesvirus 6 polymerase chain reaction findings in human immunodeficiency virus associated neurological disease and multiple sclerosis. 
  • Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. HIV Surrogate Marker Collaborative Group. 
  • Human immunodeficiency virus type 1 Tat activity in human neuronal cells: uptake and trans-activation. 
  • Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. 
  • Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. 
  • Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3',3'-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag. 
  • Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. 
  • Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. 
  • Human immunodeficiency virus vaccine development in developing countries: are efficacy trials feasible? 
  • Human immunodeficiency virus vaccines. 
  • Human papillomavirus (HPV), HPV-associated oropharyngeal cancer, and HPV vaccine in the United States--do we need a broader vaccine policy? 
  • Human papillomavirus vaccine uptake among teens before and during the COVID-19 pandemic in the United States. 
  • Hurdles to herd immunity: Distrust of government and vaccine refusal in the US, 2002-2003. 
  • Hyperexpansion of Functional Viral-Specific CD8+ T Cells in Lymphopenia-Associated MCMV Pneumonitis. 
  • Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings. 
  • Hypertension Control and Retention in Care Among HIV-Infected Patients: The Effects of Co-located HIV and Chronic Noncommunicable Disease Care. 
  • Hypoactivation in the precuneus and posterior cingulate cortex during ambiguous decision making in individuals with HIV. 
  • Hypoxia-inducible factor-1α plays roles in Epstein-Barr virus's natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter. 
  • ICP34.5-dependent and -independent activities of salubrinal in herpes simplex virus-1 infected cells. 
  • IFN-gamma production in response to neuropathogenic Cas-Br-M murine leukemia virus infection. 
  • IL-10 levels in Dengue patients: some findings from the exceptional epidemiological conditions in Cuba. 
  • IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques. 
  • IL-12/GM-CSF coadministration in an SIV DNA prime/protein boost protocol enhances Gag-specific T cells but not virus-specific neutralizing antibodies in rhesus macaques. 
  • IL-17 contributes to neutrophil recruitment but not to control of viral replication during acute mouse adenovirus type 1 respiratory infection. 
  • IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. 
  • IL28B genotypes strongly influence early viral kinetics in HIV/HCV-coinfected patients treated with peginterferon-alpha/ribavirin - implications using directly acting antivirals 
  • IL28B genotypes strongly influence early viral kinetics in HIV/HCV-coinfected patients treated with peginterferon-alpha/ribavirin - implications using directly acting antivirals 
  • IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin. 
  • INDUCTION OF BROADLY CROSS-REACTIVE HIV NEUTRALIZING ANTIBODIES IN PRIMATES USING A PRIME-BOOST REGIMEN OF HYBRID SYNTHETIC GP120 ENVELOPE PEPTIDES 
  • INDUCTION OF NEUTRALIZING ANTI-HIV ANTIBODIES IN GOATS AND RHESUS-MONKEYS WITH HYBRID SYNTHETIC PEPTIDES (T1-SP10) FROM HIV GP120 THAT CONTAIN EPITOPES RECOGNIZED BY BOTH T-CELLS AND B-CELLS 
  • IRG and GBP host resistance factors target aberrant, "non-self" vacuoles characterized by the missing of "self" IRGM proteins. 
  • ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV. 
  • Ideal cardiovascular health, biomarkers, and coronary artery disease in persons with HIV. 
  • Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. 
  • Identification of Amino Acid Residues in HIV-1 Envelope Targeted by Plasma Broadly Neutralizing Antibodies using Evolutionary Models 
  • Identification of B-chronic lymphocytic leukemia unmutated IgM germline antibodies that react with HIV-1 envelope gp41 epitopes 
  • Identification of CRF34_01B, a second circulating recombinant form unrelated to and more complex than CRF15_01B, among injecting drug users in northern Thailand. 
  • Identification of Determinants and Implementation Strategies to Increase PrEP Uptake Among Black Same Gender-Loving Men in Mecklenburg County, North Carolina: The PrEP-MECK Study. 
  • Identification of ENVS that preferentially bind the cross-reactive neutralizing Ab in chronic patient sera 
  • Identification of HIV-1 genitourinary tract compartmentalization by analyzing the env gene sequences in urine. 
  • Identification of Three Distinct Epitope Regions in the V2 Portion of gp120 
  • Identification of Transmitted/Founder Complete HIV-1 Genomes in Subjects with Acute HIV-1 Infection 
  • Identification of a 20,000-dalton protein in SSV-transformed nonproducer cells. 
  • Identification of a synthetic peptide that mimics an HIV glycoprotein 120 envelope conformational determinant exposed following ligation of glycoprotein 120 by CD4. 
  • Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120. 
  • Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes. 
  • Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models. 
  • Identification of cis-acting repressor activity within human immunodeficiency virus type 1 protease sequences. 
  • Identification of diverse papillomaviruses in captive black-and-white ruffed lemurs (Varecia variegata). 
  • Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses. 
  • Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate. 
  • Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines. 
  • Identification of personal lubricants that can cause rectal epithelial cell damage and enhance HIV type 1 replication in vitro. 
  • Identification of population at risk for future Clostridium difficile infection following hospital discharge to be targeted for vaccine trials. 
  • Identification of the orthopoxvirus p4c gene, which encodes a structural protein that directs intracellular mature virus particles into A-type inclusions. 
  • Illness Perceptions, Medication Beliefs, and Adherence to Antiretrovirals and Medications for Comorbidities in Adults With HIV Infection and Hypertension or Chronic Kidney Disease. 
  • Immune Correlates Identified in the RV144 Vaccine Efficacy Trial Impact HIV-1 Acquisition Only in the Presence of Certain HLA Class II Genes 
  • Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061. 
  • Immune Responses to PENNVAX-GP (R) HIV DNA Vaccine Plus IL-12 Are Equivalent or Superior When Delivered by Intradermal vs. Intramuscular Electroporation 
  • Immune correlates of protection for dengue: State of the art and research agenda. 
  • Immune failure in the absence of profound CD4+ T-lymphocyte depletion in simian immunodeficiency virus-infected rapid progressor macaques. 
  • Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking. 
  • Immune mechanisms responsible for vaccination against and clearance of mucosal and lymphatic norovirus infection. 
  • Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. 
  • Immunization against SIVmne in macaques using multigenic DNA vaccines. 
  • Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. 
  • Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. 
  • Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques. 
  • Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. 
  • Immunization with the Haemophilus ducreyi trimeric autotransporter adhesin DsrA with alum, CpG or imiquimod generates a persistent humoral immune response that recognizes the bacterial surface. 
  • Immunodominance and cross-reactivity of B5703-restricted CD8 T lymphocytes from HIV type 1 subtype C-infected Ethiopians. 
  • Immunogenic determinants of a neuropathogenic murine leukemia virus. 
  • Immunogenicity and Neutralization Properties of a Trimeric MPER Containing gp41 Antigen 
  • Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. 
  • Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older. 
  • Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study. 
  • Immunogenicity in Rabbits of HIV-1 SOSIP Trimers from Clades A, B, and C, Given Individually, Sequentially, or in Combination. 
  • Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells. 
  • Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection. 
  • Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. 
  • Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen. 
  • Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. 
  • Immunogenicity of a vaccine regimen composed of simian immunodeficiency virus DNA, rMVA, and viral particles administered to female rhesus macaques via four different mucosal routes. 
  • Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins. 
  • Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state. 
  • Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque. 
  • Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. 
  • Immunologic Change over 72 Weeks Following Raltegravir- Versus Efavirenz-Based Therapy in HIV/HCV-Coinfected Individuals in Vietnam. 
  • Immunologic and virologic analyses of an acutely HIV type 1-infected patient with extremely rapid disease progression. 
  • Immunologic, virologic, and pharmacologic characterization of the female upper genital tract in HIV-infected women. 
  • Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. 
  • Immunological properties of avian oncornavirus polypeptides. 
  • Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. 
  • Immunoregulation of HIV-1 broadly neutralizing antibody responses: deciphering maturation paths for antibody induction 
  • Impact of Bacterial and Human Genetic Variation on Staphylococcus aureus Infections. 
  • Impact of HIV on lung tumorigenesis in an animal model. 
  • Impact of HLA in mother and child on disease progression of pediatric human immunodeficiency virus type 1 infection. 
  • Impact of Microbiota on Resistance to Ocular Pseudomonas aeruginosa-Induced Keratitis. 
  • Impact of Simian Immunodeficiency Virus Infection on Chimpanzee Population Dynamics. 
  • Impact of Th1 CD4 Follicular Helper T Cell Skewing on Antibody Responses to an HIV-1 Vaccine in Rhesus Macaques. 
  • Impact of Vaccine Regimen on Vaccine-induced Antibody Durability 
  • Impact of a TLR-5 Ligand as Adjuvant on Immunogenicity and Efficacy of a RhCMV-SIV Vaccine 
  • Impact of a combined pediatric and adult pneumococcal immunization program on adult pneumonia incidence and mortality in Nicaragua. 
  • Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies. 
  • Impact of early life exposure to ionizing radiation on influenza vaccine response in an elderly Japanese cohort. 
  • Impact of genotypic resistance testing on physician selection of antiretroviral therapy. 
  • Impact of immediate initiation of antiretroviral therapy on HIV patient satisfaction. 
  • Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome. 
  • Impact on genetic networks in human macrophages by a CCR5 strain of human immunodeficiency virus type 1. 
  • Impaired systemic tetrahydrobiopterin bioavailability and increased dihydrobiopterin in adult falciparum malaria: association with disease severity, impaired microvascular function and increased endothelial activation. 
  • Impaired systemic tetrahydrobiopterin bioavailability and increased oxidized biopterins in pediatric falciparum malaria: association with disease severity. 
  • Implication of gut microbiota in nonalcoholic fatty liver disease. 
  • Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. 
  • Importance of a c-Myb binding site for lymphomagenesis by the retrovirus SL3-3. 
  • Importance of neutralization sieve analyses when seeking correlates of HIV-1 vaccine efficacy. 
  • Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on the Middle East respiratory syndrome coronavirus spike glycoprotein to avoid neutralization escape 
  • Improved DNA vaccination achieves long-lasting immune responses in macaques 
  • Improved Induction of Antibodies against Key Neutralizing Epitopes by HIV-1 gp120 DNA Prime-Protein Boost Compared to gp120 Protein Only Vaccination 
  • Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. 
  • Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen. 
  • Improvement of humoral immune responses in macaques using DNA/viral particle combination vaccine 
  • Improving Depression Among HIV-Infected Adults: Transporting the Effect of a Depression Treatment Intervention to Routine Care. 
  • Improving immunization data quality in Peru and Mexico: Two case studies highlighting challenges and lessons learned 
  • Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. 
  • In Vivo Gene Transfer Using a Nonprimate Lentiviral Vector Pseudotyped with Ross River Virus Glycoproteins 
  • In Vivo Profiling of Individual Multiciliated Cells during Acute Influenza A Virus Infection. 
  • In Vivo Targeting of HIV Gag to Dendritic Cells Given with Poly ICLC Is Safe and Induces Durable CD4 T Cell and B Cell Responses in Healthy Volunteers 
  • In vitro assays for detecting neutralizing and fusion-inhibiting antibodies to SIVMAC251. 
  • In vitro chick embryo cell response to strain MC29 avian leukosis virus. 
  • In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome. 
  • In vivo attenuation of simian immunodeficiency virus by disruption of a tyrosine-dependent sorting signal in the envelope glycoprotein cytoplasmic tail. 
  • In vivo bioluminescent imaging of influenza a virus infection and characterization of novel cross-protective monoclonal antibodies. 
  • In vivo genetic variability of the human immunodeficiency virus type 2 V3 region. 
  • In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. 
  • In vivo protein expression and immune responses generated by DNA vaccines expressing mycobacterial antigens fused with a reporter protein. 
  • In vivo targeting of HIV gag to dendritic cells in combination with poly ICLC is safe and immunogenic in healthy volunteers 
  • In-home mental health treatment for individuals with HIV. 
  • Inability of Simian Virus 40 To Establish Productive Infection of Lymphoblastic Cell Lines 
  • Inactivated whole SIV vaccine in macaques: evaluation of protective efficacy against challenge with cell-free virus or infected cells. 
  • Inactivation of murine xenotropic oncornavirus by normal mouse sera is not immunoglobulin-mediated. 
  • Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease. 
  • Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. 
  • Incidence of CKD with TDF and non-TDF containing antiretroviral regimens by baseline D:A:D CKD risk in people living with HIV (PLWH) 
  • Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge. 
  • Incorporating Acute HIV Screening into Routine HIV Testing at Sexually Transmitted Infection Clinics, and HIV Testing and Counseling Centers in Lilongwe, Malawi. 
  • Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles. 
  • Increase in Env-specific Binding Antibody and CD4+T Cell-responses After Month 30 Boost of gp120/MF59 Delivered Alone or With ALVAC-HIV 
  • Increased Breadth of T-cell Responses After Mosaic HIV Vaccination in Humans (HVTN 106) 
  • Increased HIV-1 Immunogenicity of Replication Competent NYVAC 
  • Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice. 
  • Increased asymmetric dimethylarginine in severe falciparum malaria: Association with impaired nitric oxide bioavailability and fatal outcome 
  • Increased asymmetric dimethylarginine in severe falciparum malaria: association with impaired nitric oxide bioavailability and fatal outcome. 
  • Increased circulating interleukin-7 levels in HIV-1-infected women. 
  • Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses. 
  • Increased expression of alpha 4 beta 1 and alpha 5 beta 1 integrins on HTLV-I-infected lymphocytes. 
  • Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF. 
  • Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine. 
  • Increased loss of CCR5+ CD45RA- CD4+ T cells in CD8+ lymphocyte-depleted Simian immunodeficiency virus-infected rhesus monkeys. 
  • Increased mtDNA levels without change in mitochondrial enzymes in peripheral blood mononuclear cells of infants born to HIV-infected mothers on antiretroviral therapy. 
  • Increased predominance of HIV-1 CRF01_AE and its recombinants in the Philippines. 
  • Increased replication of non-syncytium-inducing HIV type 1 isolates in monocyte-derived macrophages is linked to advanced disease in infected children. 
  • Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization. 
  • Increased, Durable B-Cell and ADCC Responses Associated with T-Helper Cell Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site. 
  • Increasing vaccine potency through exosome antigen targeting. 
  • Independent variation and positive selection in env V1 and V2 domains within maternal-infant strains of human immunodeficiency virus type 1 in vivo. 
  • Indirect activation of rhesus macaque (Macaca mulatta) NK cells in oral and mucosal draining lymph nodes. 
  • Induction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate. 
  • Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins. 
  • Induction of Antibodies with Long Variable Heavy Third Complementarity Determining Regions by Repetitive Boosting with AIDSVAX® B/E in RV144 Vaccinees. 
  • Induction of Antiviral Cytidine Deaminases Does Not Explain the Inhibition of Hepatitis B Virus Replication by Interferons 
  • Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization. 
  • Induction of Neutralizing Antibodies Against Autologous Viruses in HIV-1 Infected Pregnant Women Immunized With a gp120/160 Vaccine 
  • Induction of Plasma (TRAIL), TNFR-2, Fas Ligand and Plasma Microparticles After HIV-1 Transmission: Implications for HIV-1 Vaccine Design. 
  • Induction of a nonproductive conformational change in gp120 by a small molecule HIV type 1 entry inhibitor. 
  • Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains. 
  • Induction of antibodies with specificity for gp41 neutralizing epitopes by membrane anchored gp41 immunogens 
  • Induction of cytotoxic T cell responses in newborn mice by DNA immunization. 
  • Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. 
  • Induction of mucosal antibody responses by microsphere-encapsulated formalin-inactivated simian immunodeficiency virus in a male urethral challenge model. 
  • Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization. 
  • Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A. 
  • Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques. 
  • Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design. 
  • Induction of primary, antiviral cytotoxic, and proliferative responses with antigens administered via dendritic cells. 
  • Induction of viral, 7-methyl-guanosine cap-independent translation and oncolysis by mitogen-activated protein kinase-interacting kinase-mediated effects on the serine/arginine-rich protein kinase. 
  • Infant Peripartum Transmitted-founder HIV-1 Variants are Resistant to Autologous Maternal Plasma Neutralization 
  • Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy. 
  • Infant transmitted/founder HIV-1 viruses from peripartum transmission are neutralization resistant to paired maternal plasma. 
  • Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes. 
  • Infection of the HTLV-II-bearing T-cell line C3 with HTLV-III/LAV is highly permissive and lytic. 
  • Infectious mononucleosis patients temporarily recognize a unique, cross-reactive epitope of Epstein-Barr virus nuclear antigen-1. 
  • Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. 
  • Inflammasome expression and cytomegalovirus viremia in critically ill patients with sepsis. 
  • Influence of NK Cells and NK Cell Receptor Polymorphisms in the Assessment of HIV-1 Neutralization 
  • Influence of antisera to oncornavirus glycoprotein (gp71) on infections of cats with feline leukemia virus. 
  • Influence of mast cells on dengue protective immunity and immune pathology. 
  • Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses. 
  • Influenza A virus segments five and six can harbor artificial introns allowing expanded coding capacity. 
  • Influenza vaccination in children with neurologic or neurodevelopmental disorders. 
  • Influenza vaccine acceptance and hesitancy among adults hospitalized with severe acute respiratory illnesses, United States 2019-2020. 
  • Influenza viruses that require 10 genomic segments as antiviral therapeutics. 
  • Infrequent Transmission of HIV-1 Drug-Resistant Variants 
  • Inhibition of HIV type 1 infection of mononuclear phagocytes by anti-CD44 antibodies. 
  • Inhibition of HIV-1 Entry by Inducing a Nonproductive Conformational Change in gp120 
  • Inhibition of Human Adenovirus Replication by the Importin α/β1 Nuclear Import Inhibitor Ivermectin. 
  • Inhibition of Rev activity and human immunodeficiency virus type 1 replication by antisense oligodeoxynucleotide phosphorothioate analogs directed against the Rev-responsive element. 
  • Inhibition of adaptive immune responses leads to a fatal clinical outcome in SIV-infected pigtailed macaques but not vervet African green monkeys. 
  • Inhibition of an inflammatory response is mediated by a 38-kDa protein of cowpox virus. 
  • Inhibition of histone deacetylases modulates CD8+T-lymphocyte mediated virus suppression by HIV-1 viral controllers 
  • Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. 
  • Inhibition of interleukin-2 and interferon-gamma by an HIV-1 Nef-encoded synthetic peptide. 
  • Inhibition of nitric oxide synthesis increases mortality in Sindbis virus encephalitis. 
  • Inhibition of poxvirus growth by Terameprocol, a methylated derivative of nordihydroguaiaretic acid. 
  • Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission. 
  • Inhibitory effects of vesicular stomatitis virus on cellular and influenza viral RNA metabolism and protein synthesis. 
  • Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. 
  • Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication. 
  • Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors. 
  • Initiation & completion rates of hepatitis A vaccination among US pediatric populations born between 2005 and 2009. 
  • Initiation of Neutralizing Antibody B Cell Lineages by HIV Vaccine Candidates 
  • Initiation of bacteriophage T4 DNA replication and replication fork dynamics: a review in the Virology Journal series on bacteriophage T4 and its relatives. 
  • Innate antimicrobial immunity in the skin: A protective barrier against bacteria, viruses, and fungi. 
  • Innate immune responses in acute HIV-1 infection: protective or pathogenic? 
  • Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk. 
  • Insomnia in HIV-infected patients: pathophysiologic implications. 
  • Integrated Treatment for Smoking Cessation, Anxiety, and Depressed Mood in People Living With HIV: A Randomized Controlled Trial. 
  • Integration Site Choice of a Feline Immunodeficiency Virus Vector 
  • Interaction of Cryptococcus neoformans Rim101 and protein kinase A regulates capsule. 
  • Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. 
  • Interactions between cellular actin and human respiratory syncytial virus (HRSV). 
  • Interactions between copper homeostasis and the fungal cell wall affect copper stress resistance. 
  • Interactions of plus and minus strand leader RNAs of the New Jersey serotype of vesicular stomatitis virus with the cellular La protein. 
  • Interferon-Inducible CD169/Siglec1 Attenuates Anti-HIV-1 Effects of Alpha Interferon. 
  • Interferon-dependent immunoproteasome activity during mouse adenovirus type 1 infection. 
  • Interferon-gamma Responses to HIV-1 Clade A and D Peptides in Ugandan Serodiscordant Couples - the CHAVI 002 Protocol 
  • Interferon-inducible mechanism of dendritic cell-mediated HIV-1 dissemination is dependent on Siglec-1/CD169. 
  • Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo. 
  • Interleukin-2 immunotherapy and AIDS-related cytomegalovirus retinitis. 
  • Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline. 
  • Interplay between Furin and Sialoglycans in Modulating Adeno-Associated Viral Cell Entry. 
  • Interruption of antiretroviral therapy is associated with increased plasma cystatin C. 
  • Interruptions in HIV Prevention and Treatment Due to the COVID-19 Pandemic: A Cross-sectional Study of Transgender and Gender Nonbinary Adults in the U.S. 
  • Interspecies determinants of Friend leukemia virus antigens involved in cytolysis of virus-pfoducing cells. 
  • Interspecies reactivity of type C and D retrovirus p 15E and p 15C proteins. 
  • Intervening sequence between the leader region and the nucleopcapsid gene of vesicular stomatitis virus RNA. 
  • Interventions Designed to Improve HIV Continuum of Care Outcomes for Persons with HIV in Contact with the Carceral System in the USA. 
  • Interventions to improve adherence to antiretroviral therapy 
  • Intestinal Commensal Bacteria Shape the Pre-transmission Antibody Repertoire to HIV-1 Infection 
  • Intestinal Serum amyloid A suppresses systemic neutrophil activation and bactericidal activity in response to microbiota colonization. 
  • Intestinal parasites and HIV infection in Tanzanian children with chronic diarrhea. 
  • Intra-seasonal antibody repertoire analysis of a subject immunized with an MF59®-adjuvanted pandemic 2009 H1N1 vaccine. 
  • Intracellular cleavage of an SSV coded gag-related protein. 
  • Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial. 
  • Intranasal delivery of an adjuvanted modified live porcine reproductive and respiratory syndrome virus vaccine reduces ROS production. 
  • Intranasal delivery of whole cell lysate of Mycobacterium tuberculosis induces protective immune responses to a modified live porcine reproductive and respiratory syndrome virus vaccine in pigs. 
  • Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. 
  • Introduction 
  • Introduction 
  • Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS. 
  • Irgm1-deficiency leads to myeloid dysfunction in colon lamina propria and susceptibility to the intestinal pathogen Citrobacter rodentium. 
  • Is developing an HIV-1 vaccine possible? 
  • Isolation and Characterization of an Autoreactive CD4bs Broad Neutralizing Antibody from a Chronic HIV-1 Controller with Systemic Lupus Erythematosus 
  • Isolation and characterization of two group-specific antigens from feline leukemia virus. 
  • Isolation of CD4-Binding Site and V2/V3 Conformational (Quaternary) Broadly Neutralizing Antibodies from the Same HIV-1 Infected African Subject 
  • Isolation of Human Monoclonal Antibodies from HIV-Uninfected Subjects Immunized with gp120/NefTat/AS01B by Dual-Color Antigen-Specific B Cell Sorting 
  • Isolation of a clonal lineage of IgA broadly neutralizing antibodies from a chronically infected Tanzanian subject 
  • Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. 
  • Isolation of cowpox virus A-type inclusions and characterization of their major protein component. 
  • Isolation of mAbs from Sorted Single B Cells by RT/PCR for Analysis of B Cell Responses to HIV-1 MPER Epitope in Vaccinated Rhesus Macaques 
  • Isolation of two subgroup-specific leukemogenic viruses from standard avian myeloblastosis virus. 
  • Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. 
  • Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. 
  • Jaagsiekte Sheep Retrovirus Env Protein Stabilizes Retrovirus Vectors against Inactivation by Lung Surfactant, Centrifugation, and Freeze-Thaw Cycling 
  • Japanese encephalitis virus and its mechanisms of neuroinvasion. 
  • Key harm reduction interventions and their impact on the reduction of risky behavior and HIV incidence among people who inject drugs in low-income and middle-income countries. 
  • Key stakeholder perspectives on challenges and opportunities for rural HPV vaccination in North and South Carolina. 
  • Kidney and central nervous system as reservoirs of HIV infection. 
  • Kidney disease in antiretroviral-naïve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. 
  • Kidney injury biomarkers during exposure to tenofovir-based preexposure prophylaxis. 
  • Kinetics of expansion of SIV Gag-specific CD8+ T lymphocytes following challenge of vaccinated macaques. 
  • Kinetics of pneumococcal antibodies among HIV-exposed, uninfected infants in Botswana. 
  • Kinetics of poliovirus uncoating in HeLa cells in a nonacidic environment. 
  • Knowledge of the Centers for Disease Control and Prevention's 2006 routine HIV testing recommendations among New York City internal medicine residents. 
  • LAB/NTAL facilitates fungal/PAMP-induced IL-12 and IFN-γ production by repressing β-catenin activation in dendritic cells. 
  • LMP-420, a small-molecule inhibitor of TNF-alpha, reduces replication of HIV-1 and Mycobacterium tuberculosis in human cells. 
  • La autoantigen enhances and corrects aberrant translation of poliovirus RNA in reticulocyte lysate. 
  • Lack of B cell dysfunction is associated with functional, gp120-dominant antibody responses in breast milk of simian immunodeficiency virus-infected African green monkeys. 
  • Lack of Highly Poly-Functional Epitope-Specific CD8+Memory T Cell Responses during Spontaneous Control of Viremia 
  • Lack of IgA envelope-reactive antibody producing cells in terminal ileum in early and chronic HIV-1 infection 
  • Lack of enhancing effect of human anti-human immunodeficiency virus type 1 (HIV-1) antibody on HIV-1 infection of human blood monocytes and peritoneal macrophages. 
  • Lack of evidence for VPg priming of poliovirus RNA synthesis in the host factor-dependent in vitro replicase reaction. 
  • Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection. 
  • Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120. 
  • Lessons learned from human HIV vaccine trials. 
  • Levels of circulating myeloid subpopulations and of heme oxygenase-1 do not predict CD4(+) T cell recovery after the initiation of antiretroviral therapy for HIV disease. 
  • Leveraging Phylogenetics to Understand HIV Transmission and Partner Notification Networks. 
  • Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen. 
  • Limited effects of Muc1 deficiency on mouse adenovirus type 1 respiratory infection. 
  • Limited introductions and genetic variation of HIV-1 in a MSM cohort in China 
  • Lipid Components in MPER-Based Immunization Regimens Are Critical for Inducing Broadly Neutralizing Antibody Responses in 2F5 and 4E10 Knockin Mice 
  • Lipid changes associated with antiretroviral therapy: results differ by reporting approach. 
  • Lipid raft- and SRC family kinase-dependent entry of coxsackievirus B into human placental trophoblasts. 
  • Live attenuated rubella vectors expressing SIV and HIV vaccine antigens replicate and elicit durable immune responses in rhesus macaques. 
  • Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251. 
  • Local immune dysregulation and subsequent inflammatory response contribute to pulmonary edema caused by Enterovirus infection in mice. 
  • Local production of HIV variants in breast milk of chronically HIV-infected, lactating women 
  • Localization of RNA tumor virus polypeptides. I. Isolation of further virus substructures. 
  • Localization of a baculovirus-induced chitinase in the insect cell endoplasmic reticulum. 
  • Location and role of free cysteinyl residues in the Sindbis virus E1 and E2 glycoproteins. 
  • Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. VA Cooperative Study Group on AIDS Treatment. 
  • Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines. 
  • Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine. 
  • Long-term surviving influenza infected cells evade CD8+ T cell mediated clearance. 
  • Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge. 
  • Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants. 
  • Longitudinal HIV care outcomes by gender identity in the United States. 
  • Longitudinal analysis of leukocyte differentials in peripheral blood of patients with acute respiratory viral infections. 
  • Longitudinal analysis of the human antibody response to Chikungunya virus infection: implications for serodiagnosis and vaccine development. 
  • Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordance. 
  • Longitudinal patterns of initiation, persistence, and cycling on preexposure prophylaxis among female sex workers and adolescent girls and young women in South Africa. 
  • Looking for fungi in all the right places: screening for cryptococcal disease and other AIDS-related mycoses among patients with advanced HIV disease. 
  • Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. 
  • Loss of G(1)/S checkpoint in human immunodeficiency virus type 1-infected cells is associated with a lack of cyclin-dependent kinase inhibitor p21/Waf1. 
  • Loss of the perforin cytotoxic pathway predisposes mice to experimental cytomegalovirus retinitis. 
  • Low Dose Mucosal SIV Infection Restricts Early Replication Kinetics and Transmitted Virus Variants in Rhesus Monkeys 
  • Low HIV seroincidence among female commercial sex workers: a barrier for measuring HIV vaccine efficacy. 
  • Low Levels of Physical Activity Among Older Persons Living with HIV/AIDS Are Associated with Poor Physical Function. 
  • Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. 
  • MAVS Coordination of Antiviral Innate Immunity. 
  • MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival. 
  • MECHANISM OF RESISTANCE OF HIV-1 AND SIV TO COMPLEMENT LYSIS - THE ROLE OF ANTI-CELL ANTIBODIES IN VACCINE PROTECTION 
  • MF59 and ALUM, in Combination with an ALVAC-SIV/gp120 Vaccine, Induce Plasmablasts that Differ in the Expression of Homing Markers 
  • MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group. 
  • MOSAIC VACCINES ELICIT CD8+T CELL RESPONSES IN MONKEYS THAT CONFER IMMUNE COVERAGE OF DIVERSE HIV STRAINS 
  • MVA-expressed gp140 Boosts More Durable V1/V2 and gp120 Antibody Responses than gp120 Protein in Alum 
  • Macaque SHIV Induction of 2G12-like Broadly Neutralizing Antibodies 
  • Machine learning prediction of neurocognitive impairment among people with HIV using clinical and multimodal magnetic resonance imaging data. 
  • Macrophage activation associated with chronic murine cytomegalovirus infection results in more severe experimental choroidal neovascularization. 
  • Magnitude and Breadth of the Neutralizing Antibody Response in RV144 
  • Magnitude, Breadth and Duration of HIV-1 Vaccine-Elicited Neutralizing Antibody Responses 
  • Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses. 
  • Malaria vaccine trials in pregnant women: An imperative without precedent. 
  • Malassezia fungi are specialized to live on skin and associated with dandruff, eczema, and other skin diseases. 
  • Mandelic acid condensation polymer: novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry. 
  • Many globally isolated AD hybrid strains of Cryptococcus neoformans originated in Africa 
  • Many globally isolated AD hybrid strains of Cryptococcus neoformans originated in Africa. 
  • Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. 
  • Mapping and Engineering Functional Domains of the Assembly-Activating Protein of Adeno-associated Viruses. 
  • Mapping of ADCC Activity: The A32 Conformational C1 Epitope is a Dominant Target for ADCC Antibodies in Chronically HIV-1 Infected Subjects 
  • Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins. 
  • Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. 
  • Marker rescue of adeno-associated virus (AAV) capsid mutants: a novel approach for chimeric AAV production. 
  • Mass Transport Theory Improves Compartmental PK Modeling of Microbicides and Helps Guide Product Science and Development. 
  • Massive CD8 T cell response to primary HIV infection in the setting of severe clinical presentation. 
  • Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk. 
  • Maternal antibody interference contributes to reduced rotavirus vaccine efficacy in developing countries. 
  • Maternal benefits of immunization during pregnancy. 
  • Maternal determinants of timely vaccination coverage among infants in rural Bangladesh. 
  • Maternal gatekeepers: How maternal antibody Fc characteristics influence passive transfer and infant protection. 
  • Mathematical models as research tools for HPV disease 
  • Measles Virus Hemagglutinin epitopes immunogenic in natural infection and vaccination are targeted by broad or genotype-specific neutralizing monoclonal antibodies. 
  • Measuring HIV-1 incidence in northern Thailand: Prospective cohort results and estimates based on early diagnostic tests 
  • Measuring Sensory Experiences Elicited by Product Properties During Receptive Anal Sex: Implications for Prevention Design and Marketing 
  • Mechanism of action and resistant profile of anti-HIV-1 coumarin derivatives. 
  • Mechanism of injury-provoked poliomyelitis. 
  • Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. 
  • Mechanistic Insights Into Vaccine Induction of V2 Apex-directed, Heterologous Tier 2 Neutralizing Responses in CH103 UCA Knock-in Mice 
  • Medical students' knowledge of HPV, HPV vaccine, and HPV-associated head and neck cancer. 
  • Medication adherence practices of HIV/AIDS case managers: a statewide survey in North Carolina. 
  • Meet our editorial board member 
  • Mental health and HIV sexual risk behavior among patrons of alcohol serving venues in Cape Town, South Africa. 
  • Metabolic Syndrome Among Antiretroviral Therapy-Naive Versus Experienced HIV-Infected Patients Without Preexisting Cardiometabolic Disorders in Western Kenya. 
  • Metabolic Syndrome and Neurocognitive Deficits in HIV Infection. 
  • Methylfolate Trap Promotes Bacterial Thymineless Death by Sulfa Drugs. 
  • MicroRNA-122 associates with serum apolipoprotein B but not liver fibrosis markers in CHC genotype 1 infection. 
  • Microalbuminuria is associated with all-cause and AIDS mortality in women with HIV infection. 
  • Microalbuminuria predicts overt proteinuria among patients with HIV infection. 
  • Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy. 
  • Microbicide-vaccine Combination Provides Significant Protection against Vaginal SHIV-162P3 Challenge in Cynomolgous Monkeys 
  • Microparticles and Apoptotic Cells Generated from Apoptotic T Cells Inhibit Human Dendritic Cell Cytokine Production 
  • Microplanning for designing vaccination campaigns in low-resource settings: A geospatial artificial intelligence-based framework. 
  • Mind the gap from research laboratory to clinic: Challenges and opportunities for next-generation assays in human diseases. 
  • Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview. 
  • Minor-drug-resistant HIV populations and treatment failure 
  • Mismatched dsRNA (ampligen) induces protection against genomic variants of the human immunodeficiency virus type 1 (HIV-1) in a multiplicity of target cells. 
  • Missed opportunities for religious organizations to support people living with HIV/AIDS: findings from Tanzania. 
  • Mitigation of variation observed in a peripheral blood mononuclear cell (PBMC) based HIV-1 neutralization assay by donor cell pooling. 
  • Mitogen-activated protein kinase-interacting kinase regulates mTOR/AKT signaling and controls the serine/arginine-rich protein kinase-responsive type 1 internal ribosome entry site-mediated translation and viral oncolysis. 
  • Mitosis is required for production of murine leukemia virus and structural proteins during de novo infection. 
  • Modality of Primary HIV Disclosure and Association with Mental Health, Stigma, and Antiretroviral Therapy Adherence in Tanzanian Youth Living with HIV. 
  • Modeling infectious disease in mice: co-adaptation and the role of host-specific IFNgamma responses. 
  • Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. 
  • Modified vaccinia virus Ankara can activate NF-kappaB transcription factors through a double-stranded RNA-activated protein kinase (PKR)-dependent pathway during the early phase of virus replication. 
  • Modulation of HIV-1 immunity by adjuvants 
  • Modulation of HIV-1 immunity by adjuvants. 
  • Modulation of RAS Pathways as a Biomarker of Protection against HIV and as a Means to Improve Vaccine Efficacy. 
  • Modulation of Sialic Acid Dependence Influences the Central Nervous System Transduction Profile of Adeno-associated Viruses. 
  • Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. 
  • Molecular adjuvant IL-33 enhances the potency of a DNA vaccine in a lethal challenge model. 
  • Molecular analysis of the feline immunodeficiency virus protease: generation of a novel form of the protease by autoproteolysis and construction of cleavage-resistant proteases. 
  • Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. 
  • Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates. 
  • Molecular characterization of a highly divergent HIV type 1 isolate obtained early in the AIDS epidemic from the Democratic Republic of Congo. 
  • Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. 
  • Molecular cloning and restriction endonuclease mapping of the murine cytomegalovirus genome (Smith Strain). 
  • Molecular determinants and dynamics of hepatitis C virus secretion. 
  • Molecular ecology and natural history of simian foamy virus infection in wild-living chimpanzees. 
  • Molecular epidemiology of human immunodeficiency virus type 1 transmission in a heterosexual cohort of discordant couples in Zambia. 
  • Molecular evolution of human immunodeficiency virus env in humans and monkeys: similar patterns occur during natural disease progression or rapid virus passage. 
  • Molecular features and translational outlook for Epstein-Barr virus-associated gastric cancer. 
  • Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. 
  • Molecular patterns of SHIV Env-Ab coevolution in rhesus macaques recapitulate HIV-1 Env-Ab co-evolution in humans infected by HIV-1 strains bearing homologous Envs 
  • Molecular patterns of SHIV Env-Ab coevolution in rhesus macaques recapitulate HIV-1 Env-Ab co-evolution in humans infected by HIV-1 strains bearing homologous envs 
  • Molecular surveillance of HIV-1 field strains in Nigeria in preparation for vaccine trials. 
  • Molecular targets and potency of HIV-1 neutralization revealed by dynamic assessment of transmitted/founder virus antibody recognition and escape 
  • Molecular targets of anti-HIV-1 triterpenes. 
  • Monitoring progress of maternal and neonatal immunization in Latin America and the Caribbean 
  • Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1. 
  • Monoclonal antibodies that bind to the core of fusion-active glycoprotein 41. 
  • Mononuclear phagocyte accumulation in visceral tissue in HIV encephalitis: evidence for increased monocyte/macrophage trafficking and altered differentiation. 
  • Mother and daughter preferences and willingness to pay for HPV vaccination 
  • Mothers' preferences and willingness to pay for vaccinating daughters against human papillomavirus. 
  • Motivations for Reducing Other HIV Risk-Reduction Practices if Taking Pre-Exposure Prophylaxis: Findings from a Qualitative Study Among Women in Kenya and South Africa. 
  • Mouse Adenovirus Type 1 Persistence Exacerbates Inflammation Induced by Allogeneic Bone Marrow Transplantation. 
  • Mouse adenovirus type 1 infection of adipose tissue. 
  • Mouse mammary tumor virus uses mouse but not human transferrin receptor 1 to reach a low pH compartment and infect cells. 
  • Mouse strain differences in the chemokine response to acute lung infection with a murine gammaherpesvirus. 
  • Mucin-binding IgG: Characterizing a Novel Antibody Effector Function and Discovery of a New Fc Receptor 
  • Mucin-binding IgG: Characterizing a novel antibody effector function and discovery of a new Fc receptor 
  • Mucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal Challenge. 
  • Mucosal aids vaccine delivered to rhesus macaques via immuno-stimulating complexes induces low levels of virus-neutralizing antibodies and cytotoxic T cell responses that are rapidly expanded upon challenge with simian-human immunodeficiency viruses (sHIVs) 
  • Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. 
  • Mucosal co-infections and HIV-1 transmission and pathogenesis. 
  • Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk. 
  • Mucosal vaccine development for botulinum intoxication. 
  • Mucosal vaccine efficacy against intrarectal SHIV acquisition independent of anti-Env antibody 
  • Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3. 
  • Multi-analyte profiling of ten cytokines in South African HIV-infected patients with Immune Reconstitution Inflammatory Syndrome (IRIS). 
  • Multi-omics to predict acute radiation esophagitis in patients with lung cancer treated with intensity-modulated radiation therapy. 
  • Multiclade E-DNA Prime Enhances the Functional Antibody Response Induced by a Recombinant gp120 Boost in Non-human Primates 
  • Multifactorial influences underpinning a decision on COVID-19 vaccination among healthcare workers: a qualitative analysis. 
  • Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection. 
  • Multiple Pathways of HIV-1 Autologous Neutralizing Antibodies Cooperate to Drive CD4 Binding Site Broadly Neutralizing Antibody Responses 
  • Multiple and specific initiation of T4 DNA replication. 
  • Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial 
  • Multiple condom use and decreased condom breakage and slippage in Thailand 
  • Multiple gene segments control the temperature sensitivity and attenuation phenotypes of ca B/Ann Arbor/1/66. 
  • Multiple roles for sialylated glycans in determining the cardiopulmonary tropism of adeno-associated virus 4. 
  • Multiplex imaging and analysis of novel natural killer-like B cells in non-human primates 
  • Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component. 
  • Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. 
  • Multivariate analysis of FcR-mediated NK cell functions identifies unique clustering among Rhesus macaques 
  • Murine cytomegalovirus retinitis during retrovirus-induced immunodeficiency (MAIDS) in mice: interleukin-2 immunotherapy correlates with increased intraocular levels of perforin mRNA. 
  • Murine granulocyte-macrophage colony-stimulating factor expressed from a bicistronic simian immunodeficiency virus-based integrase-defective lentiviral vector does not enhance T-cell responses in mice. 
  • Murine noroviruses comprising a single genogroup exhibit biological diversity despite limited sequence divergence. 
  • Mutants of Fujinami sarcoma virus which are temperature sensitive for cellular transformation and protein kinase activity. 
  • Mutational analysis of conserved N-linked glycosylation sites of human immunodeficiency virus type 1 gp41. 
  • Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein. 
  • Mutations that confer resistance to broadly-neutralizing antibodies define HIV-1 variants of transmitting mothers from that of non-transmitting mothers. 
  • Mycobacterium tuberculosis whole cell lysate enhances proliferation of CD8 positive lymphocytes and nitric oxide secretion in the lungs of live porcine respiratory and reproductive syndrome virus vaccinated pigs. 
  • NASH in HIV. 
  • NATURAL EVOLUTION OF CLADE C SHIV NEUTRALIZATION SENSITIVITY FROM TIER 1 TO TIER 2 IS LINKED TO DIFFERENCES IN V1 AND V2 LOOP SEQUENCES IN ENV 
  • NF-kappaB cis-acting motifs of the human immunodeficiency virus (HIV) long terminal repeat regulate HIV transcription in human macrophages. 
  • NLRC3 negatively regulates CD4+ T cells and impacts protective immunity during Mycobacterium tuberculosis infection. 
  • Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. 
  • Natural Killer Cells Regulate Acute SIV Replication, Dissemination, and Inflammation, but Do Not Impact Independent Transmission Events. 
  • Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. 
  • Natural infection of a household pet red-capped mangabey (Cercocebus torquatus torquatus) with a new simian immunodeficiency virus. 
  • Natural product ligands of FKBP12: Immunosuppressive antifungal agents FK506, rapamycin, and beyond. 
  • Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. 
  • Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease. 
  • Nature of the 3'-terminal sequences of the plus and minus strands of the S1 gene of reovirus serotypes 1, 2 and 3. 
  • Naïve CD8 T cell IFNγ responses to a vacuolar antigen are regulated by an inflammasome-independent NLRP3 pathway and Toxoplasma gondii ROP5. 
  • Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents. 
  • Nef expressed from human immunodeficiency virus type 1 extrachromosomal DNA downregulates CD4 on primary CD4+ T lymphocytes: implications for integrase inhibitors. 
  • Nelfinavir inhibits maturation and export of herpes simplex virus 1. 
  • Neonatal pertussis, cocooning and maternal immunization. 
  • Neuroimaging and immunological features of neurocognitive function related to substance use in people with HIV. 
  • Neuropathies and neurological dysfunction induced by coronaviruses. 
  • Neutralization Potency Can Account for the Majority of Antibody-mediated Protection Observed in ex vivo Vaginal Explant Models of Early HIV Infection 
  • Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection. 
  • Neutralization epitopes of the HIV-1 primary isolate DH012. 
  • Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection. 
  • Neutralization of homologous and heterologous oncornaviruses by antisera against the p15(E) and gp71 polypeptides of Friend murine leukemia virus. 
  • Neutralization tiers of HIV-1. 
  • Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. 
  • Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection (Journal of Virology (2009) 83, 3, (1422-1432)) 
  • Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection. 
  • Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells. 
  • Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin. 
  • Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers. 
  • Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge. 
  • Neutralizing and ADCC Activity of Anti-HIV-1 Antibodies Against Acute Subtype C Envs: Implications for Prevention and Treatment of HIV-1 Infection 
  • Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination. 
  • Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? 
  • Neutralizing antibodies as a potential secondary protective mechanism during chronic SHIV infection in CD8+ T-cell-depleted macaques. 
  • Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. 
  • Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. 
  • Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus. 
  • Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1. 
  • Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. 
  • Neutralizing antibody responses in Africa green monkeys naturally infected with simian immunodeficiency virus (SIVagm). 
  • Neutralizing antibody responses to HIV-1 are dependent on conformational integrity of gp140 immunogens 
  • New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. 
  • New SHIV Models of bNAb Elicitation and Env-Ab Coevolution 
  • New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention and Cure. 
  • New broadly neutralizing human monoclonal antibodies targeting the 2F5 epitope 
  • New insights into the role of host cell proteins in antiviral vaccine protection. 
  • New perspectives on AIDS vaccine development: Editorial 
  • New simian immunodeficiency virus infecting De Brazza's monkeys (Cercopithecus neglectus): evidence for a cercopithecus monkey virus clade. 
  • Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. 
  • No Increase in Activated T Cells and Limited Increase in Adenovirus-specific T Cells in Colon and Rectal Mucosa Following HIV-1 DNA/rAd5 Immunization 
  • Non-AIDS-defining events among HIV-1-infected adults receiving combination antiretroviral therapy in resource-replete versus resource-limited urban setting. 
  • Non-reassuring fetal status: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. 
  • Non-replicating mucosal and systemic vaccines: quantitative and qualitative differences in the Ag-specific CD8(+) T cell population in different tissues. 
  • Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals. 
  • Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens. 
  • Nontypeable Haemophilus influenzae meningitis complicated by hearing loss in a 9-year-old HIV-infected boy. 
  • Normal chicken cells (chf-) express a surface antigen which cross-reacts with determinants of the major envelope glycoprotein (gp85) of avian myeloblastosis virus. 
  • Norwalk virus: how infectious is it? 
  • Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying env from an RV144 Volunteer to Rhesus Macaques: Coreceptor Switch and Final Recovery of a Pathogenic Virus with Exclusive R5 Tropism. 
  • Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. 
  • Novel and emerging sources of Clostridioides difficile infection. 
  • Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes. 
  • Novel circular DNA viruses in stool samples of wild-living chimpanzees. 
  • Novel function of prothymosin alpha as a potent inhibitor of human immunodeficiency virus type 1 gene expression in primary macrophages. 
  • Nuclear magnetic resonance analysis of solution conformations in C4-V3 hybrid peptides derived from human immunodeficiency virus (HIV) type 1 gp120: relation to specificity of peptide-induced anti-HIV neutralizing antibodies. 
  • Nucleic acid sequence and oncogenic properties of the HZ2 feline sarcoma virus v-abl insert. 
  • Nucleotide sequence and host La protein interactions of rabies virus leader RNA. 
  • OA011-04. Striking elevations in systemic and mucosal cytokine and chemokine levels in acute HIV-1 infection 
  • OA021-04. HIV-1 gp41 envelope MPER mutation altered epitope conformation in lipid and increased sensitivity to 2F5 and 4E10 neutralizing antibodies 
  • OA04-04. Perceived parental willingness for their adolescents to participate in future HIV prevention trials: A survey conducted amongst adolescents in Soweto 
  • OA06-04. The role of early T-cell responses in subjects with acute HIV-1 infection 
  • OPTIMIZATION OF SYSTEMIC AND MUCOSAL IMMUNE RESPONSES TO SIV AND HIV-1 ANTIGENS USING DIFFERENT PROTOCOLS OF DNA AND PROTEIN IMMUNIZATION IN MACAQUES 
  • Observations on home HIV testing. 
  • Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders. 
  • On the Discovery of TOR As the Target of Rapamycin. 
  • Oncolytic poliovirus against malignant glioma. 
  • Ontogeny of CD8+T Cells in Acute HIV-1 that Inhibit Autologous and Heterologous Transmitted/Founder (T/F) Viruses 
  • Ontogeny, Breadth, and Specificity of Circulating ADCC-Mediating Antibodies in HIV-1 Infected Individuals 
  • Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients. 
  • Opioid Use Among Those Who Have Criminal Justice Experience: Harm Reduction Strategies to Lessen HIV Risk. 
  • Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. 
  • Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial. 
  • Optimization of Systemic and Mucosal Immune Responses to SIV and HIV-1 Antigens Using Different Protocols of DNA and Protein Immunization in Macaques 
  • Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. 
  • Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen. 
  • Oral Coadministration of an Intramuscular DNA/Modified Vaccinia Ankara Vaccine for Simian Immunodeficiency Virus Is Associated with Better Control of Infection in Orally Exposed Infant Macaques. 
  • Oral SIV, SHIV, and HIV type 1 infection. 
  • Oral polio vaccine response in the MAL-ED birth cohort study: Considerations for polio eradication strategies. 
  • Origin and evolution of HIV-1 in breast milk determined by single-genome amplification and sequencing. 
  • Origins and diversity of human immunodeficiency viruses 
  • Oropharyngeal candidiasis in patients with HIV: suggested guidelines for therapy. 
  • Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy. 
  • Outcomes Up to 12 Months After Treatment With Loop Electrosurgical Excision Procedure for Cervical Intraepithelial Neoplasia Among HIV-Infected Women. 
  • Outcomes for PrEP Users in the Southern US: Persistence and STIs 
  • Outer membrane of avian myeloblastosis virus. 
  • Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity. 
  • Overcoming biological, behavioral, and structural vulnerabilities: new directions in research to decrease HIV transmission in men who have sex with men. 
  • Overexpression of p21(waf1) in human T-cell lymphotropic virus type 1-infected cells and its association with cyclin A/cdk2. 
  • Overland heroin trafficking routes and HIV-1 spread in south and south-east Asia. 
  • Overlapping epitopes in human immunodeficiency virus type 1 gp120 presented by HLA A, B, and C molecules: effects of viral variation on cytotoxic T-lymphocyte recognition. 
  • Overview of Humoral and Cellular Immune Responses to HIV Vaccination 
  • Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. 
  • P01-05. Rapid perforin upregulation dominates the HIV-specific CD8 T cell response during acute HIV-infection 
  • P03-10. Induction of neutralizing antibodies in Rhesus macaques following mucosal challenge with R5 tropic SHIV162P3 isolate 
  • P04-01. Simultaneous enumeration of HIV-1 gp41 Env-specific IgG and IgM antibody-secreting cells with a multiplex B-cell fluorospot assay 
  • P04-08. Monoclonal antibodies from patient with acute HIV-1 infection 
  • P04-11. Prevalence of neutralizing antibody responses in chronic clades A and D human immunodeficiency virus type 1 (HIV-1) infections 
  • P04-12. Characterization of leukopak PBMC phenotypes and biotypes for optimal performance in HIV-1 neutralization assays 
  • P04-18. Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: Results from the NeutNet working group 
  • P04-23. HIV-1 neutralization is impacted by the PBMC donor used for both virus growth and target cells, and the effects are neutralization reagent-specific 
  • P04-26. Immunological tolerance prevents the expression of a broadly reactive neutralizing HIV-1 antibody 
  • P04-28. Breadth and magnitude of neutralizing antibody responses in subjects infected with HIV-1 subtype D or recombinants in Rakai district, Uganda 
  • P04-44. Generation of antibody responses to HIV-1 membrane proximal external region (MPER) antigen 
  • P04-45. Characterization of the plasma cell repertoire in acute HIV-1 infection (AHI) 
  • P04-48. HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after gp120 protein vaccination or chronic HIV-1 infection 
  • P04-54 LB. Genetic signature analysis identifies the CD4i region of gp120 as a determinant of broadly NAb responses in HIV-1-infected individuals 
  • P05-12. A computationally designed immunogen elicits potent anti-V3 neutralizing antibodies 
  • P09-21 LB. Deep sequencing of HIV-1 from acute infection: Low initial diversity, and rapid but variable CTL escape 
  • P10-05. Suppression of human dendritic cell function during acute HIV infection 
  • P11-07. Characterization of a new TZM-bl cell line that expresses human FcαR(CD89) 
  • P11-21. Induction of persistent mucosal humoral and cellular responses following immunization of mice with HIV-1 envelope protein in inulin-derived adjuvants. 
  • P15-04. Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells 
  • P15-05. Evaluation and recommendations on good clinical laboratory practice (GCLP) guidelines for phase I-III HIV vaccine clinical trials 
  • P19-50. Simulation of an MPER peptide samples epitope conformations of two broadly neutralizing antibodies 
  • P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting 
  • P20-08. Glycosylation: An important factor in Env diversity 
  • P20-17. Evolution of multiple transmitted viruses during the early stage of HIV-1 infection 
  • PATHOGENICITY AND MUCOSAL TRANSMISSIBILITY OF R5-TROPIC SIMIAN/HUMAN IMMUNODEFICIENCY VIRUSES SHIVAD8 IN RHESUS MACAQUES: IMPLICATIONS FOR THEIR USE IN VACCINE STUDIES 
  • PEPFAR's evolving HIV prevention approaches for key populations--people who inject drugs, men who have sex with men, and sex workers: progress, challenges, and opportunities. 
  • PH-INDEPENDENT HIV-1 ENTRY INTO MACROPHAGE 
  • PI-6 Construction and analysis of V3 glycopeptide antigens for HIV-1 vaccine design 
  • PIV-13 Prospective respiratory epidemiologic surveillance study (press) – viral respiratory infections in a long-term care facility (LTCF) population 
  • PKC signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1, calcineurin, and Hsp90. 
  • PMTCT Option B+ Does Not Increase Preterm Birth Risk and May Prevent Extreme Prematurity: A Retrospective Cohort Study in Malawi. 
  • PRIMARY IMMUNE-RESPONSE TO HIV-INFECTION 
  • Pairing QuantiFERON gold in-tube with opt-out HIV testing in a tuberculosis contact investigation in the Southeastern United States. 
  • Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments. 
  • Parallels in intercellular communication in oomycete and fungal pathogens of plants and humans. 
  • Partial Protection from Intravenous Challenge by an Integration-defective SIV Vaccine 
  • Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate. 
  • Partial protection of simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate (Journal of Virology (2009) 83, 6 (2686-2696)) 
  • Partial resistance to infection by R5X4 primary HIV type 1 isolates in an exposed-uninfected individual homozygous for CCR5 32-base pair deletion. 
  • Participants' Explanations for Nonadherence in the FEM-PrEP Clinical Trial. 
  • Particle-to-PFU Ratio of Ebola Virus Influences Disease Course and Survival in Cynomolgus Macaques 
  • Partnerships Between a University-Affiliated Clinic and Community-Based Organizations to Reach Black Men Who Have Sex With Men for PrEP Care. 
  • Passive immunization against oral AIDS virus transmission: an approach to prevent mother-to-infant HIV-1 transmission? 
  • Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose. 
  • Passive immunization with polyclonal anti-SHIV IgG: partial protection or increased acquisition of heterologous tier 2 SHIV - depending on IgG dose 
  • Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. 
  • Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia. 
  • Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection. 
  • Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection. 
  • Pathogenesis insights from an ancient and ubiquitous spirochete. 
  • Pathogenic Correlates of Simian Immunodeficiency Virus-Associated B Cell Dysfunction. 
  • Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies. 
  • Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses. 
  • Pattern of HIV-1-gp41 Binding and Neutralizing Antibodies in Subtype C Infected Women and in their HIV-1-Seronegative Neonates 
  • Patterns of HIV-1 mRNA expression in transgenic mice are tissue-dependent. 
  • Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. 
  • Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. 
  • Pearls collections: What we can learn about infectious disease and cancer. 
  • Pediatric AIDS prognosis using somatic growth velocity. 
  • Perceived HIV Acquisition Risk and Low Uptake of PrEP Among a Cohort of Transgender Women With PrEP Indication in the Eastern and Southern United States. 
  • Perceived Interruptions to HIV Prevention and Treatment Services Associated With COVID-19 for Gay, Bisexual, and Other Men Who Have Sex With Men in 20 Countries. 
  • Perceptibility and the "Choice Experience": User Sensory Perceptions and Experiences Inform Vaginal Prevention Product Design. 
  • Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP. 
  • Perceptions of personal belief vaccine exemption policy: a survey of Arizona vaccine providers. 
  • Perceptions on HIV Pre-Exposure Prophylaxis Among Urgent Care Clinicians in the Southern United States. 
  • Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells. 
  • Perforin knockout mice, but not mice with MAIDS, show protection against experimental cytomegalovirus retinitis after adoptive transfer of immune cells with a functional perforin cytotoxic pathway. 
  • Performance of HIV Rapid Tests Among Breastfeeding, Malawian Infants. 
  • Performance of creatinine and cystatin C GFR estimating equations in an HIV-positive population on antiretrovirals. 
  • Performance of diagnostic tests to detect respiratory viruses in older adults. 
  • Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01B vaccination. 
  • Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation. 
  • Persistent coinfection of T lymphocytes with HTLV-II and HIV and the role of syncytium formation in HIV-induced cytopathic effect. 
  • Perspective: research highlights at the Duke University center for AIDS research. Immunoreconstitution in HIV infection: the role of the thymus. 
  • Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection 
  • Perturbations of the Vb-T Cell Repertoire in HIV Uninfected Neonates Born to HIV-1 Subtype C Infected Mothers: Evidence for T Cell Priming in Utero 
  • Pharmacovirological impact of an integrase inhibitor on human immunodeficiency virus type 1 cDNA species in vivo. 
  • Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. 
  • Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. 
  • Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles 
  • Phenotypic Correlates of HIV-1 Macrophage Tropism. 
  • Phenotypic and functional consequences of herpesvirus saimiri infection of human CD8+ cytotoxic T lymphocytes. 
  • Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. 
  • Phenotypic and genotypic characteristics of human immunodeficiency virus type 1 from patients with AIDS in northern Thailand. 
  • Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. 
  • Phosphatidylinositol 3-kinase regulates human immunodeficiency virus type 1 replication following viral entry in primary CD4+ T lymphocytes and macrophages. 
  • Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS. 
  • Phosphorylation of Calcineurin at a novel serine-proline rich region orchestrates hyphal growth and virulence in Aspergillus fumigatus. 
  • Phosphorylation of DHBV pre-S: identification of the major site of phosphorylation and effects of mutations on the virus life cycle. 
  • Phylogenetic Conservation of a Dominant Antibody Light Chain HIV Env V2 Binding Motif in Human and rhesus Macaque Antibodies 
  • Phylogenetic analysis of protease and transmembrane region of HIV type 1 group O. 
  • Physical exercise is associated with less neurocognitive impairment among HIV-infected adults. 
  • Pilot Integration of HIV Screening and Healthcare Settings with Multi- Component Social Network and Partner Testing for HIV Detection. 
  • Pilot Study of Pioglitazone and Exercise Training Effects on Basal Myocardial Substrate Metabolism and Left Ventricular Function in HIV-Positive Individuals with Metabolic Complications 
  • Plain language summary of Pfizer-BioNTech BNT162b2 vaccine protection against COVID-19 and its safety in participants 12- to 15-years-old 
  • Plasma and Intracellular Concentrations in HIV-Infected Patients Requiring Hemodialysis Dosed With Tenofovir Disoproxil Fumarate and Emtricitabine. 
  • Plasma carnitine in HIV-associated neuropathy. 
  • Plasmablast Phenotype and Mucosal Antibodies to V2 in Vaccine-induced Protection Against SIVmac251 
  • Plasmid models for bacteriophage T4 DNA replication: requirements for fork proteins. 
  • Plasmodium parasite exploits host aquaporin-3 during liver stage malaria infection 
  • Plasmodium parasite exploits host aquaporin-3 during liver stage malaria infection. 
  • Platelets from thrombocytopenic ponies acutely infected with equine infectious anemia virus are activated in vivo and hypofunctional. 
  • Pneumococcal conjugate vaccine introduction in Latin America and the Caribbean: progress and lessons learned 
  • Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design. 
  • Polychromatic immunophenotypic characterization of T cell profiles among HIV-infected patients experiencing immune reconstitution inflammatory syndrome (IRIS) 
  • Polychromatic immunophenotypic characterization of T cell profiles among HIV-infected patients experiencing immune reconstitution inflammatory syndrome (IRIS). 
  • Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. 
  • Polymerase chain reaction amplification and in situ hybridization for the detection of human B-lymphotropic virus. 
  • Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines. 
  • Polyoma virus infection of retinoic acid-induced differentiated teratocarcinoma cells. 
  • Polypeptides of avian RNA tumor viruses. 1. Isolation and physical and chemical analysis. 
  • Polypeptides of avian RNA tumor viruses. 3. Purification and identification of a DNA synthesizing enzyme. 
  • Polypeptides of avian RNA tumor viruses. II. Serological characterization. 
  • Polypeptides of avian RNA tumor viruses. IV. Components of the viral envelope. 
  • Polypeptides of avian RNA tumor viruses. V. Analysis of the virus core. 
  • Polypeptides of endogenous avian C-type viruses: their detection in the plasma membrane of normal and infected cells. 
  • Polypeptides of mammalian oncornaviruses. I. Isolation and serological analysis polypeptides from murine and feline C-type viruses. 
  • Polypeptides of mammalian oncornaviruses. II Characterization of murine leukemia virus polypeptide (p 15) bearing interspecies reactivity. 
  • Polypeptides of mammalian oncornaviruses. II. Characterization of a murine leukemia virus polypeptide (p15) bearing interspecies reactivity. 
  • Polypeptides of mammalian oncornaviruses. III. Localization of p 15 and reactivity with natural antibody. 
  • Polypeptides of mammalian oncornaviruses. IV. Structural components of murine leukemia virus released as soluble antigens in cell culture. 
  • Polyploidy and Mitotic Cell Death Are Two Distinct HIV-1 Vpr-Driven Outcomes in Renal Tubule Epithelial Cells. 
  • Polyreactivity and autoreactivity among HIV-1 antibodies. 
  • Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. 
  • Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques. 
  • Population genetic analyses reveal the African origin and strain variation of Cryptococcus neoformans var. grubii. 
  • Porcine Hemagglutinating Encephalomyelitis Virus Activation of the Integrin α5β1-FAK-Cofilin Pathway Causes Cytoskeletal Rearrangement To Promote Its Invasion of N2a Cells. 
  • Portable colposcopy in low-resource settings. 
  • Post-exercise heart rate recovery in HIV-positive individuals on highly active antiretroviral therapy. Early indicator of cardiovascular disease? 
  • Post-transcription cleavage generates the 3' end of F17R transcripts in vaccinia virus. 
  • Postherpetic neuralgia in immunocompetent elderly people. 
  • Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. 
  • Postnatal pre- and postexposure passive immunization strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge. 
  • Postnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variants. 
  • Postnatally-transmitted HIV-1 variants are efficient at dendritic cell trans-infection and sensitive to autologous and heterologous neutralization 
  • Postpartum depression and HIV infection among women in Malawi. 
  • Posttranslational Modifications of NPR1: A Single Protein Playing Multiple Roles in Plant Immunity and Physiology. 
  • Potent inhibition of HIV type 1 infection of mononuclear phagocytes by synthetic peptide analogs of HIV type 1 protease substrates. 
  • Potent inhibition of human immunodeficiency virus type 1 (HIV-1) replication by inducible expression of HIV-1 PR multimers. 
  • Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. 
  • Potential effects of decreased cervical cancer screening participation after HPV vaccination: an example from the U.S. 
  • Potential mechanisms for increased HIV-1 transmission across the endocervical epithelium during C. trachomatis infection. 
  • Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. 
  • Potential sources of the 1995 Venezuelan equine encephalitis subtype IC epidemic. 
  • Poxvirus genomes encode a secreted, soluble protein that preferentially inhibits beta chemokine activity yet lacks sequence homology to known chemokine receptors. 
  • Poxvirus tumor necrosis factor receptor (TNFR)-like T2 proteins contain a conserved preligand assembly domain that inhibits cellular TNFR1-induced cell death. 
  • Pre-existing albuminuria predicts AIDS and non-AIDS mortality in women initiating antiretroviral therapy. 
  • Pre-existing immunity to cytomegalovirus in macaques influences human CMV vaccine responses in preclinical models. 
  • Precise mapping of recombination breakpoints suggests a common parent of two BC recombinant HIV type 1 strains circulating in China. 
  • Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia. 
  • Predicting CD4 lymphocyte count 
  • Predicting CD4 lymphocyte count <200 cells/mm(3) in an HIV type 1-infected African population. 
  • Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study. 
  • Prediction of HIV Transmission Cluster Growth With Statewide Surveillance Data. 
  • Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants. 
  • Predictive factors of neoadjuvant immune checkpoint blockade in melanoma. 
  • Predictors of AIDS-related morbidity and mortality in a southern U.S. Cohort. 
  • Predictors of HPV vaccination in the southern US: A survey of caregivers from 13 states. 
  • Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials. 
  • Predominant envelope variable loop 2-specific and gp120-specific antibody-dependent cellular cytotoxicity antibody responses in acutely SIV-infected African green monkeys. 
  • Preexisting compensatory amino acids compromise fitness costs of a HIV-1 T cell escape mutation 
  • Preexisting compensatory amino acids compromise fitness costs of a HIV-1 T cell escape mutation. 
  • Preexisting infection with human T-cell lymphotropic virus type 2 neither exacerbates nor attenuates simian immunodeficiency virus SIVmac251 infection in macaques. 
  • Prehypertension and Retinal Arteriolar Narrowing in PWH in Tanzania. 
  • Preparatory studies for possible HIV vaccine trials in northern Thailand. 
  • Presence of diverse human immunodeficiency virus type 1 viral variants in Cameroon. 
  • Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity. 
  • Prevalence and Correlates of Electrocardiographic Abnormalities in Adults With HIV: Insights From the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). 
  • Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the Southeastern United States. 
  • Prevalence of Pretreatment and Acquired HIV-1 Mutations Associated with Resistance to Lamivudine or Rilpivirine: A Systematic Review 
  • Prevalence of chemokine and chemokine receptor polymorphisms in seroprevalent children with symptomatic HIV-1 infection in the United States. 
  • Prevention of Vaginal Transmission of Simian-Human Immunodeficiency Virus (SHIV) in Rhesus Monkeys by Small-molecule CD4-mimetic Compounds 
  • Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine. 
  • Prevention strategies: herpes zoster, post-herpetic neuralgia and immunogenicity. 
  • Primary Analysis of TRAVERSE: A Phase 1/2a Study to Assess Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost HIV Vaccine Regimens 
  • Primary and Secondary HIV Prevention Among Persons with Severe Mental Illness: Recent Findings. 
  • Primary infection by a human immunodeficiency virus with atypical coreceptor tropism. 
  • Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy. 
  • Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. 
  • Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. 
  • Priming for virus-specific CD8+ but not CD4+ cytotoxic T lymphocytes with synthetic lipopeptide is influenced by acylation units and liposome encapsulation. 
  • Priming with Adenovirus26 Vaccines Affects ALVAC-SIV/gp120 Vaccine Efficacy Tested in a SIVmac251 Challenge Model Performed One-Month Post-Vaccination 
  • Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques. 
  • Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost. 
  • Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. 
  • Private demand for a HIV/AIDS vaccine: evidence from Guadalajara, Mexico. 
  • Private demand for cholera vaccines in Beira, Mozambique. 
  • Probable antenatal depression at antiretroviral initiation and postpartum viral suppression and engagement in care. 
  • Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. 
  • Production of prostaglandin E₂ in response to infection with modified vaccinia Ankara virus. 
  • Profile of HIV-1-env Binding and Neutralizing Antibodies in Subtype C, A and B Infected Women 
  • Profiles of Neutralizing Antibody Responses in Chronically HIV-1 CRF07_BC Infected Intravenous Drug Users in Western China 
  • Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy. 
  • Profiles of neutralizing antibody responses in chronically HIV-1 clade B' infected treatment-naive former plasma donors in China 
  • Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. 
  • Program design and evaluation strategies for the Special Projects of National Significance Outreach Initiative. 
  • Progress in HIV-1 vaccine development. 
  • Progressive lentivirus infection induces natural killer cell receptor-expressing B cells in the gastrointestinal tract. 
  • Proinflammatory effects of interferon gamma in mouse adenovirus 1 myocarditis. 
  • Proliferation of HIV-infected renal epithelial cells following virus acquisition from infected macrophages. 
  • Prolonged Intervals Between Boosts Induces High Magnitude Transient V2-specific Functional Antibodies That Inhibit the Binding of V2 to alpha 4 beta 7 Integrin 
  • Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal. 
  • Properties of mouse leukemia viruses. II. Isolation of viral components. 
  • Properties of mouse leukemia viruses. XIII. Serum therapy of virus-induced murine leukemias. 
  • Properties of mouse leukemia viruses. XIV. Prevention of spontaneous AKR leukemia by treatment with group-specific antibody against the major virus gp71 glycoprotein. 
  • Properties of mouse leukemia viruses. XIX. Effective antibody therapy of AKR leukemia occurs independently of virus neutralization and produces long-term changes in the virus status of the thymus. 
  • Properties of mouse leukemia viruses. XVI. Suppression of spontaneous fetal leukemias in AKR mice by treatment with broadly reacting antibody against the viral glycoprotein gp 71. 
  • Properties of mouse leukemia viruses. XVII. Factors required for successful treatment of spontaneous AKR leukemia by antibodies against gp71. 
  • Properties of mouse leukemia viruses: XX. Variation of AKR Substrains in response to antibody therapy. 
  • Prospects for development of a vaccine against HTLV-III-related disorders. 
  • Prostaglandin E2 production during neonatal respiratory infection with mouse adenovirus type 1. 
  • Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure. 
  • Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration. 
  • Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. 
  • Protection from Rectal SHIV Infection Induced by Mucosal Vaccination with a Replication-competent VSV-HIV Chimera Delivering Env Trimers 
  • Protection from SIVmac251 Acquisition by an ALVAC/SIV/gp120 Regimen Is Not Improved by the Increase of Anti-Envelope Antibodies and T Cell Responses 
  • Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines. 
  • Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. 
  • Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells. 
  • Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys. 
  • Protective immunity to SIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles. 
  • Protein interactions among the vaccinia virus late transcription factors. 
  • Protein phosphatase 2A dephosphorylates simian virus 40 large T antigen specifically at residues involved in regulation of DNA-binding activity. 
  • Provider response and follow-up to parental declination of HPV vaccination. 
  • Provider-level rates of HEDIS-consistent HPV vaccination in a regional health plan. 
  • Providers' attitudes towards treating depression and self-reported depression treatment practices in HIV outpatient care. 
  • Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. 
  • Psychological discomfort and mental illness in patients with AIDS: implications for home care. 
  • Psychosocial and behavioral correlates of depression among HIV-infected pregnant women. 
  • Purification and serological characterization of the major envelope glycoprotein from AKR murine leukemia virus and its reactivity with autogenous immune sera from mice. 
  • Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. 
  • Putting prevention in their pockets: developing mobile phone-based HIV interventions for black men who have sex with men. 
  • QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. 
  • Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants (Journal of Virology (2009) 83, 8, (3556-3567)) 
  • Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. 
  • Quantitative and qualitative differences in the T cell response to HIV in uninfected Ugandans exposed or unexposed to HIV-infected partners. 
  • Quantitative models of the dose-response and time course of inhalational anthrax in humans. 
  • Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4. 
  • RNA interference and single particle tracking analysis of hepatitis C virus endocytosis. 
  • RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. 
  • RNA modifications go viral. 
  • RNA polymerase-associated interactions near template promoter sequences of defective interfering particles of vesicular stomatitis virus. 
  • RNA replication for the paramyxovirus simian virus 5 requires an internal repeated (CGNNNN) sequence motif. 
  • RNA replication from the simian virus 5 antigenomic promoter requires three sequence-dependent elements separated by sequence-independent spacer regions. 
  • RNA sequence and transcriptional properties of the 3' end of the Newcastle disease virus genome. 
  • RNA-transfected dendritic cells. 
  • RNAi-Based Functional Genomics Identifies New Virulence Determinants in Mucormycosis. 
  • ROP39 is an Irgb10-specific parasite effector that modulates acute Toxoplasma gondii virulence. 
  • Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge. 
  • Race and ethnicity: Risk factors for fungal infections? 
  • Racial Differences in Change in Physical Functioning in Older Male Veterans with HIV. 
  • Racial, ethnic, and gender disparities in hospitalizations among persons with HIV in the United States and Canada, 2005-2015. 
  • Randomized Controlled Trial of an Intervention to Maintain Suppression of HIV Viremia After Prison Release: The imPACT Trial. 
  • Randomized comparison of universal and targeted HIV screening in the emergency department. 
  • Randomized trial comparing the safety and antibody responses to live attenuated versus inactivated influenza vaccine when administered to breastfeeding women. 
  • Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys. 
  • Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge. 
  • Rapid and high throughput strategy for expressing human monoclonal antibodies and generating of antibody-expression stably transfected cell lines 
  • Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting 
  • Rapid global expansion of the fungal disease chytridiomycosis into declining and healthy amphibian populations. 
  • Rapid memory CD8+ T-lymphocyte induction through priming with recombinant Mycobacterium smegmatis. 
  • Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1. 
  • Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection. 
  • Rationally Designed Influenza Virus Vaccines That Are Antigenically Stable during Growth in Eggs. 
  • Rationing HIV medications: what do patients and the public think about allocation policies? 
  • Re: 'Self-controlled case series design in vaccine safety: a systematic review' - absolute and relative measures. 
  • Reactivation of Epstein-Barr Virus by HIF-1α Requires p53. 
  • Reactivity of avian RNA tumor viruses with lectins. 
  • Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant women. 
  • Reasons People Living with HIV Might Prefer Oral Daily Antiretroviral Therapy, Long-Acting Formulations, or Future HIV Remission Options. 
  • Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. 
  • RecDraw: a software package for the representation of HIV-1 recombinant structures. 
  • Recent Key Advances in Human Immununodeficiency Virus Medicine and Implications for China 
  • Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. 
  • Recently acquired and early chronic hepatitis C in MSM: Recommendations from the European treatment network for HIV, hepatitis and global infectious diseases Consensus panel: Erratum 
  • Receptor Switching in Newly Evolved Adeno-associated Viruses. 
  • Recognition and Elimination of HIV-1-infected Cells by ADCC-mediating mAbs for Prevention and Treatment of HIV-1 Infection 
  • Recognition by and in vitro induction of cytotoxic T lymphocytes against predicted epitopes of the immediate-early protein ICP27 of herpes simplex virus. 
  • Recombinant Bacillus Calmette-Guerin as a Potential Vector for Preventive HIV Type 1 Vaccines 
  • Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses. 
  • Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate. 
  • Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques. 
  • Recombinant rubella vectors elicit SIV Gag-specific T cell responses with cytotoxic potential in rhesus macaques. 
  • Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. 
  • Recombinant varicella vaccines induce neutralizing antibodies and cellular immune responses to SIV and reduce viral loads in immunized rhesus macaques. 
  • Recombination of HIV-1 gp160 Clones with Viral Backbone DNA through Co-transfection to Produce Pseudoviruses can Create Replication Competent Viruses 
  • Recombination-mediated escape from primary CD8+ T cells in acute HIV-1 infection. 
  • Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. 
  • Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. 
  • Redefining Aging in HIV Infection Using Phenotypes. 
  • Reduced adherence to antiretroviral therapy among HIV-infected Tanzanians seeking cure from the Loliondo healer. 
  • Reduced diastolic function and left ventricular mass in HIV-negative preadolescent children exposed to antiretroviral therapy in utero 
  • Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers. 
  • Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. 
  • Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials. 
  • Reflections: A Case for Intersectional Approaches in HIV Research. 
  • Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. 
  • Relapse of HIV-associated nephropathy after discontinuing highly active antiretroviral therapy. 
  • Relatedness by nucleic acid hybridization of new isolates of human T-cell leukemia-lymphoma virus (HTLV) and demonstration of provirus in uncultured leukemic blood cells. 
  • Relationship between ever reporting depressive symptoms and all-cause mortality in a cohort of HIV-infected adults in routine care. 
  • Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection. 
  • Relationship between simian virus 40 large tumor antigen expression and tumor formation in transgenic mice. 
  • Relationship of self-reported prior testing history to undiagnosed HIV positivity and HIV risk. 
  • Relationships Among HIV Infection, Metabolic Risk Factors, and Left Ventricular Structure and Function 
  • Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein. 
  • Relative resistance of HIV-1 founder viruses to control by interferon-alpha. 
  • Release of intracellular calcium stores facilitates coxsackievirus entry into polarized endothelial cells. 
  • Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. 
  • Renal epithelial cells produce and spread HIV-1 via T-cell contact. 
  • Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques. 
  • Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge. 
  • Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies. 
  • Replication of many human viruses is refractory to inhibition by endogenous cellular microRNAs. 
  • Replication of the murine cytomegalovirus genome: structure and role of the termini in the generation and cleavage of concatenates. 
  • Replication-Competent Influenza B Reporter Viruses as Tools for Screening Antivirals and Antibodies. 
  • Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC. 
  • Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system. 
  • Reply to 'Quantification of HIV-1 RNA on Dried Blood Spots' AIDS 24:475-6. 
  • Reply. 
  • Report of the WHO technical consultation on the effect of maternal influenza and influenza vaccination on the developing fetus: Montreal, Canada, September 30-October 1, 2015. 
  • Repositioning HIV protease inhibitors as cancer therapeutics 
  • Repression of the human papillomavirus E6 gene initiates p53-dependent, telomerase-independent senescence and apoptosis in HeLa cervical carcinoma cells. 
  • Requirements for species-specific papovavirus DNA replication 
  • Research in action: from AIDS to global health to impact. A symposium in recognition of the scientific contributions of Professor Joep Lange. 
  • Research on vaccines during pregnancy: protocol design and assessment of safety. 
  • Research on vaccines during pregnancy: reference values for vital signs and laboratory assessments. 
  • Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains. 
  • Residues critical for duck hepatitis B virus neutralization are involved in host cell interaction. 
  • Resistance to infection, early and persistent suppression of simian immunodeficiency virus SIVmac251 viremia, and significant reduction of tissue viral burden after mucosal vaccination in female rhesus macaques. 
  • Resistance to neutralizing antibody and expanded coreceptor usage are associated with human immunodeficiency virus type 1 isolates derived from chimpanzees with pathogenic infections. 
  • Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. 
  • Results of the NIMH collaborative HIV/sexually transmitted disease prevention trial of a community popular opinion leader intervention. 
  • Retention in HIV Care During Pregnancy and the Postpartum Period in the Option B+ Era: Systematic Review and Meta-Analysis of Studies in Africa. 
  • Retraction: eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER. 
  • Retreatment of patients co-infected with HCV and HIV-1 who failed 12 weeks of ledipasvir/sofosbuvir 
  • Retroviral DNA integration: Viral and cellular determinants of target-site selection 
  • Retroviral DNA integration: viral and cellular determinants of target-site selection. 
  • Retroviral vector gene expression in F9 embryonal carcinoma cells. 
  • Rev-independent simian immunodeficiency virus strains are nonpathogenic in neonatal macaques. 
  • Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis. 
  • Revertants and partial transformants of rat fibroblasts infected with Fujinami sarcoma virus. 
  • Reverted unmutated ancestor 2F5 VH2-5 alleles differentially bind gp41 and bacterial proteins: a genetic basis for gp41 neutralizing B cell responses 
  • Review of "Witches, Westerners, and HIV: AIDS and Cultures of Blame in Africa" by Alexander Rodlach 
  • Review of "Witches, Westerners, and HIV: AIDS and Cultures of Blame in Africa" by Alexander Rodlach 
  • Revised and updated nomenclature for highly pathogenic avian influenza A (H5N1) viruses. 
  • Revisiting the concept of a cytopathic viral infection. 
  • Rhesus Full Length Single Chain (rhFLSC) Protects Rhesus Macaques from Heterologous Intrarectal Challenge with Multiple Low Doses of SHIV162P3 
  • Rhesus immune responses to SIV Gag expressed by recombinant BCG vectors are independent from pre-existing mycobacterial immunity. 
  • Rhesus macaques that become systemically infected with pathogenic SHIV 89.6-PD after intravenous, rectal, or vaginal inoculation and fail to make an antiviral antibody response rapidly develop AIDS. 
  • Ring finger protein 121 is a potent regulator of adeno-associated viral genome transcription. 
  • Risk Factors for Incident Hypertension Within 1 Year of Initiating Antiretroviral Therapy Among People with HIV. 
  • Risk factors influencing antibody responses to Kaposi's sarcoma-associated herpesvirus latent and lytic antigens in patients under antiretroviral therapy. 
  • Risk of chronic kidney disease in people living with HIV by tenofovir disoproxil fumarate (TDF) use and baseline D:A:D chronic kidney disease risk score. 
  • Risk patterns preceding diagnosis among newly HIV-diagnosed men who have sex with men in New York City. 
  • Risks for HIV infection among gay, bisexual, and other men who have sex with men in Moscow and St. Petersburg, Russia. 
  • Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates. 
  • Role of Adjuvants in Enhancing Durability of HIV Vaccine Responses by Inducing Potent Germinal Centers and Plasma Cell Responses 
  • Role of Intestinal Microbiota in Shaping the B Cell Repertoire in HIV Infection and Env Vaccination. 
  • Role of Structural Marginalization, HIV Stigma, and Mistrust on HIV Prevention and Treatment Among Young Black Latinx Men Who Have Sex with Men and Transgender Women: Perspectives from Youth Service Providers. 
  • Role of carbohydrate in biological functions of Friend murine leukemia virus gp71. 
  • Role of carbohydrate in determining the immunochemical properties of the major glycoprotein (gp71) of Friend murine leukemia virus. 
  • Role of conserved gp41 cysteine residues in the processing of human immunodeficiency virus envelope precursor and viral infectivity. 
  • Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques. 
  • Role of immunoglobulin light chain usage and MPER specificity in counterselecting B cells expressing the broadly neutralizing antibody 2F5 
  • Role of natural killer cell function in dendritic cell-based vaccines. 
  • Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes. 
  • Rotavirus RNA polymerase requires the core shell protein to synthesize the double-stranded RNA genome. 
  • S021-04 OA. A large-scale analysis of immunoglobulin sequences derived from plasmablasts/plasma cells in acute HIV-1 infection subjects 
  • SEROLOGICAL REACTIVITY FROM HIV-1 VACCINE RECIPIENTS PARTICIPATING IN THE AIDS VACCINE CLINICAL-TRIALS NETWORK 
  • SIV PATHOGENESIS DURING ONTOGENY - THE VIRUS THRESHOLD HYPOTHESIS 
  • SIV-Specific Cytotoxic CD4+T Cells and Humoral Responses Control Rebounding Viremia in CD8-Depleted Macaques Infected with Rev-Independent SIV 
  • SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. 
  • SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques. 
  • STUDIES OF ENV-BASED RECOMBINANT IMMUNOGENS AND ROLE OF NEUTRALIZING ANTIBODY IN THE SIV MACAQUE MODEL 
  • SUPPRESSION OF HIV-1 REPLICATION BY PRIMARY AND TRANSFORMED CD8 CELLS 
  • SafeTalk, a multicomponent, motivational interviewing-based, safer sex counseling program for people living with HIV/AIDS: a qualitative assessment of patients' views. 
  • Safety and Immunogenicity of a pDNA Clade B Env Prime, rVSV Clade C Env Boost HIV-1 Vaccination Regimen in a Phase 1 Clinical Trial 
  • Safety and Pharmacokinetics of Intravenous 10-1074 and VRC01LS in Young Children. 
  • Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions. 
  • Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. 
  • Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario. 
  • Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. 
  • Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad). 
  • Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. 
  • Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida. 
  • Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12. 
  • Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial. 
  • Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative. 
  • Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trial. 
  • Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. 
  • Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. 
  • Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women. 
  • Safety and immunogenicity of three seasonal inactivated influenza vaccines among pregnant women and antibody persistence in their infants. 
  • Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents. 
  • Same-sex behavior, sexually transmitted diseases and HIV risks among young northern Thai men. 
  • Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women. 
  • Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting. 
  • Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines. 
  • Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies. 
  • Selective Activation of VRC01-class Germline Antibodies in Knock-in Mice with Diverse Precursor Repertoires 
  • Selective antiviral activity of synthetic soluble L-tyrosine and L-dopa melanins against human immunodeficiency virus in vitro. 
  • Self and non-self discrimination of intracellular membranes by the innate immune system. 
  • Semi-solid gels function as physical barriers to human immunodeficiency virus transport in vitro. 
  • Sequence analysis for full length genomes of human enterovirus 71 strains isolated in Linyi, Shandong Province 
  • Sequence at both termini of the 10 genes of reovirus serotype 3 (strain Dearing). 
  • Sequences and phylogenetic analysis of the nef gene from Thai subjects harboring subtype E HIV-1. 
  • Sequences flanking the pentanucleotide T-antigen binding sites in the polyomavirus core origin help determine selectivity of DNA replication. 
  • Sequences within a small yeast RNA required for inhibition of internal initiation of translation: interaction with La and other cellular proteins influences its inhibitory activity. 
  • Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. 
  • Sequential synthesis of small capped RNA transcripts in vitro by vesicular stomatitis virus. 
  • Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination. 
  • Serological response following re-vaccination with Salmonella typhi Vi-capsular polysaccharide vaccines in healthy adult travellers. 
  • Seroprevalence and seroincidence of HIV-1 in injection drug users using the VA system. 
  • Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. 
  • Sex difference in immune response to vaccination: A participant-level meta-analysis of randomized trials of IMVAMUNE smallpox vaccine. 
  • Sexual behavior and reproductive health among HIV-infected patients in urban and rural South Africa. 
  • Sexual behavior of HIV discordant couples after HIV counseling and testing. 
  • Sexually transmitted infections and immune activation among HIV-infected but virally suppressed youth on antiretroviral therapy. 
  • Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance 
  • Short Communication: Potential Risk of Replication-Competent Virus in HIV-1 Env-Pseudotyped Virus Preparations. 
  • Short Communication: Small-Molecule CD4 Mimetics Sensitize HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity by Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Nonhuman Primates. 
  • Short communication: HIV type 1 subtype C variants transmitted through the bottleneck of breastfeeding are sensitive to new generation broadly neutralizing antibodies directed against quaternary and CD4-binding site epitopes. 
  • Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. 
  • Short communication: characteristics of effective immune control of simian/human immunodeficiency virus in pigtail macaques. 
  • Short communication: feasibility and acceptability of developing a multisite clinical cohort of transgender people with HIV infection. 
  • Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. 
  • Short-cycle therapy in adolescents after continuous therapy with established viral suppression: the impact on viral load suppression. 
  • Sickle-trait hemoglobin reduces adhesion to both CD36 and EPCR by Plasmodium falciparum-infected erythrocytes. 
  • Signature for long-term vaccine-mediated control of a Simian and human immunodeficiency virus 89.6P challenge: stable low-breadth and low-frequency T-cell response capable of coproducing gamma interferon and interleukin-2. 
  • Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen. 
  • Simian Immunodeficiency Virus Infection Modulates CD94+ (KLRD1+) NK Cells in Rhesus Macaques. 
  • Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously immunized animals. 
  • Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque. 
  • Simian immunodeficiency virus DNA vaccine trial in macaques. 
  • Simian immunodeficiency virus-Vpx as an adjuvant for integrase defective lentiviral vector-based vaccines 
  • Simian immunodeficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines. 
  • Simian virus 40 (SV40) T antigen binds specifically to double-stranded DNA but not to single-stranded DNA or DNA/RNA hybrids containing the SV40 regulatory sequences. 
  • Simian virus 40 transcriptional complexes incorporate mercurated nucleotides into RNA in vitro. 
  • Simian-Human Immunodeficiency Virus SHIV.C.CH505 Persistence in ART-Suppressed Infant Macaques Is Characterized by Elevated SHIV RNA in the Gut and a High Abundance of Intact SHIV DNA in Naive CD4+ T Cells. 
  • Simian-Human Immunodeficiency Virus SHIV.CH505-Infected Infant and Adult Rhesus Macaques Exhibit Similar Env-Specific Antibody Kinetics, despite Distinct T-Follicular Helper and Germinal Center B Cell Landscapes. 
  • Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses. 
  • Similar T-cell immune responses induced by group M consensus env immunogens with wild-type or minimum consensus variable regions. 
  • Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up. 
  • Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. 
  • Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles. 
  • Single cell based high-throughput Ig and TCR repertoire sequencing analysis in rhesus macaques 
  • Single epitope mucosal vaccine delivered via immuno-stimulating complexes induces low level of immunity against simian-HIV. 
  • Site on the vesicular stomatitis virus genome specifying polyadenylation and the end of the L gene mRNA. 
  • Sites of copy choice replication involved in generation of vesicular stomatitis virus defective-interfering particle RNAs. 
  • Six-helix bundle assembly and characterization of heptad repeat regions from the F protein of Newcastle disease virus. 
  • Size differences among the high molecular weight RNA's of avian tumor viruses. 
  • Skipped Over: Tuning Natural Killer Cells Toward HIV Through Alternative Splicing. 
  • Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. 
  • Social Network Clustering and the Spread of HIV/AIDS Among Persons Who Inject Drugs in 2 Cities in the Philippines. 
  • Socioeconomic status largely explains integrase inhibitors-related body composition differences in chronically infected men living with HIV. 
  • Soluble Envelope Glycoprotein Trimers from a CD4-Independent HIV-1 Elicit Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies in Guinea Pigs. 
  • Somatic hypermutation to counter a globally rare viral immunotype drove off-track antibodies in the CAP256-VRC26 HIV-1 V2-directed bNAb lineage. 
  • Spatial localization of the Ebola virus glycoprotein mucin-like domain determined by cryo-electron tomography. 
  • Specific activation strategies for amplification of low CTL signals. 
  • Specificity and effector functions of non-neutralizing gB-specific monoclonal antibodies isolated from healthy individuals with human cytomegalovirus infection. 
  • Sporangiospore size dimorphism is linked to virulence of Mucor circinelloides. 
  • Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein-Barr virus-transformed human B lymphocytes. 
  • Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions. 
  • Standard ART and valproic acid have limited impact on persistent HIV infection of resting CD4(+) T-cells 
  • Standard ART and valproic acid have limited impact on persistent HIV infection of resting CD4(+) T-cells 
  • Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens. 
  • Strategies for eliciting HIV-1 inhibitory antibodies. 
  • Strategies for engaging transgender populations in HIV prevention and care. 
  • Strengthening legal frameworks for vaccination: The experiences of Armenia, Georgia, and Moldova 
  • Strong SIV gp120-specific IgG/IgA responses in milk of African green monkeys may contribute to the rarity of postnatal transmission in this species 
  • Structural Analysis of the Unmutated Common Ancestor Antibodies of the HIV Envelope V2 Antibodies CH58 and CH59 Derived from RV144 Vaccinees 
  • Structural Basis for A32-like Epitopes Involved in ADCC Response of the RV114 Vaccine Trial 
  • Structural Basis for VRC01-Like-Antibody Recognition of Variable Loops that Surround the Site of CD4 Attachment on HIV-1 Gp120 
  • Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens. 
  • Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates. 
  • Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins. 
  • Structural components of rna tumor viruses. 
  • Structural connectome differences in HIV infection: brain network segregation associated with nadir CD4 cell count. 
  • Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection. 
  • Structural determinants of insert retention of poliovirus expression vectors with recombinant IRES elements. 
  • Structural interventions in public health. 
  • Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. 
  • Structurally Mapping Antigenic Epitopes of Adeno-associated Virus 9: Development of Antibody Escape Variants. 
  • Structure and function of CC-chemokine receptor 5 homologues derived from representative primate species and subspecies of the taxonomic suborders Prosimii and Anthropoidea. 
  • Structure and orientation of expressed bovine coronavirus hemagglutinin-esterase protein 
  • Structure of herpes simplex virus glycoprotein D bound to the human receptor nectin-1. 
  • Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity. 
  • Structure-Based Stabilization of SOSIP Env Enhances Recombinant Ectodomain Durability and Yield. 
  • Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques. 
  • Structures of HIV-1 Quaternary-Structure-Preferring Antibodies, CH04 And PG9, Show Conserved Structural Elements Within a Generallly Flexible CDR H3 
  • Studies at the oncogenic virus/host interface: Dynamic regulation of Epstein-Barr virus-mediated B cell immortalization 
  • Studies of complement-activating antibodies in the SIV/macaque model of acute primary infection and vaccine protection. 
  • Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network. 
  • Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein. 
  • Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. 
  • Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine. 
  • Studies on the reproductive and cell-converting abilities of avian sarcoma viruses. 
  • Studies using a viral challenge and CD8 T cell depletions on the roles of cellular and humoral immunity in the control of an SHIV-89.6P challenge in DNA/MVA-vaccinated macaques. 
  • Studies with 873140, a novel CCR5 antagonist, demonstrate synergy with enfuvirtide and potent inhibition of enfuvirtide-resistant R5-tropic HIV-1 
  • Studies with 873140, a novel CCR5 antagonist, demonstrate synergy with enfuvirtide and potent inhibition of enfuvirtide-resistant R5-tropic HIV-1 
  • Substantial multiclass transmitted drug resistance and drug-relevant polymorphisms among treatment-naïve behaviorally HIV-infected youth. 
  • Successes and Challenges on the Road to Cure Hepatitis C. 
  • Successful prophylaxis against Pneumocystis carinii pneumonia in HIV-infected children using smaller than recommended dosages of trimethoprim-sulfamethoxazole. 
  • Superimmunity: characterization of a new gene in the immunity region of P1. 
  • Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates. 
  • Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses. 
  • Surface Plasmon Resonance Analysis of Anti-gp120 V2-Specific IgG Antibodies Generated in the RV144 Thai Trial 
  • Surface loop dynamics in adeno-associated virus capsid assembly. 
  • Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. 
  • Susceptibility to acute mouse adenovirus type 1 respiratory infection and establishment of protective immunity in neonatal mice. 
  • Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. 
  • Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy. 
  • Swine influenza H1N1 virus induces acute inflammatory immune responses in pig lungs: a potential animal model for human H1N1 influenza virus. 
  • Symposium in Honor of Hilary Koprowski's Scientific Achievements. 
  • Symptoms and recovery among adult outpatients with and without COVID-19 at 11 healthcare facilities-July 2020, United States. 
  • Syndemics of HIV with mental illness and other noncommunicable diseases: a research agenda to address the gap between syndemic theory and current research practice. 
  • Synthesis and anti-HIV activity of a series of 2-indolinones and related analogues 
  • Synthetic Biocompatible Polymers Are an Effective Delivery Platform That Elicits Potent Antibody Responses Against HIV-1 Glycopeptide Immunogens 
  • Syringe Decriminalization Advocacy in Red States: Lessons from the North Carolina Harm Reduction Coalition. 
  • Systematic Assessment of Antiviral Potency, Breadth, and Synergy of Triple Broadly Neutralizing Antibody Combinations against Simian-Human Immunodeficiency Viruses. 
  • Systematic review exploring time trends in the association between educational attainment and risk of HIV infection in sub-Saharan Africa. 
  • Systemic IgG and IgA Responses to gp70V1V2 and C1 in HIV-Infected Elite Controllers Versus Controllers and Noncontrollers on HAART 
  • Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels. 
  • T Cell Escape in Subjects with Acute HIV-1 Infection 
  • T cell inactivation by poxviral B22 family proteins increases viral virulence. 
  • T-antigen kinase inhibits simian virus 40 DNA replication by phosphorylation of intact T antigen on serines 120 and 123. 
  • T-cell based sieve analysis ties HLA A*02 to vaccine efficacy and IgA-C1 immune correlate in RV144 Thai trial 
  • T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. 
  • TCR affinity associated with functional differences between dominant and subdominant SIV epitope-specific CD8+ T cells in Mamu-A*01+ rhesus monkeys. 
  • THE ENVELOPE V3 LOOP IS THE PRIMARY DETERMINANT OF CELL TROPISM IN HIV-1 
  • THE VAST MAJORITY OF RHESUS MACAQUES INFECTED WITH THE R5-TROPIC SHIVAD8 GENERATE CROSS-REACTIVE ANTIBODIES THAT NEUTRALIZE MULTIPLE HIV-1 STRAINS 
  • TMEM41B is a host factor required for the replication of diverse coronaviruses including SARS-CoV-2. 
  • TRANSDOMINANT REV PROTEIN INHIBITS HIV REPLICATION WITHOUT AFFECTING T-CELL FUNCTION 
  • TRIGGERED: could refocused cell signaling be key to natural killer cell-based HIV immunotherapeutics? 
  • Tandemly repeated sequences are present at the ends of the DNA of raccoonpox virus. 
  • Targeted Selection of an Improbable HIV-1 Antibody Mutation Critical for Broadly Neutralizing Reactivity With a Designed Immunogen 
  • Targeted entry via somatostatin receptors using a novel modified retrovirus glycoprotein that delivers genes at levels comparable to those of wild-type viral glycoproteins. 
  • Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. 
  • Task-shifting 'gold standard' clinical assessment and safety planning for suicide risk among people living with HIV: A feasibility and fidelity evaluation in Tanzania. 
  • Taste and smell complaints in HIV-infected patients. 
  • Temporal Dynamics of CD8+ T Cell Effector Responses during Primary HIV Infection. 
  • Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. 
  • Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy. 
  • Tenofovir diphosphate concentrations in human vaginal stroma after different dosage regimens with a vaginal gel: a modeling approach. 
  • Terminal sequences of vesicular stomatitis virus RNA are both complementary and conserved. 
  • Tetravalent Janssen Mosaic Ad26/Protein HIV Vaccine Shows Increased Clade C Env-specific CD4+T-cell and Antibody Responses Versus Trivalent Vaccine 
  • The Advisory Committee on Immunization Practices recommendation regarding the use of live influenza vaccine: A rejoinder. 
  • The B cell repertoire of terminal ileum in HIV-1 infection: concentration of antigen-reactive cells in the plasma cell versus the memory B cell pool 
  • The CD8+T Cell Antiviral Inhibitory Activity Predicts the Rate of CD4+Cell Decline in Early HIV-1 Infection and Is Independent of Viral Subtype 
  • The Chlamydia trachomatis type III secretion chaperone Slc1 engages multiple early effectors, including TepP, a tyrosine-phosphorylated protein required for the recruitment of CrkI-II to nascent inclusions and innate immune signaling. 
  • The DNA binding domain of a papillomavirus E2 protein programs a chimeric nuclease to cleave integrated human papillomavirus DNA in HeLa cervical carcinoma cells. 
  • The Dose Response: Perceptions of People Living with HIV in the United States on Alternatives to Oral Daily Antiretroviral Therapy. 
  • The E5 protein of human papillomavirus type 16 perturbs MHC class II antigen maturation in human foreskin keratinocytes treated with interferon-gamma. 
  • The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity. 
  • The Epstein-Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is growth promoting in EBV-infected B cells. 
  • The Epstein-Barr virus miR-BHRF1 microRNAs regulate viral gene expression in cis. 
  • The Expression of Functional Vpx during Pathogenic SIVmac Infections of Rhesus Macaques Suppresses SAMHD1 in CD4+ Memory T Cells. 
  • The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization. 
  • The Golgi Calcium ATPase Pump Plays an Essential Role in Adeno-associated Virus Trafficking and Transduction. 
  • The HIV/AIDS epidemic among young people in China between 2005 and 2012: results of a spatial temporal analysis. 
  • The HPV vaccine: are dosing recommendations being followed? 
  • The HVTN protocol 903 vaccine preparedness study: lessons learned in preparation for HIV vaccine efficacy trials. 
  • The Haemophilus ducreyi trimeric autotransporter adhesin DsrA protects against an experimental infection in the swine model of chancroid. 
  • The ICP0 protein of equine herpesvirus 1 is an early protein that independently transactivates expression of all classes of viral promoters. 
  • The Impact of Preexposure Prophylaxis Among Men Who Have Sex With Men: An Individual-Based Model. 
  • The Influence of Social Networks on Antiretroviral Therapy Initiation Among HIV-Infected Antiretroviral Therapy-Naive Youth in Rural Kenya and Uganda. 
  • The Influenza B Virus Hemagglutinin Head Domain Is Less Tolerant to Transposon Mutagenesis than That of the Influenza A Virus. 
  • The Landscape of Targeted Immune Responses in the HIV-1 Vaccine Field. 
  • The Legacy of Past Pandemics: Common Human Mutations That Protect against Infectious Disease. 
  • The Listeria monocytogenes PASTA Kinase PrkA and Its Substrate YvcK Are Required for Cell Wall Homeostasis, Metabolism, and Virulence. 
  • The Mid-Atlantic Centers for AIDS Research Consortium: Promoting HIV Science Through Regional Collaboration. 
  • The NLRP3 inflammasome detects encephalomyocarditis virus and vesicular stomatitis virus infection. 
  • The Path to Implementation of HIV Pre-exposure Prophylaxis for People Involved in Criminal Justice Systems. 
  • The Prostaglandin E2-EP3 Receptor Axis Regulates Anaplasma phagocytophilum-Mediated NLRC4 Inflammasome Activation. 
  • The Relationship Between Efavirenz as Initial Antiretroviral Therapy and Suicidal Thoughts Among HIV-Infected Adults in Routine Care. 
  • The Relationship between Immune Responses to Tetanus Vaccine, Hepatitis B Vaccine and a Pox-protein HIV Vaccine Regimen 
  • The Reovirus σ1s Protein Is a Determinant of Hematogenous but Not Neural Virus Dissemination in Mice 
  • The Role of Lipid Reactivity of HIV-1 gp41 Membrane Proximal Antibodies in Neutralization of HIV-1: Novel Liposome Based Immunogen Design 
  • The Role of Volume in the Perceptibility of Topical Vaginal Formulations: User Sensory Perceptions and Experiences of Heterosexual Couples During Vaginal Sex. 
  • The SATE pronucleotide approach applied to acyclovir: part II. Effects of bis(SATE)phosphotriester derivatives of acyclovir on duck hepatitis B virus replication in vitro and in vivo. 
  • The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. 
  • The Tree(s) of Life: The Human Placenta and My Journey to Learn More about It. 
  • The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope. 
  • The acidic domain of the hepatitis C virus NS4A protein is required for viral assembly and envelopment through interactions with the viral E1 glycoprotein. 
  • The antibody response in HIV-1 infection. 
  • The antiviral inhibitory capacity of CD8+T cells predicts the rate of CD4+cell decline in HIV-1 infection 
  • The association between benzodiazepine use and greater risk of neurocognitive impairment is moderated by medical burden in people with HIV. 
  • The burden of dialysis-requiring acute kidney injury among hospitalized adults with HIV infection: a nationwide inpatient sample analysis. 
  • The case for a family of reverse transcriptase viruses: Retraviridae. 
  • The changing epidemiology of HIV in 2013. 
  • The changing molecular epidemiology of HIV type 1 among northern Thai drug users, 1999 to 2002. 
  • The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. 
  • The clinical management of HCV in the HIV-infected patient. 
  • The clinical utility of using Catrimox-14-treated whole blood in detecting hepatitis C virus RNA. 
  • The coenrichment of stem cells, prothymocytes, and stromal elements with ecotropic retrovirus-producing cells from the bone marrow of leukemia-prone AKR mice. 
  • The complete genome sequence, organization and affinities of carrot red leaf virus. 
  • The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines. 
  • The core and accessory genomes of Burkholderia pseudomallei: implications for human melioidosis. 
  • The cost of HIV/AIDS to businesses in southern Africa. 
  • The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries. 
  • The coxsackievirus B 3C protease cleaves MAVS and TRIF to attenuate host type I interferon and apoptotic signaling. 
  • The design and evaluation of HIV-1 vaccines. 
  • The development of CD4 binding site antibodies during HIV-1 infection. 
  • The differential binding and activity of PRO 2000 against diverse HIV-1 envelopes. 
  • The double-stranded RNA binding protein 76:NF45 heterodimer inhibits translation initiation at the rhinovirus type 2 internal ribosome entry site. 
  • The double-stranded RNA-activated protein kinase mediates viral-induced encephalitis. 
  • The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. 
  • The effect of antidepressant treatment on HIV and depression outcomes: results from a randomized trial. 
  • The effect of antipyretics on immune response and fever following receipt of inactivated influenza vaccine in young children. 
  • The effect of timing of influenza vaccination and sample collection on antibody titers and responses in the aged. 
  • The effective rate of influenza reassortment is limited during human infection. 
  • The effects of HHV-8 vMIP-II on SIVmac251 infection and replication competent and incompetent SIVmac239Delta3 vectors. 
  • The effects of leukemosuppressive immunotherapy on bone marrow infectious cell centers in AKR mice. 
  • The epidemiology of HIV and syphilis among male commercial sex workers in northern Thailand [9] 
  • The epidemiology of HIV and syphilis among male commercial sex workers in northern Thailand. 
  • The eukaryotic translation initiation factor 4E is not modified during the course of vaccinia virus replication. 
  • The evolution of virus diseases: their emergence, epidemicity, and control. 
  • The feasibility of HIV vaccine efficacy trials among Russian injection drug users. 
  • The feasibility of a clinic-based parent intervention to prevent HIV, sexually transmitted infections, and unintended pregnancies among Latino and African American adolescents. 
  • The first measles vaccine. 
  • The gamma2 late glycoprotein K promoter of equine herpesvirus 1 is differentially regulated by the IE and EICP0 proteins. 
  • The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population. 
  • The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. 
  • The highs and lows of post-transplant immunosuppression: The role of BK polyoma viral monitoring 
  • The immunological impact of adenovirus early genes on vaccine-induced responses in mice and nonhuman primates. 
  • The impact of HIV-1 infection on phenotypic and functional parameters of cellular immunity in chimpanzees. 
  • The impact of ethnicity/race on the association between the Veterans Aging Cohort Study (VACS) Index and neurocognitive function among HIV-infected persons. 
  • The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. 
  • The increase in global HIV epidemics in MSM. 
  • The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy. 
  • The initial nucleotide sequence of DNA transcribed from avian myeloblastosis virus 70 S RNA by RNA-dependent DNA polymerase. 
  • The interaction of a series of hybridoma IgGs with reovirus particles. Demonstration that the core protein lambda 2 is exposed on the particle surface. 
  • The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen. 
  • The metabolic fate of independently initiated VSV mRNA transcripts. 
  • The mode of death of pig kidney cells infected with cowpox virus is governed by the expression of the crmA gene. 
  • The molecular epidemiology of HIV-1 among male sex workers in northern Thailand. 
  • The natural history of HIV-1 infection in young Thai men after seroconversion. 
  • The need for inclusion of pregnant women in COVID-19 vaccine trials. 
  • The next opportunity in anti-malaria drug discovery: the liver stage. 
  • The normal organization of the lateral posterior nucleus in the golden hamster and its reorganization after neonatal superior colliculus lesions 
  • The nucleocapsid region of HIV-1 Gag cooperates with the PTAP and LYPXnL late domains to recruit the cellular machinery necessary for viral budding. 
  • The optimization of pediatric vaccine regimens to prevent mother-to-child transmission of HIV through breast milk 
  • The pertussis vaccine controversy in Great Britain, 1974-1986. 
  • The pigtail macaque (Macaca nemestrina) model of COVID-19 reproduces diverse clinical outcomes and reveals new and complex signatures of disease. 
  • The plus strand of reovirus gene S2 is identical with its in vitro transcript. 
  • The polymorphic pseudokinase ROP5 controls virulence in Toxoplasma gondii by regulating the active kinase ROP18. 
  • The polypyrimidine tract binding protein is required for efficient picornavirus gene expression and propagation. 
  • The potential uses of preexposure prophylaxis for HIV prevention among people who inject drugs. 
  • The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine. 
  • The protein kinase Tor1 regulates adhesin gene expression in Candida albicans. 
  • The rational design and development of a dual chamber vaginal/rectal microbicide gel formulation for HIV prevention. 
  • The regional pattern of abnormal cerebrovascular reactivity in HIV-infected, virally suppressed women. 
  • The relation of prophylactic inoculations to the onset of poliomyelitis. 1950. 
  • The risks and benefits of childhood bacille Calmette-Guérin immunization among adults with AIDS. International MAC study groups. 
  • The role of bone marrow and thymic elements in the initiation and spread of virus production in the AKR thymus. 
  • The role of dynamin in HIV type 1 Env-mediated cell-cell fusion. 
  • The role of host genetics in the natural history of HIV-1 infection: the needles in the haystack. 
  • The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative. 
  • The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. 
  • The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills. 
  • The second-largest subunit of the poxvirus RNA polymerase is similar to the corresponding subunits of procaryotic and eucaryotic RNA polymerases. 
  • The sequence at the termini of four genes of the three reovirus serotypes. 
  • The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid. 
  • The sequence of the reovirus serotype 3 L3 genome segment which encodes the major core protein lambda 1. 
  • The sequences of reovirus serotype 3 genome segments M1 and M3 encoding the minor protein mu 2 and the major nonstructural protein mu NS, respectively. 
  • The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae. 
  • The structural polypeptides of equine infections anemia virus. 
  • The surface envelope protein gene region of equine infectious anemia virus is not an important determinant of tropism in vitro. 
  • The tripartite associations between bacteriophage, Wolbachia, and arthropods 
  • The tripartite associations between bacteriophage, Wolbachia, and arthropods. 
  • The use of a urinary estrone conjugates assay for detection of optimal mating time in the cynomolgus macaque (Macaca fascicularis). 
  • The veterans aging cohort study index is associated with concurrent risk for neurocognitive impairment. 
  • The viral and cellular microRNA targetome in lymphoblastoid cell lines. 
  • The viral transmembrane protein: A target for the discovery of novel antivirals 
  • Therapeutic Vaccination With a Combination of IDLV-SIV-Gag and IDLV-PGT121 Results in Prolonged Virus Control in Chronically SHIV-infected Macaques 
  • Therapy of acute and fulminant hepatitis B. 
  • There's Much Yet to be Done: Diverse Perspectives on HPV Vaccination. 
  • Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers. 
  • Three-dimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomography. 
  • Thrombotic thrombocytopenic purpura during immune reconstitution. 
  • Thy1+ NK [corrected] cells from vaccinia virus-primed mice confer protection against vaccinia virus challenge in the absence of adaptive lymphocytes. 
  • Thymopoiesis in HIV-infected adults after highly active antiretroviral therapy. 
  • Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. 
  • Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. 
  • Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques. 
  • Timing of retroviral infection influences anamnestic immune response in vaccinated primates. 
  • Titan cells formation in Cryptococcus neoformans is finely tuned by environmental conditions and modulated by positive and negative genetic regulators. 
  • Titered Mucosal Challenge of Rhesus Macaques with SIVmac251 Recapitulates HIV Vaccine Efficacy in Humans 
  • To be or not IIb: a multi-step process for Epstein-Barr virus latency establishment and consequences for B cell tumorigenesis. 
  • To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment. 
  • Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV. 
  • Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques. 
  • Topical microbicides: the time has come. 
  • Topography of a flexible ribonucleoprotein helix: protein-protein contacts in Sendai virus nucleocapsids. 
  • Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies. 
  • Toward understanding microbiota homeostasis in the plant kingdom. 
  • Towards a population-based threshold of protection for COVID-19 vaccines. 
  • Toxoplasma gondii serology in HIV-infected patients: the development of central nervous system toxoplasmosis in AIDS. 
  • Tracking KLRC2 (NKG2C)+ memory-like NK cells in SIV+ and rhCMV+ rhesus macaques. 
  • Trajectories of Depressive Symptoms, Neurocognitive Function, and Viral Suppression With Antiretroviral Therapy Among Youth With HIV Over 36 months. 
  • Transactivation of BKV and SV40 early promoters by BKV and SV40 T-antigens. 
  • Transcription factor AP-2 regulates human immunodeficiency virus type 1 gene expression. 
  • Transcription in mouse embryo cells permissively infected by murine cytomegalovirus. 
  • Transcription of a poxvirus early gene is regulated both by a short promoter element and by a transcriptional termination signal controlling transcriptional interference. 
  • Transcription of orthopoxvirus telomeres at late times during infection. 
  • Transcription of the terminal loop region of vaccinia virus DNA is initiated from the telomere sequences directing DNA resolution. 
  • Transcriptional Profiling Confirms the Therapeutic Effects of Mast Cell Stabilization in a Dengue Disease Model. 
  • Transcriptional and posttranscriptional regulation of cytokine gene expression in HIV-1 antigen-specific CD8+ T cells that mediate virus inhibition. 
  • Transcriptionally abundant major histocompatibility complex class I alleles are fundamental to nonhuman primate simian immunodeficiency virus-specific CD8+ T cell responses. 
  • Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes. 
  • Transfer RNAs associated with vesicular stomatitis virus. 
  • Transgenic plants expressing potato virus X ORF2 protein (p24) are resistant to tobacco mosaic virus and Ob tobamoviruses. 
  • Transient compartmentalization of simian immunodeficiency virus variants in the breast milk of african green monkeys. 
  • Translation by the adenovirus tripartite leader: elements which determine independence from cap-binding protein complex. 
  • Transmission of HIV by antigen presenting cells during T-cell activation: prevention by 3'-azido-3'-deoxythymidine. 
  • Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007. 
  • Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. 
  • Transport and transport properties of tenofovir from microbicide gels into vaginal tissue: analysis using Raman spectroscopy. 
  • Traumatic stress and the mediating role of alcohol use on HIV-related sexual risk behavior: results from a longitudinal cohort of South African women who attend alcohol-serving venues. 
  • Treating depression within the HIV "medical home": a guided algorithm for antidepressant management by HIV clinicians. 
  • Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014. 
  • Trivalent inactivated influenza vaccine (TIV) immunogenicity in children 6 through 23 months of age: do children of all ages respond equally? 
  • Tryptophan degradation is associated with risk-taking propensity in methamphetamine users with treated HIV infection. 
  • Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. 
  • Two genes on A/J chromosome 18 are associated with susceptibility to Staphylococcus aureus infection by combined microarray and QTL analyses. 
  • Two levels of restriction by mouse or cat cells of murine sarcoma virus coated by endogenous xenotropic oncornavirus. 
  • Two-Year Follow-Up of Macaques Developing Intermittent Control of the Human Immunodeficiency Virus Homolog Simian Immunodeficiency Virus SIVmac251 in the Chronic Phase of Infection. 
  • Two-year impacts on employment and income among adults receiving antiretroviral therapy in Tamil Nadu, India: a cohort study. 
  • Ulk1 Governs Nerve Growth Factor/TrkA Signaling by Mediating Rab5 GTPase Activation in Porcine Hemagglutinating Encephalomyelitis Virus-Induced Neurodegenerative Disorders. 
  • Ultraviolet-light-inactivated Cas-Br-M murine leukemia virus induces a protective CD8+ cytotoxic T lymphocyte response in newborn mice. 
  • Understanding COVID-19 vaccine uptake during pregnancy: 'Hesitance', knowledge, and evidence-based decision-making. 
  • Understanding HIV epidemics: aggregate viral load metrics and 'smoking guns'. 
  • Understanding Retention in Pre-Exposure Prophylaxis Care in the South: Insights from an Academic HIV Prevention Clinic. 
  • Understanding human variation in infectious disease susceptibility through clinical and cellular GWAS. 
  • Understanding orthopoxvirus interference with host immune responses to inform novel vaccine design. 
  • Understanding the HIV Epidemic Among MSM in Baltimore: A Modeling Study Estimating the Impact of Past HIV Interventions and Who Acquired and Contributed to Infections. 
  • Uniocular vascular occlusion in a paraplegic hybrid monkey. A clinicopathologic study. 
  • Unique cellular and humoral immunogenicity profiles generated by aerosol, intranasal, or parenteral vaccination in rhesus macaques. 
  • Unique evolution of the UPR pathway with a novel bZIP transcription factor, Hxl1, for controlling pathogenicity of Cryptococcus neoformans. 
  • Unique glycan signatures regulate adeno-associated virus tropism in the developing brain. 
  • Unisexual reproduction drives evolution of eukaryotic microbial pathogens. 
  • Unselected mutations in the human immunodeficiency virus type 1 genome are mostly nonsynonymous and often deleterious. 
  • Update on Aplaviroc: An HIV Entry Inhibitor Targeting CCR5 
  • Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis. 
  • Urine processing impacts uric acid level in HIV-infected adults: implications for diagnosing tenofovir-associated proximal tubulopathy. 
  • Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV. 
  • Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein. 
  • Use of electric cell-substrate impedance sensing as a tool for quantifying cytopathic effect in influenza A virus infected MDCK cells in real-time. 
  • Use of glomerular filtration rate estimating equations for drug dosing in HIV-positive patients. 
  • Use of mobile phones for improving vaccination coverage among children living in rural hard-to-reach areas and urban streets of Bangladesh. 
  • Utility of a brief computerized battery to assess HIV-associated neurocognitive impairment in a resource-limited setting. 
  • Utility of rapid antibody tests to exclude HIV-1 infection among infants and children aged <18 months in a low-resource setting. 
  • Utilization of Sialylated Glycans as Coreceptors Enhances the Neurovirulence of Serotype 3 Reovirus 
  • Utilization of health care services in hard-to-reach marginalized HIV-infected individuals. 
  • Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41. 
  • Utilization of medical treatments and adherence to antiretroviral therapy among HIV-positive adults with histories of childhood sexual abuse. 
  • Utilization of mental health and substance abuse care for people living with HIV/AIDS, chronic mental illness, and substance abuse disorders. 
  • Utilizing Mucin-tethered HIV IgG to Enhance HIV Vaccine Function 
  • V1/V2-directed antibodies elicited in RV144 vaccinees bind to a structurally polymorphic site 
  • V1V2 IgG and Antibody Fc Effector Functions in a Subtype C ALVAC-HIV and Bivalent Subtype C gp120/MF59 HIV-1 Vaccine Trial in South Africa 
  • V2-Reactive Antibodies in RV144 Vaccinees' Plasma 
  • V3-SPECIFIC NEUTRALIZING ANTIBODIES IN SERA FROM HIV-1 GP160-IMMUNIZED VOLUNTEERS BLOCK VIRUS ATTACHMENT AND ACT SYNERGISTICALLY WITH HUMAN MONOCLONAL-ANTIBODY TO THE CONFORMATION-DEPENDENT CD4 BINDING REGION OF GP120 
  • VACCINATION AGAINST MUCOSAL CHALLENGES WITH HETEROLOGOUS R5 CLADE C SHIV: PREVENTION OF INFECTION AND CORRELATES OF PROTECTION 
  • VACCINE-INDUCED MUCOSAL B CELLS ARE CORRELATED WITH DELAYED SIVMAC251 ACQUISITION FOLLOWING RECTAL CHALLENGE OF FEMALE BUT NOT MALE RHESUS MACAQUES 
  • Vaccination against herpes zoster in developed countries: state of the evidence. 
  • Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. 
  • Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660. 
  • Vaccination with Live Attenuated Simian Immunodeficiency Virus (SIV) Protects from Mucosal, but Not Necessarily Intravenous, Challenge with a Minimally Heterologous SIV. 
  • Vaccination with Vaxfectin(®) adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia. 
  • Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge. 
  • Vaccination with the immediate-early protein ICP47 of herpes simplex virus-type 1 (HSV-1) induces virus-specific lymphoproliferation, but fails to protect against lethal challenge. 
  • Vaccination with vif-deleted feline immunodeficiency virus provirus, GM-CSF, and TNF-alpha plasmids preserves global CD4 T lymphocyte function after challenge with FIV. 
  • Vaccine Induced Epitope Specific Antibodies to the SIV Envelope Are Distinct from Those Induced to the HIV-1 Envelope 
  • Vaccine Induction of V2 Apex-directed, Cross-reactive Neutralizing Antibodies in CH01 UCA "HC Only" Knock-in Mice 
  • Vaccine coverage and adherence to EPI schedules in eight resource poor settings in the MAL-ED cohort study. 
  • Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques. 
  • Vaccine knowledge and practices of primary care providers of exempt vs. vaccinated children 
  • Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. 
  • Vaccine-Elicited IgG Subclasses and Functional Antibodies 
  • Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site. 
  • Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates. 
  • Vaccine-Mediated Inhibition of the Transporter Associated with Antigen Processing Is Insufficient To Induce Major Histocompatibility Complex E-Restricted CD8+ T Cells in Nonhuman Primates. 
  • Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope. 
  • Vaccine-elicited memory B cells expressing ADCC-mediating antibodies lacking recognition of the V2 region did not correlate with protection of NHPs 
  • Vaccine-elicited systemic and mucosal humoral responses of lactating rhesus monkeys vaccinated with the transmitted/founder HIV Envelope 1086C 
  • Vaccine-induced ADCC-mediating antibodies target unique and overlapping envelope epitopes 
  • Vaccine-induced Activation of Inflammasome in Classical Monocytes and Th2 Cell Responses Correlates With Decreased Risk of SIVmac251 Acquisition 
  • Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide. 
  • Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge. 
  • Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. 
  • Vaccines and immunology: Overview 
  • Validation of a brief screening instrument for substance abuse and mental illness in HIV-positive patients. 
  • Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. 
  • Variation in interferon sensitivity and induction among strains of eastern equine encephalitis virus. 
  • Vertical HIV-1 Transmission in the Setting of Maternal Broad and Potent Antibody Responses. 
  • Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. 
  • Viral cell death inhibitor MC159 enhances innate immunity against vaccinia virus infection. 
  • Viral genetic evolution in macaques infected with molecularly cloned simian immunodeficiency virus correlates with the extent of persistent viremia. 
  • Viral glycoprotein synthesis studies in an established line of Japanese quail embryo cells infected with the Bryan high-titer strain of Rous sarcoma virus. 
  • Viral glycoprotein synthesis under conditions of glucosamine block in cells transformed by avian sarcoma viruses. 
  • Viral regulatory region effects on vertical transmission of polyomavirus SV40 in hamsters. 
  • Viral transcription is necessary and sufficient for vesicular stomatitis virus to inhibit maturation of small nuclear ribonucleoproteins. 
  • Viral vectored granulocyte-macrophage colony stimulating factor inhibits vaccine protection in an SIV challenge model: protection correlates with neutralizing antibody. 
  • Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus. 
  • Virological characterization of treatment naive subjects failing an aplaviroc-based regimen with either lamivudine/zidovudine or lopinavir/ritonavir 
  • Virology under the Microscope-a Call for Rational Discourse. 
  • Vironome of Kaposi sarcoma associated herpesvirus-inflammatory cytokine syndrome in an AIDS patient reveals co-infection of human herpesvirus 8 and human herpesvirus 6A. 
  • Virulence genes of poxviruses and reoviruses. 
  • Virus particle release from glycosphingolipid-enriched microdomains is essential for dendritic cell-mediated capture and transfer of HIV-1 and henipavirus. 
  • Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques. 
  • Viruses and oncogenes in brain tumors. 
  • Vulnerability to COVID-19-related Harms among Transgender Women with and Without HIV Infection in the Eastern and Southern U.S. 
  • WHAT IS THE FATE OF COMPLEMENT-OPSONIZED HIV 
  • WTAP Targets the METTL3 m6A-Methyltransferase Complex to Cytoplasmic Hepatitis C Virus RNA to Regulate Infection. 
  • Who will enroll? Predicting participation in a phase II AIDS vaccine trial. 
  • Whole Blood Transcriptional Monitoring of Acute HIV-1 Infection Reveals Differential Signatures of Host Immune Activation 
  • Wide variation in the multiplicity of HIV-1 infection among injection drug users. 
  • Wild Mandrillus sphinx are carriers of two types of lentivirus. 
  • Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand. 
  • World Health Organization's stage 4 conditions among adults accessing outpatient HIV care: a retrospective cohort study in Kisumu, Kenya. 
  • XIAP regulates cytosol-specific innate immunity to Listeria infection. 
  • XRN1 stalling in the 5' UTR of Hepatitis C virus and Bovine Viral Diarrhea virus is associated with dysregulated host mRNA stability. 
  • XVIII. Effective treatment of AKR leukemia with antibody to gp7 1 eliminates the neonatal burst of ecotropic AKR virus producing cells. 
  • Yersinia pestis activates both IL-1β and IL-1 receptor antagonist to modulate lung inflammation during pneumonic plague. 
  • Yes, research matters. 
  • Yoga lifestyle intervention reduces blood pressure in HIV-infected adults with cardiovascular disease risk factors 
  • Youth, Technology, and HIV: Recent Advances and Future Directions. 
  • Zebrafish: a see-through host and a fluorescent toolbox to probe host-pathogen interaction. 
  • c-Myc Represses Transcription of Epstein-Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection. 
  • eHealth to Enhance Treatment Adherence Among Youth Living with HIV. 
  • epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals. 
  • n-Butyrate, a cell cycle blocker, inhibits early amplification of duck hepatitis B virus covalently closed circular DNA after in vitro infection of duck hepatocytes. 
  • net P01-01. The blood transcriptional response to early acute HIV infection is transient and responsive to antiretroviral therapy 
  • rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1 
  • α-Hemolysin promotes uropathogenic E. coli persistence in bladder epithelial cells via abrogating bacteria-harboring lysosome acidification. 
• 

  Keywords of People

  • Broverman, Sherryl A., Professor of the Practice of Biology, Biology
  • Coyne, Carolyn, George Barth Geller Distinguished Professor of Immunology, Cell Biology
  • Demarest, James Francis, Adjunct Assistant Professor in the Department of Immunology, Integrative Immunobiology
  • Gromeier, Matthias, Professor of Neurosurgery, Cell Biology
  • Heaton, Nicholas Scott, Associate Professor of Molecular Genetics and Microbiology, Cell Biology
  • Sorelle, Elliott, Postdoctoral Associate, Molecular Genetics and Microbiology